Molecular characterisation of the Herpes Simplex Virus-1 LATP2 enhancer region. by English, C.
REFERENCE ONLY
UNIVERSITY OF LONDON THESIS
Degree Year T o o b  Name of Author 10 ° U  ^  c
COPYRIGHT
This is a thesis accepted for a Higher Degree of the University of London. It is an 
unpublished typescript and the copyright is held by the author. All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
COPYRIGHT DECLARATION
1 recognise that the copyright of the above-described thesis rests with the author and 
that no quotation from it or information derived from it may be published without the 
prior written consent of the author.
Theses may not be lent to individuals, but the Senate House Library may lend a copy 
to approved libraries within the United Kingdom, for consultation solely on the 
premises of those libraries. Application should be made to: Inter-Library Loans, 
Senate House Library, Senate House, Malet Street, London WC1E 7HU.
REPRODUCTION
University of London theses may not be reproduced without explicit written 
permission from the Senate House Library. Enquiries should be addressed to the 
Theses Section of the Library. Regulations concerning reproduction vary according 
to the date of acceptance of the thesis and are listed below as guidelines.
A. Before 1962. Permission granted only upon the prior written consent of the 
author. (The Senate House Library will provide addresses where possible).
B. 1962 -1974. In many cases the author has agreed to permit copying upon 
completion of a Copyright Declaration.
C. 1975 - 1988. Most theses may be copied upon completion of a Copyright 
Declaration.
D. 1989 onwards. Most theses may be copied.
This thesis comes within category D.
This copy has been deposited in the Senate House Library, Senate House,
LOANS
This copy has been deposited in the Library of
Malet Street, London WC1E 7HU.
C:\Documents and Settings\Iproctor\Local SettingsYTemporary Internet FiIes\OLKS\Copyright - thesis (2).doc

MOLECULAR CHARACTERISATION OF THE 
HERPES SIMPLEX VIRUS 1 LATP2 ENHANCER 
REGION
CHRISTIE ENGLISH
A thesis submitted for the degree of 
Doctor of Philosophy 
at University College London
Department of Immunology and Molecular Pathology 
The Windeyer Institute of Medical Sciences 
University College London 
46, Cleveland Street 
London W 1T 4J F
November 2005
1
UMI Number: U591973
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U591973
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Abstract
Abstract
HSV1 vectors have previously been produced with the ability to direct long-term 
expression of a transgene within the nervous system. These viruses have an 
arrangement of the latency promoter and enhancer regions LAP1 and LATP2 such 
that LATP2 exerts long-term expression onto LAP1 and an exogenous promoter at the 
same time, in a back-to-back fashion.
To characterise the LATP2 region, two series of vectors were produced containing 
deletion mutations of the region placed in different orientations to LAP1 within the 
context of the original vectors. The vectors were tested in vitro and in vivo in the PNS 
and a potentially repressive region within LATP2 was identified. The enhancer activity 
of the region was also localised to a defined area.
As the HSV1 genome is associated with histones and modification of these is a 
method of transcriptional control, histone modification could be one mechanism that 
the virus uses to keep the l_AT region active during latency. This was investigated by 
examining the acetylation of histones associated with the LAT region, including 
LATP2, at lytic and latent timepoints in an in vitro system by ChIP assay. These 
studies found that although no significant differences in acetylation at different loci of 
LATP2 was found, the LAT regulatory region generally appears to be more associated 
with hyperacetylated histones during latency than non-LAT promoters and that this 
increased acetylation is conferred onto an exogenous promoter when placed within the 
LAT region.
The findings in this thesis should provide insight into the functioning of the LAT region 
and may allow the development of improved HSV1 vectors for gene therapy in the 
nervous system.
2
Acknowledgements
Acknowledgements
I would like to thank Rob Coffin for supervising this PhD and Biovex Ltd for providing 
the funding required.
My thanks go to all of the members of the lab that I have worked with throughout the 
course of this PhD, too many to name all. However, I really appreciate all the help 
afforded to me by Jill, James, Caroline, Mike, Ruth, Sarah and Xiaopeng in learning 
the ropes in the early days. Since then, I am very grateful for the continued help given 
by everyone in the lab past and present. Special thanks to Sonia for the help with 
those mice (!) and for proofreading for me; also to Kevin for proofreading and help with 
editing. Thanks to all of my other fellow PhD’ers for the sympathy and support when 
things went wrong along the way!
Thanks also go to my non-lab friends for providing years of encouragement in my 
scientific endeavours. A big big thankyou to Mum, Dad, Claire and Cath, for the 
continued love and support. Finally to Dave, whose patience and belief in me 
throughout this PhD has been invaluable - 1 couldn’t have done it without you.
3
Table of contents
Table of Contents
Abstract..................................................................................................................................... 2
Acknowledgements.................................................................................................................. 3
Table of contents......................................................................................................................4
List of figures.......................................................................................................................... 12
List of tables............................................................................................................................17
Abbreviations.......................................................................................................................... 18
CHAPTER 1: INTRODUCTION...........................................................................................24
1.1 Herpes Simplex Viruses.............................................................................................25
1.1.1 HSV1 and 2 ....................................................................................................25
1.1.2 HSV1 Biology.................................................................................................26
1.1.2.1 Cell attachment and entry..............................................................28
1.1.2.2 Configuration of viral DNA..............................................................30
1.1.2.3 The lytic cycle...................................................................................31
1.1.2.3.1 The IE genes....................................................................32
1.1.2.3.2 The E genes..................................................................... 35
1.1.2.3.3 The L genes..................................................................... 35
1.1.2.3.4 Encapsidation, virion assembly and egress................ 37
1.1.2.4 Latency.............................................................................................. 38
1.1.2.4.1 Establishment and maintenance of latency..................38
1.1.2.4.2 Reactivation.......................................................................40
1.1.2.4.3 The LATs...........................................................................42
1.1.2.4.4 The latency promoters.................................................... 46
1.1.2.4.4.1 LAP1................................................................. 47
1.1.2.4.4.2 LAP2................................................................. 49
1.1.3 Long-term expression from the LAT region................................................52
Table of contents
1.1.4 The use of HSV1 as a gene therapy vector.............................................. 58
1.2 An overview of transcriptional regulation..................................................................62
1.2.1 Promoters....................................................................................................... 62
1.2.2 Enhancers...................................................................................................... 63
1.2.3 Transcriptional regulation by epigenetic mechanisms.............................64
1.2.3.1 Chromatin structure......................................................................... 64
1.2.3.2 Histone modification in transcriptional control..............................67
1.2.3.3 Nucleosome remodelling complexes............................................ 69
1.2.3.4 Interaction of chromatin remodellers and histone modifiers 70
1.2.3.5 Insulators and barriers.................................................................... 70
1.3 Thesis aims....................................................................................................................73
CHAPTER 2: MATERIALS AND METHODS.................................................................... 74
2.1 Laboratory reagents..................................................................................................... 75
2.1.1 Standard buffers and solutions....................................................................75
2.2 Molecular Biology..........................................................................................................76
2.2.1 Bacterial strains and growth conditions...................................................... 76
2.2.1.1 Propagation of bacteria................................................................... 76
2.2.1.2 Long-term storage of bacteria........................................................76
2.2.1.3 Preparation of competent XL1-blue cells......................................76
2.2.1.4 Transformation of XL1-blue cells................................................... 77
2.2.2 DNA extraction and purification...................................................................77
2.2.2.1 Small-scale plasmid DNA extraction and purification.................77
2.2.2.2 Large-scale plasmid DNA extraction and purification................ 78
2.2.3 Cloning............................................................................................................ 78
2.2.3.1 Restriction digests............................................................................ 78
2.2.3.2 Isolation of DNA fragments.............................................................79
2.2.3.3 Blunt-end reactions.......................................................................... 79
5
Table of contents
2.2.3.4 Phosphatase treatment...................................................................79
2.2.3.5 Agarose gel electrophoresis.......................................................... 80
2.2.3.6 Phenol extraction of DNA............................................................... 80
2.2.3.7 DNA ligations....................................................................................81
2.2.3.8 Colony characterisation using a radiolabelled probe................. 81
2.2.3.8.1 Colony transfer................................................................ 81
2.2.3.8.2 Radiolabelling DNA probes............................................ 82
2.2.3.8.3 Hybridisation.....................................................................82
2.2.4 Polymerase chain reaction (PCR).............................................................. 83
2.2.4.1 Standard PCR reaction...................................................................83
2.2.4.2 PCR of viral DNA............................................................................ 83
2.2.5 Preparation of cDNA....................................................................................83
2.2.6 DNA sequencing........................................................................................... 84
2.2.7 Viral DNA preparation.................................................................................. 84
2.2.8 Southern blotting.......................................................................................... 84
2.2.8.1 DNA preparation.............................................................................. 85
2.2.8.2 DNA transfer..................................................................................... 85
2.2.8.3 Membrane analysis..........................................................................85
2.3 Tissue Culture............................................................................................................... 86
2.3.1 Mammalian cell lines....................................................................................86
2.3.1.1 Baby hamster kidney cells...............................................................86
2.3.1.2 27/12/M:4 cells..................................................................................86
2.3.1.3 ND7 cells...........................................................................................87
2.3.1.4 Vero cells...........................................................................................87
2.3.1.5 HT1080 cells..................................................................................... 87
2.3.2 Cell line storage.............................................................................................87
2.3.3 Primary cultures.............................................................................................88
2.3.3.1 Coating coverslips............................................................................ 88
6
Table of contents
2.3.32  Dissection and digestion of dorsal root ganglia.......................... 88
2.3.3.3 Dispersion and plating of dorsal root ganglia...............................89
2.3.4 Transient transfection assays..................................................................... 89
2.3.4.1 DNA transfections............................................................................89
2.3.4.2 Detection of p-Galactosidase by X-Gal staining......................... 90
2.3.4.3 p-Galactosidase activity assay.......................................................90
2.3.5 Virus construction and propagation.............................................................90
2.3.5.1 Homologous recombination transfections.....................................91
2.3.5.2 Viral plaque assay............................................................................91
2.3.5.3 Purification of viral recombinants by plaque selection............... 92
2.3.5.4 High titre viral stock production......................................................92
2.3.5.4.1 Filtration of viral stocks.................................................. 93
2.3.6 Growth curves................................................................................................93
2.4 In vivo work...................................................................................................................94
2.4.1 Footpad delivery............................................................................................ 94
2.4.1.1 Detection of p-Galactosidase activity in extracted D R G ............. 94
2.4.1.2 Detection of GFP in extracted D R G ..............................................95
2.4.2 Stereotaxic injections.....................................................................................95
2.4.2.1 Detection of p-Galactosidase activity in extracted brains............ 96
2.5 Statistical analysis........................................................................................................96
CHAPTER 3: CONSTRUCTION AND TESTING OF HSV1 VECTORS CONTAINING 
LATP2 DELETION CONSTRUCTS (I)............................................................................... 97
3.1 Introduction.................................................................................................................... 98
3.2 Identification of potential binding sites within LATP2............................................101
3.3 LATP2 deletion plasmids..........................................................................................104
3.3.1 Method of construction............................................................................... 104
3.4 In vitro testing of plasmid constructs........................................................................110
7
Table of contents
3.5 Vector construction...................................................................................................115
3.6 In vitro testing of recombinant vectors.................................................................. 118
3.6.1 Viral plaque characteristics....................................................................... 118
3.6.2 Growth curves.............................................................................................121
3.6.3 Infection of cell lines...................................................................................121
3.7 In vivo testing of recombinant vectors....................................................................129
3.7.1 Testing in the PNS...................................................................................... 129
3.7.1.1 LATP2 activity 3 days post-injection............................................131
3.7.1.2 LATP2 activity 1 month post-injection........................................ 134
3.8 Discussion..................................................................................................................138
CHAPTER 4: CONSTRUCTION AND TESTING OF HSV1 VECTORS CONTAINING 
LATP2 DELETION CONSTRUCTS (II)............................................................................ 140
4.1 Introduction.................................................................................................................141
4.2 LATP2 deletion plasmids......................................................................................... 142
4.2.1 Series 2 plasmids -  LATP2 in the opposite orientation to LAP1.........142
4.2.1.1 Method of construction.................................................................. 142
4.2.2 Series 3 plasmids -  LATP2 in the same orientation as LAP1........... 143
4.2.3 Analysis of plasmids...................................................................................145
4.3 In vitro testing of plasmids constructs....................................................................149
4.3.1 The effect of LATP2 deletions on lacZ expression within the series of 
plasmids...................................................................................................... 155
4.3.1.1 Series 2 plasmids -  LATP2 in the opposite orientation to LAP1
........................................................................................................ 155
4.3.1.2 Series 3 plasmids -  LATP2 in the same orientation as LAP1156
4.3.2 The effect of orientation of LATP2 deletions on lacZ expression.........157
4.4 Vector Construction.................................................................................................. 159
4.5 In vitro testing of recombinant vectors...................................................................162
8
Table of contents
4.5.1 Viral plaque characteristics....................................................................... 162
4.5.2 Growth curves.............................................................................................165
4.5.3 Infection of cell lines...................................................................................167
4.5.4 The effect of LATP2 deletions on lacZ expression within the series of
viruses.........................................................................................................176
4.5.4.1 Series 2 viruses -  LATP2 in the opposite orientation to LAP1....
........................................................................................................ 176
4.5.4.2 Series 3 viruses -  LATP2 in the same orientation as LAP1 ...176
4.5.5 The effect of orientation of LATP2 deletions on lacZ expression 177
4.6 In vivo testing of recombinant vectors....................................................................178
4.6.1 Testing in the PNS...................................................................................... 178
4.6.1.1 LATP2 activity 3 days post-injection...........................................178
4.6.1.1.1 Series 2 viruses -  LATP2 in the opposite orientation to 
LAP1.................................................................................183
4.6.1.1.2 Series 3 viruses -  LATP2 in the same orientation as 
LAP1.................................................................................183
4.6.1.1.3 The effect of orientation of LATP2 deletions on lacZ 
expression during lytic infection.....................................184
4.6.1.2 LATP2 activity 1 month post-injection....................................... 185
4.6.1.2.1 Series 2 viruses -  LATP2 in the opposite orientation to 
LAP1.................................................................................191
4.6.1.2.2 Series 3 viruses -  LATP2 in the same orientation as 
LAP1.................................................................................191
4.6.1.2.3 The effect of orientation of LATP2 deletions on long­
term lacZ expression......................................................192
4.7 Discussion...................................................................................................................193
9
Table of contents
CHAPTER 5: OPTIMISATION AND APLICATION OF THE CHROMATIN 
IMMUNOPRECIPITATION ASSAY FOR STUDYING THE ACETYLATION OF THE 
GENOME OF HSV1............................................................................................................199
5.1 Introduction................................................................................................................ 200
5.1.1 In vitro models of latency..........................................................................202
5.1.2 Choice of viruses for analyses.................................................................204
5.1.3 The chromatin immunoprecipitation (ChIP) assay................................. 206
5.2 Materials and methods............................................................................................208
5.2.1 TUJ1 staining.............................................................................................. 208
5.2.2 ChIP assay...................................................................................................208
5.2.2.1 Crosslinking and sonication.........................................................209
5.2.2.2 Immunoprecipitation..................................................................... 209
5.2.2.3 Washing and reversal of cross-links.......................................... 210
5.2.2.4 Clean-up and purification............................................................ 210
5.2.3 PCR............................................................................................................... 211
5.2.4 Quantitative PCR.........................................................................................211
5.2.5 Nuclei Isolation............................................................................................ 211
5.3 Optimisation of the in vitro models.........................................................................212
5.3.1 Lytic model...................................................................................................212
5.3.2 Latent model.................................................................................................213
5.3.3 Production of LATs in vitro......................................................................... 216
5.3.4 Nucleosomal structure of the virus in vitro............................................... 221
5.4 Optimisation of the sonication procedure..............................................................223
5.4.1 Volume of buffer for sonication................................................................. 223
5.4.2 Time of sonication.......................................................................................224
5.5 Choice of antibody.................................................................................................... 226
5.6 Optimisation of PCR.................................................................................................226
5.7 Validation of the assay............................................................................................. 229
10
Table of contents
5.8 Initial ChIP assays.....................................................................................................231
5.8.1 Analysis of the samples by PCR..............................................................231
5.8.2 Analysis of the samples by PCR and Southern blot............................. 234
5.8.3 Analysis of the samples by quantitative PCR.........................................238
5.8.3.1 Primer validation........................................................................... 238
5.8.3.2 Detection of acetylated latent virus............................................. 241
5.8.3.3 Detection of acetylated lytic virus................................................245
5.9 Use of the optimised ChIP assay to analyse the acetylation of two HSV1 
vector genomes......................................................................................................... 250
5.9.1 Acetylation of the LAT regulatory region.................................................256
5.9.2 Acetylation of the exogenous CMV promoter.........................................257
5.10 Discussion.................................................................................................................. 259
CHAPTER 6: DISCUSSION..............................................................................................265
REFERENCES.................................................................................................................... 273
11
List of figures
List of figures
CHAPTER 1
Figure 1-1 Diagram of the HSV1 virion and the structure of the genome................ 27
Figure 1-2 Cell surface receptors and viral glycoproteins that participate in HSV1
entry................................................................................................................ 29
Figure 1-3 The HSV1 lytic gene regulatory cascade................................................... 36
Figure 1-4 Organisation of the LAT region...................................................................43
Figure 1 -5 Schematic representation of the two LAT promoters............................... 51
Figure 1-6 Cassettes used within HSV1 with long-term expression..........................57
Figure 1 -7 Core promoter elements.............................................................................. 62
Figure 1 -8 Schematic diagram of a nucleosome......................................................... 66
Figure 1 -9 Two types of insulator function.................................................................... 72
CHAPTER 3
Figure 3-1 Diagram of the LATP2 region and the surrounding genome................... 99
Figure 3-2 Schematic diagram of the structure of 1764/UL43/pR20.9................... 100
Figure 3-3 Sequence of LATP2 showing putative TF binding sites......................... 103
Figure 3-4 Schematic of LATP2 deletion cassettes..................................................106
Figure 3-5 Gel photos showing PCRs on all five plasmid constructs with primers
for each section of LATP2 and the respective PCR program used.... 107 
Figure 3-6 Structure of the LATP2 deletion cassettes in UL43 flanking regions.. 109
Figure 3-7 LacZ activity of LATP2 deletion plasmids In Vitro.................................. 111
Figure 3-8a GFP expression from plasmids in BHK cells............................................112
Figure 3-8b GFP expression from plasmids in ND7 cells............................................ 113
Figure 3-9 Homologous recombination to produce recombinant HSV vectors.... 116
Figure 3-10 Southern Blot analysis of Viral Recombinants.........................................117
Figure 3-11 Plaque phenotype of two replication competent vectors........................ 119
Figure 3-12 LATP2 deletion virus plaques showing lacZ and GFP expression 120
12
List of figures
Figure 3-13 Growth Curves of the LATP2 deletion viruses.........................................121
Figure 3-14 In vitro p-galactosidase assays............................................................... 124
Figure 3-15a BHK cells infected at MOI = 0 .1 .......................................................125
Figure 3-15b ND7 cells infected at MOI = 1 ...................................................................126
Figure 3-15c ND7 cells infected at MOI = 5 ...................................................................127
Figure 3-16 LacZ expression from LATP2-deletion viruses 3 days post-injection in
Balb/C mice.................................................................................................132
Figure 3-17 Photographs of lacZ and GFP expression from LATP2-deletion
viruses 3 days post-injection in Balb/C mice..........................................133
Figure 3-18 LacZ expression from LATP2-deletion viruses 1 month post-injection
in Balb/C SCID mice.................................................................................136
Figure 3-19 Representative ganglia from Balb/C SCID mice 1 month post-injection
showing lacZ and GFP expression...........................................................137
CHAPTER 4
Figure 4-1 Schematic representation of LATP2 deletion cassettes......................... 144
Figure 4-2 Gel photos showing PCRs on all seven plasmid constructs with
primers for each section of LATP2 and the respective PCR program
used.............................................................................................................. 145
Figure 4-3 Schematic representation of the cassettes in the UL43 flanking
regions..........................................................................................................147
Figure 4-4 Digestion with Not1 of the cassettes in UL43 flanking regions 148
Figure 4-5 LacZ activity of series 2 & 3 LATP2 deletion plasmids in vitro 150
Figure 4-6a Photographs of transient transfections in BHK cells -  series 2
plasmids....................................................................................................... 151
Figure 4-6b Photographs of transient transfections in BHK cells -  series 3
plasmids........................................................................................................152
13
List of figures
Figure 4-6c Photographs of transient transfections in ND7 cells -  series 2
plasmids....................................................................................................... 153
Figure 4-6d Photographs of transient transfections in ND7 cells -  series 3
plasmids....................................................................................................... 154
Figure 4-7 Homologous recombination to produce recombinant HSV vectors.... 159
Figure 4-8a Southern blot analysis of viral recombinants -  series 2 viruses.160
Figure 4-8b Southern blot analysis of viral recombinants -  series 3 viruses.161
Figure 4-9a Example plaques expressing lacZ-  series 2 viruses.............................163
Figure 4-9b Example plaques expressing lacZ- series 3 viruses.............................164
Figure 4-10a Growth curves of series 2 viruses.......................................................... 166
Figure 4-1 Ob Growth curves of series 3 viruses.......................................................... 166
Figure 4-11 In vitro |3-Galactosidase assays...............................................................169
Figure 4-12a Examples of infected BHK cells -  series 2 viruses.............................. 170
Figure 4-12b Examples of infected BHK cells -  series 3 viruses.............................. 171
Figure 4-12c Examples of infected ND7cells (MOI = 1) -  series 2 viruses............... 172
Figure 4-12d Examples of infected ND7cells (MOI = 1) -  series 3 viruses............... 173
Figure 4-12e Examples of infected ND7cells (MOI = 5) -  series 2 viruses...............174
Figure 4-12f Examples of infected ND7cells (MOI = 5) -  series 3 viruses...............175
Figure 4-13 LacZ expression from LATP2-deletion viruses 3 days post-injection in
Balb/C mice.................................................................................................180
Figure 4-14a Representative ganglia 3 days post-injection showing lacZ expression
-  series 2 viruses........................................................................................ 181
Figure 4-14b Representative ganglia 3 days post-injection showing lacZ expression
-  series 3 viruses........................................................................................ 182
Figure 4-15 LacZ expression from LATP2-deletion viruses 1 month post-injection
in Balb/C SCID mice...................................................................................187
Figure 4-16a Example ganglia 1 month post-injection showing lacZ expression -  
series 2 viruses............................................................................................189
14
List of figures
Figure 4-16b 
Figure 4-17
CHAPTER 5 
Figure 5-1
Figure 5-2 
Figure 5-3 
Figure 5-4
Figure 5-5 
Figure 5-6
Figure 5-7
Figure 5-8
Figure 5-9
Figure 5-10
Figure 5-11 
Figure 5-12 
Figure 5-13 
Figure 5-14
Example ganglia 1 month post-injection showing lacZ expression -
series 3 viruses.......................................................................................... 190
Schematic illustration of the proposed location of enhancer and long­
term expression functions within LATP2................................................ 197
Schematic diagram showing the structures of the two viruses used in
the acetylation study...................................................................................205
Basic illustration of the ChIP assay......................................................... 207
1764 4- 27-pR19GFP virus in the complementing cell line 27/12/M:4212
1764 4- 27-pR19GFP virus in a panel of non-complementing cell lines
.......................................................................................................................214
1764 4- 27-pR19GFP virus in a 1° DRG Culture...................................215
1764 4- 27-pR19GFP virally infected and TUJ1 -stained primary DRG
culture...........................................................................................................216
PCR on cDNA made from RNA of ND7 cells infected with 1764 4- 27-
CMVGFP/5................................................................................................. 218
PCR on cDNA made from RNA of a primary DRG culture infected with
1764 4- 27- CMVGFP/5............................................................................ 219
ND7 cells infected with 1764 4- 27- pR19GFP and 1764 4- 27-
CMVGFP/5 after 3 days.............................................................................220
Micrococcal nuclease digestion of HSV1 lytic and latent viral
chromatin..................................................................................................... 222
Sonication of infected samples.................................................................225
Optimisation of PCR conditions for primers used in ChIP assays........228
PCR for ChIP assay validation.................................................................229
Agarose gel from PCR of input samples from uninfected and infected 
cell lines........................................................................................................231
15
List of figures
Figure 5-15 PCR from ChIP assay of 1764 4- 27- CMVGFP-5 virus in lytic and
latent infections........................................................................................... 233
Figure 5-16 ChIP assay on 1764 4- 27- pR19GFP in ND7 cells 3 days p.i............. 235
Figure 5-17 ChIP assay on 1764 4- 27- pR19GFP on ND7 and 27/12/M:4 cells. .237
Figure 5-18 PCR of 1764 4- 27- CMVGFP/5 viral DNA using all primers at 60°C
annealing temperature............................................................................... 239
Figure 5-19 Standard curves generated by qPCR...................................................... 240
Figure 5-20 Standard curves for ChIP assay on ND7 cells infected with 1764 4-
27- CMVGFP/5 3 days p.i..........................................................................242
Figure 5-21 IP values obtained for each promoter tested in 1764 4- 27-
CMVGFP/5................................................................................................. 243
Figure 5-22 Relative acetylation of histone H3 at promoters in 1764 4- 27- 
CMVGFP/5 3 days p.i. in ND7 cells compared to at the TK promoter.244 
Figure 5-23 Standard curves for ChIP assay on 27/12/M:4 cells infected with 1764
4- 27- pR19GFP 1 day p.i..........................................................................247
Figure 5-24 IP values obtained for each promoter tested in 1764 4- 27- pR19GFP
......................................................................................................................248
Figure 5-25 Relative acetylation of histone H3 at promoters in 1764 4- 27- 
pR19GFP 1 day p.i. in 27/12/M:4 cells compared to at the TK
promoter.......................................................................................................249
Figure 5-26 Acetylation values of promoters within 1764 4- 27- CMVGFP/5 during
acute and latent infection..........................................................................252
Figure 5-27 Acetylation values of promoters within 1764 4- 27- pR19GFP during
acute and latent infection...........................................................................253
Figure 5-29 Comparison of acetylation of histone H3 at promoters in two different
viral vectors..................................................................................................255
Figure 5-29 Mean acetylation values (IP/Input) relative to CMV acetylation values 
in two different viral vectors.......................................................................258
16
List of tables
List of tables
CHAPTER 3
Table 3-1 Primers used in PCR reactions for I.ATP2 deletion fragments................. 107
Table 3-2 Averaged counts of /acZ-positive neurons 3 days p.i................................. 132
Table 3-3 Averaged counts of /acZ-positive neurons 1 month p.i...............................136
CHAPTER 4
Table 4-1 Difference in size of fragment ‘x’ depending on the orientation of each
cassette............................................................................................................147
Table 4-2 Averaged counts of /acZ-positive neurons 3 days p.i................................. 179
Table 4-3 Averaged counts of /acZ-positive neurons 1 month p.i...............................186
CHAPTER 5
Table 5-1 Primers used in RT PCR reactions............................................................... 217
Table 5-2 PCR primers used for detection in the ChIP assay................................... 227
Table 5-3 IP values from qPCR for ND7 cells infected with 1764 4- 27- CMVGFP/5
3 days p.i.......................................................................................................... 243
Table 5-4 IP values from qPCR of 27/12/M:4 cells infected with 1764 4- 27- 
pR19GFP 1 day p.i......................................................................................... 248
17
Abbreviations
Abbreviations
A adenosine
BHK baby hamster kidney
BHV bovine herpes virus
bp base pair
BSA bovine serum albumin
C cytosine/centigrade
CAT chloramphenicol acetyltransferase
ChIP chromatin immunoprecipitation
CMC carboxymethylcellulose
CMV cytomegalovirus
CNS central nervous system
(M
OO
carbon dioxide
CPE cytopathic effect
CPRG chlorophenolred-G-D-galactopyranoside
CRE cyclic AMP response element
DEPC diethylpyrocarbonate
DMEM Dulbecco’s modified Eagle’s medium
DMF dimethylformamide
DMSO dimethylsulphoxide
DNA deoxyribonucleic acid
DRG dorsal root ganglia
ds double stranded
E early gene
EBV Epstein Barr virus
EDTA ethylenediaminetetra-acetic acid
EGFP enhanced green fluorescent protein
18
Abbreviations
Egr early growth
elF eukaryotic initiation factor
ER endoplasmic reticulum
FCS foetal calf serum
FGM full growth media
Fig figure
g gram
G guanosine
Gal galactosidase
gB glycoprotein B (similarly for other glycoproteins)
GFP green fluorescent protein
GDNF glial-derived neurotrophic factor
H histone
Hr(s) hour(s)
HAT histone acetyltransferase
HBSS Hank’s balanced salt solution
HCF host cell factor
HD AC histone deacetylase
HEBES HEBES transfection buffer
HMBA hexamethylene bisacetamide
HMG high motility group
HMT histone methyltransferase
HSDNA herring sperm DNA
HSV herpes simplex virus
HVEM herpesvirus entry mediator
IAA isoamyl alcohol
ICP infected cell polypeptide
IE immediate early gene
19
Abbreviations
IFN interferon
ig immunoglobulin
ip immunoprecipitation/immunoprecipitated
IRES internal ribosomal entry site
K lysine
Kb kilobase
KDa kilodalton
L late gene
LAP Latency active promoter
LAT latency associated transcript
LATP LAT promoter
LB Luria Bertani
LMP low melting point
LTE long-term expression
LTR long-terminal repeat
M molar
mg milligram
MHC major histocompatibility complex
min(s) minute(s)
mL millilitre
mm millimetre
mM millimolar
MMLV murine moloney leukaemia virus
MOI multiplicity of infection
mRNA messenger RNA
MS master stock
MW molecular weight
NaCI sodium chloride
20
Abbreviations
NaOH sodium hydroxide
ND7 mouse neuroblastoma DRG fusion cell line
ng nanogram
NGF nerve growth factor
nM nanomole
NP40 nonidet P40
nt nucleotide
oct octamer
OD optical density
O/N overnight
ORF open reading frame
ori origin of replication
P plasmid
pA polyA; polyadenylation
PBS phosphate buffered saline
PCR polymerase chain reaction
PFA paraformaldehyde
pfu plaque forming units
p.i. post-infection/post-injection
PML pro-myeolytic leukaemia
PNS peripheral nervous system
pol polymerase
qPCR quantitative PCR
R arginine
RL repeated long
RNA ribonucleic acid
rpm revolutions per minute
RS repeated short
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Abbreviations
RSV rous sarcoma virus
RT room temperature
S serine
SD standard deviation
SDS sodium dodecyl sulphate
SEM standard error of the mean
S/N supernatant
SSC standard sodium citrate
SV40 simian virus 40
T thymidine
TAE tris-acetate EDTA buffer
TAP transporter of antigen processing
TE Tris/EDTA
TF transcription factor
TG trigeminal ganglia
TIF trans-inducing factor
TK thymidine kinase
Tm melting temperature
TNF tumour necrosis factor
Tris tris-acetate EDTA buffer
TSA trichostatin A
UL unique long
Us unique short
USF upstream stimulatory factor
V volt
vhs virion host shut-off
VP virion protein
v/v volume for volume
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VZV varicella zoster virus
WT wild type
w/v weight for volume
X-Gal 4-chloro, 5-bromo, 3-indolyl-p-galactosidase
pg microgram
pL microlitre
I^M micromole
-ve negative
+ve positive
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1.1 HERPES SIMPLEX VIRUSES
The herpesviruses are classified into 3 types: a, p and y. This distinction is made by 
the tissue tropism, cytopathology and the duration of the replicative cycle of the virus.
The a-herpesviruses infect humans, have a short replicative cycle and are neurotropic, 
although in vivo and in vitro they have been shown to infect a broad range of cell types 
as well as neurons. Members of the a subfamily are herpes simplex virus 1 (HSV1), 
herpes simplex virus 2 (HSV2) and varicellar zoster virus (VZV).
The p- and y-herpesviruses have a slower replicative cycle and infect a narrower range 
of cells, primarily those of lymphatic or glandular origin, p-herpesviruses are typified by 
cytomegalovirus (CMV) and y-herpesviruses by epstein barr virus (EBV).
All herpesviruses are able to establish and maintain latent infections for the lifetime of 
the host, with the ability to reactivate in response to appropriate stimuli and thus cause 
symptoms long after the time of primary infection.
1.1.1 HSV 1 and 2
HSV1 is endemic within the human population, with approximately 80% of individuals 
testing positive for antibodies to HSV1, although a considerably lower percentage 
show symptoms of the disease. HSV2 is a little less prevalent within the population 
(Rouse and Gierynska 2001). Both viruses infect mucosal surfaces of either the 
orofacial (HSV1) or genital (HSV2) region and produce the symptoms of cold sores or 
genital herpes respectively (Whitley 1996). Very rarely they can cause ocular infection 
or infect the central nervous system (CNS) and cause encephalitis (Kennedy 1984).
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1.1.2 HSV1 Biology
HSV1 is a large (150-200nm in diameter) enveloped virus with a distinct virion 
structure characteristic of the herpesviruses. An HSV virion consists of a core 
containing viral DNA, an icosahedral capsid; a tegument containing viral proteins 
(about 65% of the virion mass consisting of approximately 14 proteins) and a lipid 
bilayer envelope through which protrude viral glycoprotein spikes (Wildy et al. 1960). 
The virion structure is illustrated in figure 1-1 a.
The viral genome is a linear double-stranded DNA molecule packaged within the 
capsid (Becker et al. 1968). It is approximately 152Kb long and encodes at least 80 
genes either essential for replication or non-essential (i.e. they can be deleted without 
affecting virus growth). The genome is composed of long and short unique segments 
(UL and Us respectively) flanked by terminal repeat regions (RL and Rs respectively). 
The unique segments are covalently linked and can invert relative to each other to 
generate four possible isoforms that are equally functional and exist in equimolar 
concentrations in infected cells (Hayward et al. 1975; Jacob et al. 1979; Roizman 
1979).
HSV1 contains 3 origins of replication: one in the UL region (called OriL) and one in 
each of the Rs regions (OriS). Either Ori is sufficient for replication (Igarashi et al. 
1993; Polvino-Bodnar et al. 1987). The structure of one viral genome isoform is shown 
in figure 1-1 b.
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Glycoproteins
Capsid
Double
stranded DNA
Tegument
Lipoprotein
envelope
Figure 1-1 Diagram of the HSV1 virion and the structure of the genome
a. The HSV virion consists of double-stranded DNA protected by a 
nucleocapsid and surrounded by the tegument proteins. The lipoprotein 
envelope studded with glycoproteins surrounds the internal structures.
b. The HSV genome is organised into the unique long and short regions 
flanked by the long and short repeats (a, b and c). The ‘a’ regions contain 
sequences for packaging. The three origins of replication are also shown.
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1.1.2.1 Cell attachment and entry
HSV1 infects cells of the mucosal epithelia, replicates and following which the virus 
enters nearby nerve endings. Initial contact of HSV with a cell is with heparan sulphate 
(HS) of the cell surface proteoglycan, to which the virus binds (Shukla and Spear 
2001). Two of the virion glycoproteins, gC or gB are able to bind to heparan sulphate. 
gB requires the presence of gC for binding and if both are missing, binding is greatly 
reduced (Herold etal. 1994).
For entry into the cell, the virus then requires gD to bind to any one of several cell 
surface receptors. There are 3 classes of entry receptors: herpes virus entry mediator 
(HVEM or HVEa), which is a member of the TNF receptor family; nectin-1, a member 
of the immunoglobulin superfamily; and specific sites in heparan sulphate generated 
by certain 3-O-sulfotransferases (Shukla et al. 1999). Nectin-1 is involved in neuronal 
entry (Richart et al. 2003), whilst heparin sulphate and HVEM are expressed in a 
variety of cell types and are highly conserved amongst mammals (Shukla and Spear 
2001), which may go someway to explain the broad host range for HSV1, at least in 
cell culture.
The binding of gD to one of the cell-surface receptors triggers fusion of the viral 
envelope with the cell membrane (Morgan et al. 1968). This requires the action of the 
glycoproteins gB and a heterodimer of gH-gL, although the exact mechanism by which 
fusion occurs is unknown. The interaction of viral glycoproteins and cell-surface 
receptors is illustrated in figure 1-2.
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FUSION
BINDING 3-O-S
HS gC
HVEM
Nectin-1
Adapted from (Spear 2004)
Figure 1-2 Cell surface receptors and viral glycoproteins that participate in HSV1 
entry
Five of the viral glycoproteins are involved in entry of the host cell. Binding is 
mediated by gB and/or gC to heparan sulphate (HS) chains, which facilitates 
gD binding with one of the cell surface receptors, which in turn leads to fusion.
Following fusion, the viral nucleocapsid and tegument enter the cell cytoplasm. The 
nucleocapsid and some tegument proteins (e.g. VP16) are transported to the nucleus 
via microtubules by the cellular motor protein dynein (Sodeik et al. 1997). Other 
tegument proteins such as vhs and US11 remain in the cytoplasm. Once at the 
nucleus, the nucleocapsid empties the DNA into the nucleus through a nuclear pore 
demonstrated by the fact that empty viral capsids have been shown to accumulate at 
the nuclear envelope and associate with nuclear pore structures (Batterson et al. 
1983; Sodeik et al. 1997).
Once in the nuclei, the viral genome may participate either in a lytic or a latent 
infection.
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1.1.2.2 Configuration of viral DNA
There is some debate as to the conformation that the viral DNA takes up on entering 
the cell nucleus. It was thought for many years that soon after entry, the linear DNA is 
circularised, possibly by the involvement of the cellular RCC1 (regulator of 
chromosome condensation) (Poffenberger and Roizman 1985; Umene and Nishimoto
1996). It is then thought to maintain this structure whether undergoing the lytic cycle, 
where the circular genome is a template for replication, or entering latency where the 
genome is mainly dormant (see section 1.1.2.4).
However some evidence has recently been provided for a linear template for viral DNA 
replication (Jackson and DeLuca 2003) regulated by ICPO, as in one study, circular 
genomes were only seen with ICPO mutants where lytic replication is inhibited. This 
data however has recently been challenged by experiments that again showed circular 
genomes early in infection that are not inhibited by ICPO (Strang and Stow 2005).
Whichever conformation the viral DNA takes, it is deposited at ND10 or PML bodies 
within the host nucleus where IE gene transcription ensues (Maul and Everett 1994). It 
is not known whether the genomes diffuse to the ND10 sites or are deposited there by 
the cell, but this occurs in the absence of prior viral protein synthesis.
It was previously thought that the viral genome was not associated with nucleosomes 
during lytic replication (Leinbach and Summers 1980). However, recent experiments 
repeating this work showed that the viral DNA does indeed take on a nucleosomal 
structure early in infection and also that it has associated histone modifications 
consistent with an active genome (Kent et al. 2004). The role of histone modifications 
in the regulation of the HSV genome will be discussed in chapter 5.
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1.1.2.3 The lytic cycle
During lytic infection, viral proteins in the tegument direct cellular resources away from 
host cell metabolism to the virus’ advantage. E.g. vhs (UL41) shuts off cellular protein 
synthesis and degrades mRNAs (Fenwick and McMenamin 1984; Schek and 
Bachenheimer 1985; Strom and Frenkel 1987), although this includes viral mRNAs as 
well as those of the host.
During the lytic cycle, the HSV1 genes are transcribed and expressed in a highly 
regulated cascade in groups classified as immediate early (IE) or a, early (E) or (3, and 
late (L) or y relating to their time of expression from initial infection (Honess and 
Roizman 1974). The lytic gene cascade is illustrated in figure 1-3.
Transcription of the IE genes is stimulated by the HSV tegument protein VP16 (or 
vmw65), brought into the nucleus by host cell factor (HCF) along with the viral DNA 
(Batterson et al. 1983; La Boissiere et al. 1999). VP16 interacts with at least two 
cellular proteins to achieve this. Oct-1 is a POU domain transcription factor (Sturm et 
al. 1988) that recognises and binds to the TAAT region of the TAATGARAT regulatory 
elements found in each IE gene promoter. VP16 forms a complex with HCF and then 
binds to the Oct-1/TAATGARAT complex through the POU domain and the GARAT 
sequence (Gerster and Roeder 1988; Katan et al. 1990; Kristie and Sharp 1990; 
O'Hare etal. 1988; Preston etal. 1988; Stern and Herr 1991; Stringer et al. 1990; Xiao 
and Capone 1990). Recently the Oct-1 protein has been shown to only be required at 
a low multiplicity of infection (MOI) (Nogueira et al. 2004), suggesting that interactions 
of VP16 with other factors may also be important. A potent VP16 transcriptional 
activation domain then activates IE gene transcription, probably through interaction 
with TFIIB and TFIID (Gupta et al. 1996; Stringer et al. 1990; Triezenberg et al. 1988). 
Mutation of VP16 produces a virus greatly reduced in infectious properties (Ace et al.
1989). One other potential function of VP16 is its interaction with vhs, which it is
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thought to downregulate and therefore prevent degradation of viral mRNAs (Lam et al. 
1996; Matis etal. 2001; Mossman etal. 2000).
Transactivation by VP16 of IE gene transcription occurs without prior viral protein 
synthesis. There are 5 IE gene products -  infected cell polypeptide (ICP) 0, 4, 22, 27 
and 47. With the exception of ICP47, all of the IE gene transcripts regulate the 
expression of the remaining genes. Transcription of these and all subsequent viral 
genes is carried out by the host cell’s RNA polymerase II (Alwine et al. 1974; Costanzo 
etal. 1977).
1.1.2.3.1 The IE genes
ICPO is a multifunctional protein. It is not essential for viral replication, but ICPO mutant 
viruses are impaired for growth at low multiplicities of infection (MOIs) (Sacks and 
Schaffer 1987; Stow and Stow 1986). It is a non-specific transactivator and can induce 
the expression of all classes of viral gene promoters as well as non-HSV promoters 
(Everett 1984; Gelman and Silverstein 1985; Nabel et al. 1988; O'Hare and Hayward 
1985; Quinlan and Knipe 1985). ICPO also interacts with ICP4, increasing activation of 
gene expression (Gelman and Silverstein 1986; Quinlan and Knipe 1985). ICPO is a 
RING finger zinc-binding protein with E3 ubiquitin ligase activity which appears to 
target many cellular proteins for degradation via the proteasome pathway (Everett et 
al. 1999; Lomonte et al. 2001). ICPO accumulates at PML bodies, also called ND10s, 
which is also where viral replication occurs, and causes their disaggregation (Everett 
and Maul 1994; Maul et al. 1993; Maul and Everett 1994). One other possible function 
of ICPO is that is thought to be involved in inhibiting the host cell’s interferon and 
antiviral responses early in infection (Eidson et al. 2002). ICPO null viruses can infect 
cells, but the genomes then tend to become quiescent. This repression can be 
overcome by introducing ICPO in trans (Harris et al. 1989; Samaniego et al. 1998; Zhu 
et al. 1990). ICPO has a possible function in latency and reactivation because the gene 
is transcribed antisense to the LAT gene (see later) and viruses lacking ICPO are
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unable to reactivate (Halford and Schaffer 2001). The finding that ICPO does not 
accumulate in the nucleus of neuronal cells may account for the preference to 
establish latency in these cells (Chen et al. 2000) and may be the reason that the 2kB 
LAT potentially encodes a protein which can substitute for its function (Thomas et al. 
1999a).
ICP4 is an essential regulatory protein encoded by the RS1 gene and is therefore 
present twice in the viral genome. It is necessary for the activation of both early and 
late gene expression (Watson and Clements 1980). It also functions to repress the 
expression of some viral genes, including itself, which it carries out via a direct binding 
to the respective gene promoters (DeLuca et al. 1985; O'Hare and Hayward 1985). 
The activation function is thought to occur via interaction with components of the basal 
transcription apparatus but not by direct binding. ICP4 can bind the HMG1 protein, 
which has the ability to cause DNA bending, and it is thought to then facilitate the 
interaction of ICP4 with TFIID (Carrozza and DeLuca 1998; Carrozza and DeLuca 
1996; Grondin and DeLuca 2000; Gu et al. 1993; Gu et al. 1995; Gu and DeLuca 
1994; Kuddus et al. 1995). Certain mutations in ICP4 effect early, but not late gene 
expression, suggesting that ICP4 may act differently on these promoters. Work has 
shown that this is in fact due to the interaction with different TFs or the I nr element, 
depending on whether the promoter is for an E or L gene (DeLuca et al. 1984; DeLuca 
and Schaffer 1988; Zabierowski and DeLuca 2004).
ICP27 is also essential for the replication of HSV1 and has multiple functions, both 
transcriptional and post-transcriptional. ICP27 is required for the progression of the 
expression cascade from E to L gene expression (McCarthy et al. 1989; Rice and 
Knipe 1990; Sacks et al. 1985) and transactivates a subset of early genes involved in 
DNA replication and also downregulates the expression of some IE and E genes via 
interaction with ICP4 and ICPO (Hardwicke et al. 1989; McCarthy et al. 1989; 
McGregor etal. 1996; McMahan and Schaffer 1990; Rice and Knipe 1990; Sacks et al.
33
Chapter 1 Introduction
1985; Sekulovich etal. 1988; Uprichard and Knipe 1996). Post-transcriptionally ICP27 
inhibits mRNA splicing, which gives an advantage to viral over cellular transcripts, as 
only four viral transcripts contain introns, and three of these are in IE genes which are 
spliced before maximal inhibition takes place (Hardy and Sandri-Goldin 1994). The 
inhibition has been shown to occur through the interaction of ICP27 with a cellular 
protein known to inhibit splicing (Bryant et al. 2000). Another important function of 
ICP27 is that it binds RNA and shuttles it to the cytoplasm from the nucleus, thus 
mediating the export of intronless viral mRNA (Mears and Rice 1998; Phelan et al. 
1996; Sandri-Goldin 1998; Soliman etal. 1997).
ICP22 is not essential for viral replication in all situations (Sears et al. 1985), but it is 
necessary for the optimal expression of some late genes. ICP22 interacts with several 
cell cycle regulated proteins including cdc2 protein kinase that is activated in HSV- 
infected cells. Cdc2 kinase is involved in expression of the same set of late genes 
activated by ICP22 and thus possibly this function is mediated by the kinase (Advani et 
al. 2000). Another function of ICP22 is that it modifies the host RNA pol II by 
phosphorylating the large subunit. This generates a novel form that specifically 
represses host cell transcription (Long et al. 1999; Rice et al. 1995; Spencer et al.
1997). Finally, ICP22 also increases the stability and splicing of ICPO mRNA (Carter 
and Roizman 1996).
ICP47 is non-essential for viral replication, but plays an important role in evading host 
immune responses. It does this by blocking presentation of viral peptides at the cell 
surface (Jackson and Peterson 1993). ICP47 binds to the transporter of antigen 
processing (TAP) complex and prevents peptide binding and thus translocation into 
the endoplasmic reticulum (ER) (Hill et al. 1995; Hill et al. 1994).
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1.1.2.3.2 The E genes
Following IE gene expression, the E genes are transcribed. E gene products are 
primarily involved in viral DNA synthesis and encode proteins such as DNA binding 
proteins (e.g. ICP8, DNA polymerase, thymidine kinase (TK) and ribonucleotide 
reductase (RR)) as well as the ori binding proteins and the helicase/primase complex. 
When the E gene products are present in sufficient quantities, DNA replication can 
begin (Challberg 1986; Conley etal. 1981; Purifoy etal. 1977; Wu etal. 1988).
As mentioned, viral DNA replication occurs at ND10 structures in the nucleus and as 
synthesis progresses, the progeny DNA molecules accumulate in globular structures 
called replication compartments (Quinlan et al. 1984). DNA replication proceeds from 
the viral template, which as discussed in section 1.1.2.2, is thought to occur from a 
circular template by a rolling-circle mechanism producing concatemeric molecules. 
This is then cleaved and packaged into single units which make up the progeny 
genomes (Jacob etal. 1979).
1.1.2.3.3 The L genes
Concurrently with DNA replication, viral late genes start to be expressed, whilst early 
gene expression begins to subside. The majority of the late genes encode structural 
proteins of the capsid, tegument and envelope and on synthesis of these, progeny 
viral particles begin to assemble.
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Figure 1-3 The HSV1 lytic gene regulatory cascade
Transcription of IE genes is transactivated by VP16. Expression of IE genes is 
required for expression of E and L genes. Known regulatory effects are marked 
in red (positive) and blue (repressive). There are a number of other interactions 
between IE genes that contribute to the regulation, which have been left off for 
purposes of clarity.
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1.1.2.3.4 Encapsidation, virion assembly and egress
Encapsidation of viral DNA occurs in replication compartments (Lamberti and Weller 
1998; Ward et al. 1996). Capsids form in the nucleus and require at least 7 capsid 
proteins. The process does not require any cellular factors (Newcomb et al. 1999). The 
viral DNA is packaged into capsids through recognition of the ‘a’ sequence and 
cleavage of the concatemers occurs at this time also through sequences at the same 
site (Deiss et al. 1986; Poffenberger and Roizman 1985; Stow et al. 1983). The exact 
mechanism of this nucleocapsid formation is not well understood however.
The fully formed nucleocapsids bud through the inner nuclear membrane (Vlazny et al. 
1982). During this process they acquire a tegument and some of these tegument 
proteins, e.g. VP16, are required for envelopment at the inner nuclear membrane 
(Weinheimer et al. 1992).
There are two proposed routes of virion egress. The first is the re-envelopment model, 
in which enveloped virions would fuse with the outer nuclear membrane and release 
nucleocapsids into the cytoplasm. These would then re-envelope by budding into the 
Golgi compartment and subsequently are secreted from the cell via a vesicular route 
(Siminoff and Menefee 1966). The second pathway is the lumenal pathway model in 
which enveloped virions would traffic from the nucleus to the Golgi compartment in 
vesicles or within the lumen of the endoplasmic reticulum (ER) and be released from 
the cell by a normal secretory route (Enquist et al. 1998). The re-envelopment pathway 
appears to have more supporting evidence than the lumenal pathway (Granzow et al. 
2001; Skepperetal. 2001).
Viral spread from cell to cell can occur through the extracellular space as well as 
through cell junctions. The gE and gl glycoproteins are required for this method of 
virus movement (Dingwell et al. 1994; Dingwell and Johnson 1998). In neurons, there 
is limited replication of HSV1; therefore the virus is transported from neuron to neuron
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via the nerve terminals. This occurs more rapidly than to other non-neuronal cells 
(Kuypers and Ugolini 1990).
1.1.2.4 Latency
Following productive infection in the mucosal epithelium, HSV1 enters the innervating 
sensory neurons and is transported to the ganglia where it can establish a life-long 
latent state. During this time, no lytic-cycle genes are expressed and the genome is 
transcriptionally silent apart from the duplex LAT region, which produces RNA species 
called LATs. Periodic reactivation can occur, leading to lytic infections in the same or 
similar sites as the initial infection.
1.1.2.4.1 Establishment and maintenance of latency
It is thought that the outcome of infection is determined early on and that the lytic cycle 
and latency can reflect distinct pathways. During the first few days following mouse 
footpad infection, neurons of the dorsal root ganglia (DRG) either produce lytic cycle 
proteins or LATs but not both (Margolis et al. 1992). Where limited replication of virus 
is supported in sensory neurons (Knotts et al. 1974; Kramer et al. 1998), this is 
eventually turned off (or in some cases to a very low level) and the genomes tend to 
turn quiescent without producing LATs. These differences in the establishment of 
latency have lead to a number of theories as to by which mechanism it occurs.
There is much evidence to show that latency can be established without prior lytic 
gene expression. An ICP4- virus cannot express E or L proteins but has been shown 
to establish latency (Dobson et al. 1990; Katz et al. 1990; Sedarati et al. 1993) and 
also the //?1814 virus which has a mutation in VP16 and so prevents transactivation of 
the IE genes (Ace et al. 1989) can establish latency as efficiently as wild-type virus 
(Ecob-Prince et al. 1993; Steiner et al. 1990; Valyi-Nagy et al. 1991; Valyi-Nagy et al. 
1992).
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It was suggested that factors present in neurons but not other cells might lead to this 
block in replication. One possibility is based on the suggestion that in cells which are 
not permissive for a lytic infection, splice variants of the POU domain protein Oct-2 
compete with Oct-1 for the TAATGARAT binding site (Lillycrop et al. 1991). These 
isoforms cannot interact with VP 16 and so transactivation of the IE gene promoters 
does not ensue (Lillycrop et al. 1993). It was reported that when the Oct-2 splice 
variants were transfected into cells that were permissive for HSV1 replication, IE gene 
expression was dramatically reduced. It was proposed that this would then abort the 
lytic infection at an early stage and force the virus into latency. In support of this, Oct-1 
is a ubiquitous cellular protein whereas the Oct-2 isoforms are only found in neurons, 
consistent with the primary sites of establishment of lytic and latent infections, 
respectively. However, there have been failed attempts to reproduce these findings 
and there has been some controversy over whether the type of neurons capable of 
harbouring a latent infection actually express Oct-2 (Hagmann et al. 1995; Turner et al.
1996). Therefore, if Oct-2 is involved with the repression of IE gene transcription, it 
may not be the only factor and other POU-domain proteins found in neurons have also 
been implicated (Hagmann etal. 1995; Turner et al. 1997).
Other possibilities for the block to IE gene transcription include the observation that 
HCF is distributed differently in neuronal and non-neuronal cells. In neurons, HCF is 
found in the cytoplasm, whereas in most other cell-types it is found in the nucleus 
(Kristie et al. 1995; Kristie et al. 1999). It is therefore possible that in neurons VP16 is 
not transported to the nucleus and consequently IE genes do not become transcribed 
(La Boissiere et al. 1999). However, experiments which have shown that latency can 
be established even in the presence of functional VP16 suggest that this may not be 
the whole answer either (Sears et al. 1991).
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On establishment of latency, the infected cell can harbour up to several hundred 
copies of the viral genome (Efstathiou et al. 1986; Hill et al. 1996b; Hill et al. 1996a; 
Rock and Fraser 1983), although the number appears to be virus-strain dependent 
(Sawtell et al. 1998; Sawtell 1998). The number of harboured genomes appears to be 
maintained consistently throughout latency (Sedarati et al. 1989; Sedarati et al. 1993) 
as does the number of genomes expressing LATs (Hill et al. 1996a). However, it has 
been shown by in situ hybridisation that the number of neurons containing HSV1 DNA 
is 2-3 fold greater than the number of LAT-expressing neurons (Mehta et al. 1995). 
The LATs and their function in the maintenance of latency and reactivation will be 
discussed in more detail later.
1.1.2.4.2 Reactivation
During a clinical latent infection, a subset of the neurons containing latent genomes 
can reactivate, whereby infectious virus is carried in an anterograde fashion by axonal 
transport to peripheral sites of original infection (Colberg-Poley et al. 1981).
Reactivation can be caused by physical or psychological stress in humans (Young et 
al. 1976). In animal models, reactivation stimuli include neurectomy (Walz et al. 1974), 
chemical stimuli (Harbour et al. 1983), UV irradiation (Spurney and Rosenthal 1972), 
mild trauma (Hill et al. 1978) and transient hyperthermia (Sawtell and Thompson 
1992).
It is likely that viral replication during reactivation involves a different pathway to initial 
replication on infection, as VP 16 is not present in latently-infected cells, is a late gene, 
is not necessarily able to translocate to the nucleus and is not sufficient to stimulate 
reactivation (La Boissiere et al. 1999; Sears et al. 1991). It was shown that the first 
events leading to viral replication in reactivating neurons are initiation of DNA 
replication (Nichol et al. 1996) and expression of E genes (Tal-Singer et al. 1997), 
although there is also evidence that neuronal damage or other stimuli possibly activate
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cellular transcription factors (TFs) that substitute for VP16 and/or IE proteins to initially 
target the ICPO promoter, resulting in expression of ICPO (Loiacono et al. 2003; Tal- 
Singer etal. 1998).
As mentioned, it has been shown that the genome copy number in latently infected 
cells is virus-strain specific and that this relates to the ability to reactivate in vivo and 
the probability of doing so (Sawtell et al. 1998; Sawtell 1998). Deleting the same 
371 bp of the LAT region from two different virus strains and obtaining two different 
reactivation phenotypes illustrated this (Loutsch etal. 1999).
Various other deletions from viral genomes have led to an understanding of which 
genes are required for reactivation. A TK-null virus was able to establish a latent 
infection, but was unable to reactivate (Coen et al. 1989). ICPO is also not required for 
establishment of latency, but again is needed for reactivation (Cai et al. 1993; 
Clements and Stow 1989; Gordon et al. 1990; Leib et al. 1989), which lends further 
weight to the hypothesis that it is the ICPO promoter that is the first target in the 
reactivation process.
Viruses deleted in the LAT region are able to establish a latent infection, although it is 
thought more poorly than LAT-positive viruses (Izumi et al. 1989; Perng et al. 2000b; 
Perng et al. 2000a; Sedarati et al. 1989; Thompson and Sawtell 1997). Reactivation 
also does not absolutely depend on the presence of LAT in the genome (Block et al. 
1990; Ho and Mocarski 1989), but LAT-negative viruses reactivate with reduced 
frequency than wild-type viruses and not spontaneously (Block et al. 1993; Leib et al. 
1989; Perng et al. 1994). The spontaneous reactivation function of LAT in the rabbit 
model has been localised to a 348bp region within the first 1.5kb of the 8.3kb primary 
transcript (see below) (Bloom et al. 1996; Perng et al. 1996). It also appears that not 
all viruses that produce LATs reactivate (Ecob-Prince and Hassan 1994). Thus the
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exact function of the LAT region in the establishment, maintenance and reactivation of 
the HSV genome is not completely understood.
1.1.2.4.3 The LATs
The LATs are a family of RNA transcripts, originating from the complementary DNA 
strand to ICPO. They were first identified in latently infected sensory neurons by in situ 
hybridisation of murine ganglia and by northern blot (Stevens et al. 1987). They were 
also detected in rabbits and humans at around the same time (Croen et al. 1987; Rock 
etal. 1987; Spivack and Fraser 1987).
The LATs are generally thought to be the only genes to be transcribed during latency, 
although very low level expression of other genes has been shown during this time by 
PCR, including ICP4 and TK (Kramer and Coen 1995).
There are 3 species of LAT -  colinear transcripts of a minor 8.3kb species and two 
major species; one of 2kb that is spliced from the 8.3kb and another of 1.5kb that is 
further spliced from the 2kb LAT (Spivack and Fraser 1987; Wechsler et al. 1988b; 
Wechsler et al. 1988a). These are illustrated in figure 1-4. The 8.3kb transcript is only 
found during lytic infection and is polyadenylated (Dobson etal. 1989; Zwaagstra etal.
1990). The two smaller LATs are thought to be non-polyadenylated stable introns with 
a lariat structure. The unusual stability is attributed to a non-conventional splice- 
junction that is not recognised by cellular degradation factors (Krummenacher et al. 
1997; Mukerjee et al. 2004; Thomas et al. 2002a; Zabolotny et al. 1997). The 2kb LAT 
is produced during lytic infection and then a further splicing event occurs when latency 
has been established to form the 1.5kb LAT (Alvira et al. 1999).
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TATA
LAP2
Primary minor LAT (8.3kb)
ICPO (antisense)
Figure 1-4 Organisation of the LAT region
The LAT region is located in the long repeat regions of the genome, thus is 
present in two copies as indicated. The primary LAT is an unstable 8.3kb 
transcript. The major species are the smaller spliced LATs of 1.5 and 2 kb. The 
LATs are transcribed antisense and partially complementary to the gene for 
ICPO. The two latency-associated promoters are also shown (see section 
1.1.2.3.4).
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Since the LATs are the most abundant transcripts detected during latency it would 
seem reasonable to assume they have some role in the establishment of latency, 
and/or in maintenance and/or reactivation.
Despite this fact, the exact function of LATs still remains elusive after much 
investigation. On initial discovery, because they are transcribed antisense to ICPO, it 
was assumed that they would account for latency by blocking expression of ICPO, 
either keeping the ICPO transcripts in the nucleus, or binding with them and causing 
them to be degraded by dsRNA nucleases. Thus it was somewhat surprising, when as 
mentioned above, it was found that LAT- viruses still established a latent infection, 
albeit less efficiently than wild-type viruses (Izumi et al. 1989; Sedarati et al. 1989).
Interaction of LATs with ICPO has actually been demonstrated by the fact that LAT 
suppresses ICPO mRNA early in infection in vitro, as well as ICP4 and ICP27 mRNA, 
suggesting that a function of LAT could be to promote a latent infection and by 
ongoing production, allow latency to be maintained by the suppression of IE genes 
(Mador et al. 1998). Also, LAT-null mutant viruses led to increased accumulation of 
ICPO RNA in vitro (Arthur et al. 1998), reinforcing the argument that LATs suppress 
lytic gene expression. It was suggested that this block could be overcome upon 
reactivation by the E genes being expressed without the prior expression of the IE 
genes (Tal-Singer et al. 1997). More recently, however, it was demonstrated that a 
direct antisense mechanism between the 2 kb LAT and ICPO does not appear to occur 
in non-neuronal cell lines (Burton et al. 2003). These authors suggest that LAT effects 
are cell type specific and that it is unlikely that an antisense mechanism is mediated by 
the 2 kb LAT in vivo.
It has been shown that during latency the 2kb LAT is found in the nucleus, but in lytic 
infection, it can also be detected in the cytoplasm, where it interacts with ribosomal 
proteins, suggesting that perhaps LAT transcripts have a role in affecting the
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translational machinery or have a structural role in the ribosomal complex, perhaps 
serving to downregulate translation of IE genes and turn the virus towards a latent 
state (Ahmed and Fraser 2001; Goldenberg et al. 1997; Nicosia et al. 1994; Spivack 
and Fraser 1987; Stevens etal. 1987).
The observation of several ORFs within the LAT region has led to the suggestion that 
LAT might encode a protein that functions during latency (Lagunoff and Roizman 
1994). Furthermore, the related a-herpesvirus bovine herpes virus 1 (BHV1) produces 
a protein from within its LAT region, which possibly functions to prevent death of 
latently infected neurons (Schang et al. 1996). However, the fact that the HSV LAT 
transcripts are intranuclear during latency has not led to a great deal of support for this 
idea. Despite this, conserved ORFs have been found in the major 2kb LAT and 
deregulated expression of the largest of these has been shown to significantly 
enhance the growth of viruses deficient in IE genes and most notably ICPO (Thomas et 
al. 1999a). A myc-tagged version of this protein also colocalised to ND10 structures in 
vivo (Thomas et al. 2002b). This led the authors to propose a model whereby the LAT 
RNA acts as an antisense transcript to ICPO during the establishment and 
maintenance of latency but expresses a protein during reactivation, compensating for 
the lack of ICPO and other IE genes and thus allowing the lytic cycle to proceed. 
However, because if this protein were expressed, it would be tightly regulated and only 
be very rarely expressed, it has proved difficult to detect. As well as this, mutation of 
the LAT ORFs has failed to produce a phenotypically changed latency profile in animal 
models and thus this work has proved controversial.
A further role suggested for LAT is in keeping the latently infected neurons alive, either 
by dampening toxic IE gene expression or by preventing apoptosis.
Reducing IE gene expression as a means of promoting neuronal survival was first 
suggested as a function of LAT by groups investigating LAT in vivo (Chen et al. 1997;
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Garber et al. 1997; Perng et al. 1999). It was observed that the virulence of the virus 
increased when the LAT gene was deleted and increased IE levels were seen. Other 
work carried out in vitro also gave weight to the theory that this was effected by LATs 
(Farrell etal. 1991; Mador et al. 1998).
There is also a fair amount of data showing LAT to be involved in preventing 
apoptosis, or programmed cell death. Apoptosis is a mechanism used by infected cells 
to prevent the spread of foreign infection, such as that of a virus. Therefore, viruses 
have had to evolve the ability to prevent this to ensure their survival.
An anti-apoptotic effect of LAT was first shown using plasmids containing the first 
1.5kb of the 8.3kb LAT in neuronal and non-neuronal cells in vitro. This 1.5kb 
sequence protected cells from apoptosis when induced chemically (Inman et al. 2001). 
Further similar plasmid studies with different parts of the LAT region confirmed this 
and localised the region required for the apoptotic function to two separate areas of 
the first 1.5kb of the 8.3kb RNA (Ahmed et al. 2002; Henderson et al. 2002; Jin et al. 
2003). Recently, the apoptotic function has been tested in vivo and localised to the 
LAP1 promoter and the first 1.5kb of the 8.3kb LAT (Branco and Fraser 2005). 
Furthermore, replacement of this region with an unrelated anti-apoptotic gene showed 
a similar prevention of neuronal death in vivo (Jin et al. 2005).
With respect to all of the possible functions ascribed to the LATs, it is likely that no one 
individual aspect provides the whole picture, but that each contributes somehow to the 
workings of this multi-functional region.
1.1.2.3.4 The latency promoters
There are two promoters involved in the production of LATs. These are named latency 
-  active promoter 1 (LAP1) and latency -  active promoter 2 (LAP2) and their different 
roles will be discussed below. Their position in the LAT region is shown in figure 1-4.
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1.1.2.4.4.1 LAP1
LAP1 was the first LAT promoter to be identified. It was mapped to a region >660bp 
upstream of the major 2kb LAT start site and confirmed as the promoter responsible 
for expression of the LATs during lytic infection of cultured neuronal and non-neuronal 
cells (Zwaagstra etal. 1989; Zwaagstra etal. 1990).
LAP1 contains classic RNA pol II transcriptional regulatory sites, including a TATA 
box, Sp1 sites and a CAAT element (Wechsler et al. 1989; Zwaagstra et al. 1989). 
Primer extension analyses identified transcription initiation as coming from a location 
28 nucleotides downstream of the TATA box (Zwaagstra et al. 1990). The constitutive 
basal activity was mapped to a region -2  to -161 bp upstream of the initiation site 
(Zwaagstra et al. 1991).
It was discovered that deletion of the promoter region causes an absence of LATs in 
mice during latency (Mitchell et al. 1990). This was narrowed down to the region 
around the TATA box, which has been shown to be crucial for LAT expression during 
latency. A slight mutation of the TATA box causes a severe reduction in LAT 
expression (Nicosia etal. 1993; Rader et al. 1993; Soares etal. 1996).
Many studies have identified cis-acting elements within LAP1 that contribute to 
efficient transcription. CAT assays in neuronal and non-neuronal cell lines showed that 
LAP1 has neuronal specificity (Batchelor and O'Hare 1990; Devi-Rao et al. 1991; 
Morrow and Rixon 1994; Zwaagstra et al. 1990). Specifically, a LAT promoter binding 
factor (LBPF) sequence was identified approximately 64bp upstream of the 
transcription start site. Deletion of this element resulted in 30 times less activity of 
LAP1 (Zwaagstra et al. 1991). It was subsequently found that upstream stimulatory 
factor (USF) proteins can bind to the LBPF sequence and therefore these may be 
involved in the activation at this element (Kenny et al. 1997).
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It was also shown that LAT expression in neurons is specifically regulated during 
latency and it was proposed that in the absence of viral proteins this must be actioned 
by cellular factors. In neuronal cells, LAP1 is activated by nerve growth factor (NGF) 
and sodium butyrate through the Ras/Raf pathway in several regions of the promoter; 
thus this is a potential mechanism through which the promoter is activated during 
latency (Frazier et al. 1996a; Frazier et al. 1996b).
LAP1 also contains two cAMP response element (CRE)-like elements; CRE-1 and 
CRE-2 (Kenny et al. 1994; Leib et al. 1991). It was shown that LAP1 is able to bind 
cAMP and respond to it; therefore it was proposed that this has a potential role in 
reactivation (Leib et al. 1991). Further investigation concluded that mutation of CRE-1 
does cause a reduction in induced and spontaneous reactivation in vivo (Bloom et al.
1997). Both CRE-like elements have also been shown to bind members of both 
ATF/CREB and AP-1 factors, suggesting that other cellular pathways could be 
involved in regulation of LAP1 (Kenny etal. 1994; Millhouse etal. 1998).
Additional cellular factors implicated in LAP1 regulation are the early growth response 
factor (EGR) family of TFs. These are inducible TFs that have been shown to inhibit 
LAP1 activity in vitro by binding to an element immediately downstream of the TATA 
box. EGR was shown to compete with and displace TATA binding proteins (TBPs) at 
the start site to prevent transcription (Chiang et al. 1996; Tatarowicz et al. 1997). 
Despite this, the absence of detectable EGR in trigeminal ganglia has thrown doubt 
onto the relevance of this finding.
Regulation of LAP1 by HSV1 proteins has been investigated and it was shown that 
ICPO can up-regulate activity in neuronal cells by binding to the promoter (Batchelor 
and O'Hare 1992). Conversely, ICP4 downregulates LAP1 during productive infection 
by binding to a sequence near the transcription start site, in the same way that it 
downregulates its own promoter (Farrell et al. 1994). Furthermore, ICP4 inhibits
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activation by USF at the transcription start site and therefore must interact with the 
general transcription complex to cause repression (Rivera-Gonzalez et al. 1994). The 
exact implications of these interactions are not properly understood, but it would seem 
that the IE proteins may act upon LAP1 in order to maintain LAT expression at an 
appropriate level during lytic expression and the establishment of latency.
The discovery that deletion of LAP1 did not prevent the production of LATs during lytic 
infection led to the proposal that another LAT promoter may exist (Nicosia et al. 1993).
1.1.2.4.4.2 LAP2
Two fairly extensive studies set about identifying the location and nature of the 
putative second LAT promoter of HSV-1. Goins et al (Goins et al. 1994) tested the 
promoter activity of constructs consisting of regions downstream of LAP1 with varying 
deletions, in CAT assays. The region lacks a TATA box, but does have functional 
promoter activity. This was thus named LAP2. The region of LAP2 allowing maximal 
CAT expression in their assay contains an Sp1 site, putative AP2 and E2F sites. The 
basal promoter activity contained homology to the initiator element found in other 
TATA-less housekeeping gene promoters. Goins et al identified a region that 
modulates the basal activity of LAP2, which contains an AP2 site and a CT rich 
element, consisting of a core sequence often found within the promoters of many 
cellular RNA polymerase II housekeeping genes. These atypical promoters are very 
GC rich, which it was predicted might attract TFs and/or alter nucleosome structure. 
Such promoters also often possess upstream TATA box elements similar to the 
situation with LAP2.
LAP2 was shown to only work in the forward direction and Goins et al found that when 
LAP1 and LAP2 were present, LAP1 reduced the activity from LAP2 in transient 
assays. ICP4 was able to reduce the basal LAP2 activity despite absence of a binding 
site. It was therefore proposed that ICP4 possibly interferes with and prevents TFs
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from binding to LAP2. On testing the promoter activity of LAP2 in vivo, it was found 
that LAP2 is only active at lytic times (Goins et al. 1994). It was suggested that LAP1 
and LAP2 might not be independent latency promoters but form part of a complex 
promoter-regulatory region.
Chen et al (Chen et al. 1995) used deletions of LAP1 and/or LAP2 in viruses to 
examine the relative contributions of each promoter during lytic infection in vitro and 
during latent infection in vivo. They determined that LAP2 is predominantly responsible 
for 2kb LAT production during acute infection and that this is dependant upon viral 
DNA replication. During latency, LAP1 was primarily responsible for 2kb LAT 
accumulation, LAP2 alone producing no LAT. The production of LAT by LAP1 was 
increased by the presence of LAP2 however, suggesting that LAP2 may play a role 
during latency other than as a promoter.
One other group investigated the role of LAP2 in HSV2 (Yoshikawa et al. 1996). They 
found less sequence homology between LAP2 than LAP1 as compared to HSV1. They 
observed that deleting the LAP2 promoter diminished LAT production in lytic and latent 
infections and that LAP2 could not produce LATs alone during latency. This concurred 
with the findings with HSV1 LAP2, the only difference being that LAP2 appeared to 
have no influence on LAT expression during latency from LAP1.
The two LAT promoters and their constitutive elements are illustrated in figure 1-5.
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LAP1 LAP2
Adapted from (Jones 2003)
Figure 1-5 Schematic representation of the two LAT promoters
The LAT promoters contain numerous c/s-acting elements that can be bound 
by cellular transcription factors or viral proteins. LAP2 contains elements 
similar to TATA-less housekeeping gene promoters.
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1.1.3 Long-term expression from the LAT region
The knowledge that HSV1 remains latent for the lifetime of the host, with the majority 
of the genome shut-down and just the LAT region transcriptionally active, led to a 
search to find the mechanism by which the virus achieves this. The ability to harness 
this mechanism and use it to enable continued transgene expression is desirable for 
use in gene therapy applications.
Most groups researching this area used the lacZ gene linked to the latency promoters 
in order to ascertain which elements of the LAT region were responsible for the 
phenomenon. One study inserted lacZ 136bp downstream of the 2kb LAT start site 
and the virus expressed p-galactosidase (p-gal) for at least 56 days p.i. (Ho and 
Mocarski 1989). However, this was fortuitous placement, as it happened to be just 
after the LAP2 promoter, which had not been identified at the time and was 
subsequently shown to be helpful in latent expression (see below).
However some early experiments, before the identification of the LAT promoters, 
simply inserted lacZ linked to an endogenous promoter into the virus at various loci 
and looked for latent expression. Most of these resulted in no latent expression, 
although one, in which the murine moloney leukaemia virus (MMLV) LTR promoter 
was linked to lacZ and inserted into ICP4, expressed p-gal for at least 24 weeks in 
mouse sensory neurons (Dobson et al. 1990). It has since been suggested that this 
was seen due to the proximity of the insertion to the LAT region, which allowed the 
continued expression. This arrangement was also used in a virus injected into the 
hippocampus. Again, p-gal was seen expressed for up to 6 months, although it was 
reported that the expression was very low and could only be detected by PCR (Bloom 
etal. 1995).
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Before the discovery of LAP2, lacZ and NGF were used to replace 1.5kb downstream 
of the LAP1 TATA box and although both genes were expressed highly in lytic 
infection, they were turned off during latency, suggesting that other elements were 
required than just LAP1 for latent expression (Coffin et al. 1996; Margolis et al. 1993). 
This shut-off of expression was also found using deletion mutants of LAP1 driving lacZ 
(Dobson etal. 1995).
As use of the MMLV LTR had been previously successful in driving long-term 
expression, this was linked to LAP1 driving lacZ expression in the gC gene of HSV1 
(Lokensgard et al. 1994). This construct was shown to express lacZ during latency, 
whereas both promoters alone did not. Therefore, the authors suggested that a region 
similar to the MMLV LTR must exist in HSV1 to allow LAP1 to remain active, perhaps 
by maintaining an open nucleosomal structure of the region. The MMLV LTR was 
again shown to allow a long-term function when linked to LAP1 by inserting it 
upstream and in the reverse orientation to LAP1 and driving lacZ. This different 
arrangement of the promoters still allowed latent expression in mice 18 months after 
injection (Carpenter and Stevens 1996).
On identifying the LAP2 promoter, this was linked to lacZ and inserted into the gC 
locus and shown to express p-gal in the TG of infected mice during latency, although 
expression was weak (Goins et al. 1994).
Following discovery of the LAP2 promoter, several groups looked at the long-term 
expression given when leaving both promoters intact in the virus. One approach was 
to insert an internal ribosome entry site (IRES) after all recognised LAT regulatory 
sequences at the time, thus allowing expression of lacZ from the LAT region 
(Lachmann and Efstathiou 1997). This virus did not express p-gal in cultured cells, but 
when injected into mice, staining of sensory ganglia increased with the onset of 
latency and persisted, suggesting that the reporter gene was under true latent
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promoter control. This virus was also used to investigate long-term expression in the 
CNS (Smith et al. 2000). The authors reported that the virus gave latent expression in 
motor neurons for longer than other types of cells (up to 1 year), suggesting that the 
I.AT promoter region may have a preference for these types of neurons during latency.
Another group used an element consisting of 1.1 kb downstream of I.AP1, 
encompassing I.AP2 plus another approximately 500bp downstream, named the long­
term expression element (LTE). This was placed adjacent to LAP1 in both orientations 
and then used to drive lacZ expression by placing the reporter gene within an intron 
(Lokensgard et al. 1997). These cassettes were introduced into the virus at the gC 
gene. The LTE allowed long-term expression of p-gal in murine ganglia in both 
directions, but was most effective when in the forward orientation and downstream of 
LAP1.
The same group performed further investigations with the LTE. They constructed 
cassettes that linked the LTE in both orientations to TK and CMV promoters and 
compared them to the LTE linked to LAP1, in transient assays. They also made 
equivalent viruses of the LAP1-LTE arrangement (with the cassettes in gC) and tested 
them in vitro and in vivo (Berthomme et al. 2000). They showed that the LTE region 
contains enhancer activity in a non cell-type specific and non promoter-type specific 
fashion. In a virus in vitro, the LTE increased expression from LAP1 only when in the 
forward orientation, which they suggested could be promoter activity using a TATA box 
present just before the 3’ end of the LTE that could be activated by ICP4. In vivo, the 
LTE increased expression from LAP1 during lytic and latent infection. The LTE 
functioned in both directions, although the forward direction enhanced activity better 
than the reverse. The authors suggested that LAP2 has promoter activity during acute 
infection, but that the enhancer activity of the region takes over during latency.
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The LTE was also tested in our laboratory for its ability to confer long-term activity onto 
exogenous promoters (Palmer et al. 2000). An equivalent region downstream of LAP1, 
named LATP2, was linked to a minimal NSE promoter, the CMV promoter and the 
MMLV LTR in the LAT region and in other loci of HSV1 and showed an ability to confer 
long-term expression onto all of these promoters when tested in mice in vivo, by the 
presence of p-gal during latent timepoints in infected ganglia. The authors suggested 
that LATP2 might be able to locally remodel the viral chromatin to allow continued 
expression during latency, such that exogenous promoters placed adjacent to the 
region took on this open conformation and remained active.
The arrangement of the LAT region promoters and regulatory elements, as well as the 
ability of various arrangements of the region to direct long-term expression is 
illustrated in figure 1-6.
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Figure 1-6 Cassettes used within HSV1 with long-term expression
a. Diagram of the LAT region showing the LAT promoters and the 
LTE/LATP2. Significant restriction sites have been marked.
b. Long-term cassettes that have been inserted into the LAT region.
c. Long-term cassette used in ICP4.
d. Long-term cassettes that have been inserted into the gC gene. (SA and 
SD = splice acceptor and splice donor respectively).
References as follows:
b(i): (Carpenter and Stevens 1996); b(ii): (Ho and Mocarski 1989); b(iii): 
(Lachmann and Efstathiou 1997), (Smith et al. 2000);b(iv): (Palmer et al. 
2000).
c: (Dobson etal. 1990).
d(i) : (Lokensgard et al. 1994): d(ii) : (Goins et al. 1994); d(iii) : (Lokensgard et 
al. 1997); d(iv): (Berthomme etal. 2000).
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1.1.4 The use of HSV1 as a gene therapy vector
The discovery that HSV1 can be used to express transgenes during latency as 
described above, makes it an attractive gene therapy vector. This is especially so for 
therapy to the nervous system as HSV1 naturally infects both the PNS (mainly) and 
the CNS (occasionally). Its property of the ability to be transported in a retrograde 
manner is also appealing as it means the virus is transported to sites distal to infection, 
which are often inaccessible for surgery.
The development of HSV1 vectors for gene therapy, as well as focusing on long-term 
gene expression has also been directed at the level of disablement of virus required to 
allow gene delivery without causing toxicity to the target cells and therefore death of 
the cells and often the infected animal, especially when introduced into the CNS.
The first genes to be deleted from viruses with the view to reducing toxicity were the 
neurovirulence factors. These include ICP6, ICP34.5 and TK, which are only essential 
for growth in non-dividing cells such as neurons; therefore they can be deleted without 
affecting virus growth but reducing replication in neurons. Deletion of TK alone 
resulted in a still lethal virus after high doses of inoculation in mice (Ho and Mocarski 
1988; Palella et al. 1988). Deleting ICP34.5 gives the greatest amount of 
neuroattenuation, but a virus with this deletion alone resulted in very low efficiency of 
transduced neurons in the PNS and CNS (Coffin et al. 1996) and it also expressed 
viral antigens that caused a host immune response resulting in severe inflammation in 
the brain (McMenamin etal. 1998a; McMenamin etal. 1998b).
This showed that further-disabled viruses would be required for successful gene 
delivery vectors. This was achieved by deleting IE genes. ICP4- viruses have 
significantly reduced gene expression (Chiocca et al. 1990; DeLuca et al. 1985; 
Dobson et al. 1990; Johnson et al. 1992a; Johnson et al. 1992b). However, the 
remaining IE genes are still expressed and when this virus was injected into the brain,
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although this showed reduced virulence compared to wild-type, it still resulted in 
significant tissue damage (Chiocca et al. 1990). Other IE genes were deleted, 
including those for ICPO or ICP27, or combinations of genes for ICP4/ICP22 and 
ICP4/ICP47 (Johnson et al. 1992a). These viruses however were still found to be toxic 
to neurons. Triple deletions of genes for ICP4, ICP22 and ICP27 were found to be 
significantly less toxic than other combinations of deletions (Krisky et al. 1998; Wu et 
al. 1996). Deleting all the IE genes from a virus resulted in infected cells that looked 
indistinguishable from non-infected cells (Samaniego et al. 1998). However, these 
viruses require complementing cell lines to grow that provide all of the IE genes, which 
are very toxic and as such the cell lines are only usable up to about passage 15 
(Samaniego etal. 1997).
A different approach to reducing toxicity was to delete or inactivate the VP16 gene and 
therefore prevent transactivation of all of the IE genes. The protein cannot be deleted 
as it has an essential structural role, but it can be mutated in the C-terminal domain so 
that it cannot transactivate the IE genes but still retains its structural integrity (Ace et 
al. 1989). The resulting virus gives a 90% reduction in IE gene expression. This 
mutation can be complemented by adding hexamethylene bisacetamide (HMBA) to 
the growth media (McFarlane et al. 1992). This mutation has been combined with 
deletions of ICPO and ICP4 to give a virus with no visible cytotoxicity to cells (Preston 
and Nicholl 1997). This virus was subsequently used to deliver long-term gene 
expression in the PNS (Marshall et al. 2000).
However, when the VP16 mutation is combined with IE gene deletions in a virus, 
complementation by HMBA is insufficient to give effective virus growth. To overcome 
this problem, cell lines expressing the equine herpesvirusl homologue of VP16 (EHV1 
gene 12) along with ICP4 and ICP27 were developed and found to successfully grow 
multiply disabled viruses in culture (Thomas et al. 1999b). This combination of 
deletions and mutation of VP16, along with a deletion in the ICP34.5 gene has allowed
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development of a viral vector completely replication incompetent that can efficiently be 
grown in culture and widely express transgene in the brain for at least 1 month without 
causing damage (Lilley etal. 2001).
Persistent expression of transgenes in the brain has however not been achieved very 
effectively long-term, even with apparently non-toxic vectors. Latency promoters 
appear to have altered kinetics in the CNS to the PNS and seem to turn off over time. 
This is seen with the virus described above (Lilley et al. 2001) and also with other 
viruses such as a VP16-/ICP0-/ICP4- virus that expresses p-gal under the control of 
the LAT promoter region for up to 180 days in the brain, but this can only be detected 
by PCR after 4 weeks (Scarpini et al. 2001). One group claim that use of a multiply- 
disabled virus expressing transgenes under the control of the LAP2 promoter only, 
allows continued expression in the brain for at least 6 months, in biologically relevant 
quantities (Puskovic et al. 2004), although as LAP1 and not LAP2 has been shown to 
be active during latency, this is somewhat questionable.
The level of replication-competence required in a vector appears to differ for the PNS 
and CNS. Studies in the PNS show that a virus just deleted for ICP34.5 and with a 
mutated VP 16 is non-toxic to dorsal root ganglia (DRG) when injected into the footpad 
(Coffin et al. 1996; Palmer et al. 2000). Further deletions of ICP4 and ICP27 reduced 
latent gene delivery in the PNS, suggesting that a certain amount of initial viral 
replication is advantageous in this case for latent transgene expression (Palmer et al.
2000). However, better transgene delivery in the brain is given by a virus additionally 
deleted for ICP4 and ICP27, as discussed above (Lilley et al. 2001).
Applications of optimised HSV1 vectors are potentially very wide reaching. Vectors 
can be used to deliver potentially therapeutic molecules to neurons in vitro and in vivo, 
which as well as a therapeutic tool is also a useful means of research into neurological 
diseases.
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Examples of such applications are the delivery of Bcl-2 and GDNF to the rat substantia 
nigra, allowing 6-hydroxydopamine-induced degeneration of these neurons to be 
prevented (Natsume et al. 2001; Yamada et al. 1999). The opioid precursor 
preproenkephalin was delivered to mice spinal ganglia and demonstrated to have an 
anti-hyperalgesic effect (Wilson et al. 1999). Also, a disabled vector expressing NGF 
has been produced and shown to protect rat DRG neurons in an in vitro model of 
oxidative stress (Goins et al. 1999). Parkinson’s disease is a good contender for HSV1 
mediated gene therapy and delivering tyrosine hydroxylase (TH) to produce dopamine 
by HSV1 has been shown (During et al. 1994), as has using a combination of the 
delivery of TH and aromatic acid decarboxylase (Sun et al. 2003). These are just a few 
examples of a wide-range of uses for which HSV1 vectors have been suggested.
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1.2 AN OVERVIEW OF TRANSCRIPTIONAL REGULATION
1.2.1 Promoters
In eukaryotic transcription, the promoter is the site where the RNA pol II binds to the 
DNA to initiate transcription. Promoters of genes that synthesise mRNA are typically 
located immediately upstream of the initiation site. Some, but not all of these 
promoters contain the consensus sequences TATAAA (known as the TATA box), 
where the RNA polymerase binds. In humans approximately 32% of promoters 
possess a TATA box (Suzuki et al. 2001). The TATA box is usually about 30bp 
upstream of the first base to be transcribed.
Initiator (Inr) elements are found in both TATA-containing and TATA-less promoters. 
This is a consensus sequence surrounding the start site for transcription.
Downstream core promoter elements (DPEs) are most commonly found in TATA-less 
promoters and are located 28 to 32 bases downstream of the Inr site. The core 
promoter elements are illustrated in figure 1-7.
-31 to -26 -2 to +4 +28 to +32
  — 11
Other regulatory TATAbox Inr DPE
elements such as 
SP1 or CCAAT box
Figure 1-7 Core promoter elements
Numbering refers to +1 as being the starting point of transcription within the Inr 
element.
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The RNA polymerase II cannot bind to naked DNA, but requires TFs to bind efficiently. 
At least 6 basal TFs are required, known as TFIIA, B, D, E, F and H (Buratowski et al. 
1989; Sopta et al. 1989). TFIIB and D are the first two factors to bind to the promoter 
and thus have a critical role in the recognition of core promoter motifs. This then allows 
recruitment of RNA pol II, either independently of the other TFs, or along with them in 
a holoenzyme form. This holoenzyme contains other protein components that appear 
to be involved in opening the chromatin structure (see later) and allowing in further 
TFs.
TFIID binds the TATA box where present, or in the absence, binds to another DNA 
binding protein present which in turn recognises the Inr element. In this way the 
transcription initiation complex (TIC) is brought to the correct location for transcription 
to occur.
Control of transcription occurs by one way or another altering the number of RNA pol II 
molecules moving along the DNA i.e. by activation or repression.
1.2.2 Enhancers
Enhancers are DNA sequences that can activate the use of a promoter, therefore 
controlling the rate of transcription. They can act at great distances from the related 
promoter and can be in either orientation and in the 5’ or 3’ position relative to it 
(Maniatis et al. 1987). In many cases enhancers are tissue-specific and are important 
in controlling the expression of genes in the correct tissue. Enhancers bind different 
factors that recognise sequence motifs within them. There may be a range of motifs, 
the proteins to which bind acting together to produce strong activation of transcription. 
The complex of different proteins bound to an enhancer is called an enhanceosome.
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It is thought that enhancers function by causing a change in the chromatin structure 
leading to nucleosomal displacement (see later) and/or by direct interaction with the 
proteins of the transcriptional apparatus. Thus the enhanceosome complex recruits 
both chromatin modifiers and the RNA polymerase II holoenzyme to direct enhanced 
transcription (Giese et al. 1995; Grosschedl 1995; Thanos and Maniatis 1995). When 
direct interaction of the enhancer with the transcriptional apparatus occurs and the 
enhancer is a long distance from the promoter, then it is thought that ‘looping out’ of 
the intervening DNA probably occurs.
Silencers are the opposite of enhancers in that they repress rather than activate 
transcription. Apart from that, the mechanisms of action are probably similar, allowing 
inhibitory proteins to bind to the transcriptional apparatus, or causing a less permissive 
chromatin structure to form (Brand et al. 1985).
As enhancers and silencers are often separated from the promoter of intent by other 
promoters that are not affected, insulator elements provide a means by which 
inappropriate transcription or repression of such is prevented. Insulator elements are 
sequences that provide a ‘block’ to the enhancer or silencer activity, the way in which 
they function depending on the mechanism of action of the enhancer/silencer. They 
bind a protein that either prevents the enhancer being brought into contact with the 
promoter, or that prevents the opening or closing of the local chromatin structure.
1.2.3 Transcriptional regulation by epigenetic mechanisms
1.2.3.1 Chromatin structure
Eukaryotic DNA exists in a compacted form, associated with proteins in a form known 
as chromatin. The associated proteins are called histones, which are very rich in the 
amino acids lysine (K) and arginine (R), which causes the histone to be positively
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charged and thus tightly bind the negatively charged DNA, by electrostatic 
interactions.
The basic repeat unit of chromatin is the nucleosome, which consists of a histone 
octamer made up of 2 molecules each of the four core histones H2A, H2B, H3 and H4. 
Approximately 146bp of DNA is wound around the core, by almost 2 full turns. One 
histone H1 molecule binds to the outside of the nucleosome and allows tighter winding 
of the DNA (Kornberg 1974; Olins and Olins 1974; Van Holde etal. 1974).
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Figure 1-8 Schematic diagram of a nucleosome
The histone proteins H2A, H2B, H3 and H4 exist as dimers, making up the 
core of the histone, with 146bp of DNA wrapped around them. A single histone 
H1 helps to bind the nucleosome.
The nucleosomes are joined together by small stretches of linker DNA. DNA that is in 
a nucleosomal form can be digested by micrococcal nuclease (MNase) between the 
nucleosomes to give a ladder of characteristically sized fragments, relating to the 
number of nucleosomes per fragment (the mono-nucleosomal band is 146bp) (Lacy 
and Axel 1975).
Tightly bound chromatin is known as heterochromatin and is largely inaccessible to the 
transcriptional machinery. Actively transcribed genes, or those with the potential to be 
transcribed are also found arranged on nucleosomes, but the chromatin is in a more 
open structure known as euchromatin, which allows the transcriptional machinery to 
access the DNA. Stretches of euchromatin can be identified by digestion with DNasel,
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which will only digest DNA not associated with nucleosomes and that is accessible to 
the enzyme (Weintraub and Groudine 1976).
Histone H1 binds more tightly to methylated DNA, therefore transcriptionally inactive 
DNA is often methylated and in a heterochromatic form (McArthur and Thomas 1996). 
Methylation mainly occurs on cytosine residues (Razin and Riggs 1980) and is carried 
out by the protein MeCP2 which binds methylated CG resulting in the formation of a 
multi-protein complex which includes a histone deacetylase (Jones et al. 1998; Nan et 
al. 1997; Nan et al. 1998). Histone deacetylation results in a tightening of the 
chromatin structure and is a marker of transcriptional inactivity (see below).
Trans-factors can open up the chromatin by causing either nucleosomes to dissociate 
from the DNA temporarily and allow in TFs, or TFs can bind to the nucleosome and 
disrupt the structure (Adams and Workman 1993). Once nucleosomes in the promoter 
region of a gene are disrupted then other TFs can bind. DNase 1 sites are often found 
at enhancers, suggesting that enhancers allow binding of factors that then alter the 
local chromatin structure and facilitate transcription from the related promoter (Zaret 
and Yamamoto 1984). There are two classes of chromatin modifying factors: histone 
modifiers and ATP-dependent nucleosome remodelling complexes. These are both 
described below.
1.2.3.2 Histone modification in transcriptional control
The core histone tails protrude from the nucleosome and are susceptible to a variety of 
covalent modifications including methylation, phosphorylation, ubiquitination and 
acetylation; the latter being the most common. The modifications alter the structure of 
the chromatin in different ways, either by causing a direct tightening or loosening by 
allowing the histones to more tightly interact, or by indirectly allowing facilitation of 
other modifications to occur.
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Histones H3 and H4 can be methylated on R and K residues and although this has 
been known for a long time, the relevance was not understood (Murray 1964). The 
function was unknown due to the lack of knowledge about methylating enzymes. Thus, 
when methyltransferases were discovered this provided evidence for the involvement 
of methylation in transcriptional regulation (Chen et al. 1999; Rea et al. 2000; Schek 
and Bachenheimer 1985). Methylation of histones is associated with transcriptional 
inactivation.
Phosphorylation of the core histones can also occur; although it appears to be an 
indirect regulator of transcriptional activity. For example phosphorylation of S10 on H3 
inhibits methylation of K9 on H3 and promotes acetylation of K14 on H3, by creating a 
more favourable substrate for histone acetyl-transferases (HATs). This then leads to 
transcriptional activation (Cheung et al. 2000; Lo et al. 2000; Sassone-Corsi et al. 
1999).
Histones H2A and perhaps H2B are able to be ubiquitinated. This modification is 
associated with increased transcriptional activity and is prevalent at the 5’ end of 
transcriptionally active genes (Varshavsky etal. 1982).
Acetylation of histones was first linked to transcriptional activation in the 1960s (Allfrey 
et al. 1964). Histones with acetylated N-terminal histone tails bind DNA and other 
histones of adjacent nucleosomes with reduced affinity and thus allow a loosening of 
the nucleosomal and chromatin structure (Hong et al. 1993; Puig et al. 1998). When 
the first nuclear acetylase GCN5 was discovered (Brownell et al. 1996) and the first 
deacetylase, HDAC1 (Taunton et al. 1996), the importance of histone acetylation as a 
method of transcriptional control was underlined. It was then found that other 
activators of transcription have HAT activity such as p300/CBP and the TAFt|250 
subunit of TFIID (Mizzen etal. 1996; Ogryzko etal. 1996; Yang etal. 1996).
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HATs function by transferring an acetyl group from acetyl-coenzyme A to the e-amino 
acid group of lysines on H3 and H4, reducing the net positive charge and therefore the 
interaction with the DNA and other histones, such that the nucleosome structure is 
loosened (Allfrey et al. 1964). Acetylation and deacetylation occur in synergy to 
achieve appropriate levels of transcription.
1.2.3.3 Nucleosome remodelling complexes
The second class of chromatin modifier is the ATP-dependant nucleosome- 
remodelling complexes such as the SWI/SNF family. These work by allowing an 
exchange between condensed and more accessible nucleosome configuration, either 
through histone octamer transfer and/or nucleosome sliding (Hamiche et al. 1999; 
Schnitzler et al. 1998; Whitehouse et al. 1999). The SWI/SNF complexes are thought 
to be recruited to promoters via interactions with DNA binding proteins, as they do not 
recognise specific sequences (Vignali et al. 2000). These could be either 
transcriptional activators as in the case of the glucocorticoid receptor that has been 
shown to recruit SWI/SNF to the responsive promoter (Deroo and Archer 2001), or 
transcriptional repressors such as UME6 (Goldmark et al. 2000).
1.2.3.4 Interaction of chromatin remodellers and histone modifiers
The covalent modifiers of histones and the ATP-dependent chromatin remodellers are 
likely to work together to modulate transcriptional activation and repression. Studies on 
the yeast HO promoter showed that the SWI/SNF complex and then a HAT binds to it 
prior to transcription and that the SWI/SNF complex is required if acetylation is to 
occur (Cosma et al. 1999; Krebs et al. 1999). It has been shown that the inter­
dependence is more likely to affect deacetylation rates (Imbalzano et al. 1994; Logie et 
al. 1999; Tong et al. 1998). However, this is not a strict rule; the two can usually 
function independently.
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One model of co-operation proposed is that the SWI/SNF complex creates a ‘fluid’ 
chromatin environment which is then locked into place by covalent modifications of 
histone tails (Kingston and Narlikar 1999). It is hypothesised that alteration of the 
chromatin by one method may make it easier for the other to work e.g. by increasing 
accessibility to the DNA or histones. It does appear that there is no strict order in 
which these different actions of chromatin remodelling and modification occur and that 
they are likely to function synergistically to regulate transcription.
1.2.3.5 Insulators and barriers
As a genome has a combination of silenced and active genes, these are organised 
into chromatin domains that are maintained independently to their surroundings 
through the establishment of chromatin boundaries.
As mentioned above, (section 1.2.2), insulator elements bind proteins that can provide 
a block to regulatory elements such that their action is not imparted onto inappropriate 
genes. Another function of insulators is to prevent the self-propagating spread of 
chromatin condensation onto neighbouring gene loci thus affecting gene expression 
(Elgin and Grewal 2003). There are two types of insulator function -  one that blocks 
the effect of enhancer activity and one that creates barriers to compartmentalise the 
different chromatin conformations.
Although the two functions are separate, they can exist within the same factor. For 
example, the HS4 element contains both functions. The insulator function requires the 
protein CCCTC binding factor (CTCF) to bind (Bell et al. 1999) as do a number of 
different insulator elements. The barrier function of the HS4 element does not however 
require CTCF to function (Recillas-Targa et al. 2002).
A sharp transition between the hypoacetylated inactive region and the hyperacetylated 
active chromatin domain is seen at the locus of a barrier insulator (Hebbes et al. 1994) 
and it has been shown that the maintenance of transcriptional activity within the
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flanking barrier elements of a region is dependent upon continued acetylation which in 
turn is dependent upon the presence of the barrier elements. This led to the 
hypothesis that insulators prevent histone deacetylation within the active region 
(Pikaart et al. 1998). Evidence to back up this theory came when the HS4 insulator 
was found to be hyperacetylated, suggesting that it attracts a high-level of histone 
acetylases. Furthermore, maintenance of acetylation was essential for HS4 to prevent 
the silencing of transgenes placed adjacent to it (Litt et al. 2001a; Litt et al. 2001b; 
Mutskov et al. 2002).
It has been found that the active chromatin region must be flanked on both ends by 
insulator barriers to protect it from silencing. A barrier at one end only has no effect 
(Pikaart et al. 1998).
The two different functions of insulators can be exemplified by the fact that within an 
active chromatin domain, flanked by barriers, insulators of enhancer function can also 
exist. Figure 1-9 provides an illustration of how this can occur.
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Repressed
heterochromatin
'Active’ euchromatin
Barrier Insulator Barrier Insulator
PromoterEnhancer
Insulator
Adapted from (Burgess-Beusse etal. 2002)
Figure 1-9 Two types of insulator function
a. Barrier function allows distinct compartments of active euchromatin without 
the encroachment of adjacent condensed chromatin.
b. Enhancer-blocking function prevents activation of inappropriate promoters 
when placed between enhancer and promoter.
1.3 THESIS AIMS
As shown previously, the LATP2 region of HSV1 has properties that appear to allow 
continued expression of transgenes from LAT or non-LAT promoters, which would 
otherwise not be active during viral latency. This has great potential in the design of 
HSV1 vectors for gene therapy, where continued expression of therapeutic genes is 
often required. To optimise the long-term expression capabilities of the vectors, it 
would be advantageous to understand how the LATP2 region confers this ability onto 
other promoters.
This thesis therefore aims to identify which regions of LATP2 are responsible for the 
long-term expression properties and which, if any, could be dispensed with in order to
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improve the function of this region. Deletion mutants of LATP2 were to be created and 
tested in viruses based on an existing HSV-1 long-term expression vector in order to 
assess LATP2 activity.
This thesis also studies the mechanism by which the LAT region remains active 
throughout latency and how LATP2 confers this activity onto adjacent promoters. As 
the HSV1 genome exists in a chromatin-like structure during latency, whether the 
modification of histones at this time is responsible for this phenomenon is to be 
explored by comparing the acetylation status of LAT and non-LAT regions at this time.
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CHAPTER 2: 
MATERIALS AND METHODS
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2.1 LABORATORY REAGENTS
Unless otherwise stated, all chemicals were from Merck Ltd. (Poole, Dorset, UK), 
Roche Biochemicals (Lewes, East Sussex, UK) or Sigma Chemical Company Ltd. 
(Poole, Dorset, UK) and were of analytical grade. General disposable plasticware was 
purchased from Sterilin (Stone, Staffordshire, UK) or Greiner (Stonehouse, 
Gloucester, UK).
Additional laboratory materials and reagents were supplied from one of the following:
Insight Biotechnology Ltd. (London, UK); Nunc (Roskilde, Denmark); Amersham 
International pic. (Little Chalfont, UK); Qiagen (Chatsworth, USA); Gibco-BRL Life 
Technologies Ltd. (Paisley, Renfrewshire, UK); Bio-Rad (Hemel Hempstead, UK); 
Promega Corporation (Madison, Wisconsin, USA); Whatman International Ltd. 
(Maidstone, Kent, UK); Pharmacia Biotechnology Ltd. (St Albans, UK); Millipore Ltd. 
(Watford, UK); Stratagene Ltd. (Cambridge, UK); Marligen Bioscience Inc. (USA); New 
England Biolabs Inc. (Hitchin, Hertfordshire, UK); Upstate Biotechnology 
(Buckinghamshire, UK).
All oligonucleotide primers were constructed by Invitrogen Custom Primers (Paisley, 
Renfrewshire, UK).
2.1.1 Standard buffers and solutions
PBS: NaCI (137mM), KCI (2.7mM), Na2HP04.7H20  (4.3mM), KH2P 04 (1.4mM)
TE: Tris-HCI (10mM), EDTA (1mM), pH8.0
TAE: Tris base (400mM), sodium acetate (200mM), EDTA (20mM), pH8.3 
Luria Bertani (LB) media: 1% (w/v) Bacto®-tryptone
1 % (w/v) NaCI
0.5% Bacto®-yeast extract
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2.2 MOLECULAR BIOLOGY
2.2.1 Bacterial strains and growth conditions
The XL-1 Blue (Stratagene Ltd, Cambridge, UK) strain of E.coli was used for all 
plasmid cloning.
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F’proAB Laclq ZAM15, TN 10 (Tet)r]
2.2.1.1 Propagation of bacteria
XL1-Blue (XL1-B) cells were grown in LB media containing either no antibiotic or 
100pg/mL ampicillin overnight in a Gallenkamp orbital shaker at 200rpm/37°C. LB 
media was autoclaved at 120°C for 20 mins at 10lb/square inch. Stocks of ampicillin 
were made at 100mg/mL in 50% (v/v) ethanol and stored at -20°C for up to 3 months. 
Colonies of XL1-B were isolated by growing on LB plates containing 2% Bacto®-agar.
2.2.1.2 Long-term storage of bacteria
An overnight culture of the XL1-B cells was diluted 1:10 into fresh LB media and 
incubated with shaking at 200 rpm at 37°C for 1 hour. An equal volume of 100% 
glycerol was then added and the two solutions were thoroughly mixed. The 
glycerol/bacteria solution was aliquoted into cryo-vials and frozen at -80°C.
2.2.1.3 Preparation of competent XL1-blue cells
Competent XL1-B cells were prepared using a standard calcium chloride technique 
(Sambrook et al. 1987). A 5mL starter culture (containing no antibiotic) of XL1-B was 
grown overnight at 200rpm/37°C, which was then used to inoculate 100mL of LB 
(containing no antibiotic) and the culture grown to an OD580 of 0.4-0.55 units. The 
bacteria were then pelleted in a Jouan CR422 centrifuge at 2000rpm for 10 mins at 
4°C and any excess LB removed. The cells were resuspended in 10mL ice-cold
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100mM CaCI2 and incubated on ice for 1 hour. The cells were then pelleted as before, 
resuspended in 4mL ice-cold CaCI2 and then incubated on ice until required.
2.2.1.4 Transformation of XL1-blue cells
200pL competent XL1-B cells were transformed by the addition of DNA and 
subsequent incubation on ice for 20 mins. The cells were then heat-shocked for 90 
secs, at 42°C. The cells were then incubated on ice for a further 2 mins. 800pL LB was 
then added to the cells and then incubated in an orbital shaker for 1 hour at 37°C and 
200rpm. The cells were then pelleted and resuspended in 100pL of LB and plated onto 
LB-agar plates containing 100|jg/mL of ampicillin. If detection of p-Galactosidase was 
required, plates containing 50pL of 20mg/mL stock of 4-CI, 5-bromo, 3-indolyl-p- 
galactosidase (X-Gal, Insight Biotechnology Ltd., UK) dissolved in DMF were used.
2.2.2 DNA extraction and purification
2.2.2.1 Small-scale plasmid DNA extraction and purification
The “mini-prep” extraction method used is based on an alkaline lysis method (Birnboim 
and Doly 1979). Single colonies of XL1-B cells were used to inoculate 5mL LB 
containing 100|jg/mL ampicillin and were incubated in an orbital shaker overnight at 
200rpm/37°C. The cells from 1.5mL of culture were then pelleted by centrifugation in 
an Eppendorf 5417C microfuge at 9000rpm for 1 min at room temperature. The cells 
were then resuspended in 100pL resuspension buffer (50mM Tris-HCL pH7.5, 10mM 
EDTA pH 8, 100pg/mL RNase-A). Cells were lysed by addition of 200pL lysis buffer 
(200mM NaOH, 1% (v/v) Triton X-100) and then 150pL of neutralisation buffer (3M 
NaOAc, pH5.5) was added. The cell lysate was centrifuged in an Eppendorf 5417C 
microfuge for 3 mins at 13000rpm at room temperature and the pelleted precipitate 
removed with a hypodermic needle bent at the tip. 500pL of isopropanol was added to
77
Chapter 2 Materials and methods
the remaining supernatant, mixed and then centrifuged for 5 mins at 13000rpm at 
room temperature. The supernatant was removed and the DNA pellet washed with 
500pL 70% (v/v) ethanol. The pellet was air dried and then resuspended in 50pL of 
double-distilled water (ddH20). Plasmid ‘mini-prep’ DNA was stored at -20°C.
2.2.2.2 Large-scale plasmid DNA extraction and purification
Large-scale plasmid DNA extractions were performed to produce high grade DNA for 
cloning, isolation of DNA fragments and transfections (section 2.3.4.1). 100pL of an 
overnight culture of transformed XL1-B cells was used to inoculate 400mL LB 
containing 100|jg/mL ampicillin and incubated in an orbital shaker overnight at 
200rpm/37°C. 100mL of the culture was centrifuged at 3500rpm for 10mins at room 
temperature. Plasmid DNA was then extracted using the Concert Midi-Prep kit 
(Marligen, USA) as per the manufacturer’s instructions. A typical yield of ‘midi-prep’ 
DNA was 200pg, which was resuspended in 200pL ddH20. Exact quantification of the 
DNA in each preparation was done by measuring the absorbance of the DNA at 
260nm in a UV spectrophotometer. The concentration of DNA was calculated using 
the Beer-Lambert equation such that concentration (pg/nriL) = AU x 50x dilution factor.
2.2.3 Cloning
2.2.3.1 Restriction digests
Restriction digests were performed on plasmid DNA for clonal analysis. Digests were 
carried out in a total volume of 20pL, containing either 5pL of ‘mini-prep’ DNA (section
2.2.2.1) or 1pL of ‘midi-prep’ DNA (section 2.2.22). 10 units of each restriction enzyme 
were added in the appropriate buffer. The volume was made up to 20pL with ddH20. 
Digests were incubated from 1 hr -  overnight at the appropriate temperature for the 
enzyme being used. Digestion products were then run on a 0.8 - 2% agarose gel
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(dependent on expected band sizes) (section 2.2.3.5) and visualised on a UV 
transilluminator.
2.2.3.2 Isolation of DNA fragments
Restriction digests required for isolation of DNA fragments for cloning were carried out 
in a total volume of 20pL containing ~5pg ‘midi-prep’ DNA, 10 units of each enzyme 
and the appropriate buffer. The volume was made up to 20pL with ddH20. Digests 
were incubated at the appropriate temperature for 1 hr -  overnight. Digestion products 
were then run on a 1% low-melting-point agarose gel and visualised on a UV 
transilluminator. Required bands were carefully excised using a scalpel blade. DNA 
was then extracted from the agarose using the GFX™ PCR and Gel Band Purification 
Kit (Amersham, UK) as per the manufacturer’s instructions. The DNA was eluted in a 
final volume of 20pL ddH20.
2.2.3.3 Blunt-end reactions
When there were no compatible restriction sites for cloning, sticky-ends were blunted 
by filling in their 3’ overhangs using T4 DNA polymerase (Promega, USA). After 
restriction digest, 1pL of a 25mM stock dNTPs (dATP, dCTP, dGTP, dTTP) and 15 
units of T4 DNA polymerase were added. The reaction was incubated for 30 mins at 
37°C. If subsequent restriction digests were to be performed, the reaction was heat- 
inactivated at 80°C for 30 mins and then cooled on ice prior to the addition of further 
restriction enzymes.
2.2.3.4 Phosphatase treatment
To prevent possible religation of vector ends, the vector DNA was dephosphorylated 
using shrimp alkaline phosphatase (SAP). Vector DNA was extracted using the GFX™ 
PCR and Gel Band Purification Kit (Amersham, UK) according to manufacturer’s 
instructions. DNA was resuspended in a total volume of 50pl ddH20  containing 1x 
phosphatase buffer and 5 units SAP. The reaction was incubated for 45 mins at 37°C,
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then 10 mins at 65°C to inactivate the SAP. DNA was again extracted as before and 
resuspended in 10pl ddH20.
2.2.3.5 Agarose gel electrophoresis
0.5-1.5% (w/v) agarose gels were made using 1x TAE (0.4 M Tris base, 0.2 M sodium 
acetate, 20 mM EDTA pH8.3). Ethidium bromide was added to a final concentration of 
0.5pg/ml. Approximately 0.1 volume of 10x loading buffer (1x TAE, 50% v/v glycerol, 
0.025% bromophenol blue) was added to DNA samples prior to loading. 1 kilobase 
(kb) ladder DNA marker was used as a size marker. DNA was electrophoresed at 80- 
120mA until the fragments were well separated. Bands were visualised on a UV 
transilluminator and photographed with Polaroid film.
2.2.3.6 Phenol extraction of DNA
When DNA restriction digestions needed to be purified, a phenol extraction was 
performed by the standard technique (Sambrook et al. 1987; Sambrook and Russell
2001). This was necessary if a digestion required two enzymes and a compatible 
buffer could not be found, or when linearised DNA was used in transfections (section
2.3.4.1). Digestions were made up to a total volume of 400pL with ddH20. An equal 
volume of phenol/chloroform/IAA (24:24:1) was added and the mixture vortexed 
thoroughly before centrifugation at 12000rpm for 2 mins in an Eppendorf 5417C 
microfuge. The aqueous layer was removed and an equal volume of chloroform/IAA 
(24:1) was added. The mixture was vortexed thoroughly and pulse-centrifuged. The 
aqueous layer was removed and to this was added 40pL (0.1 x volume) of 3M NaOAc 
(pH5.5) and 880pL (2 x volume) of ice-cold ethanol. The mixture was vortexed and 
then left at -70°C for 10 mins, before centrifugation for 15 mins at 13000rpm, 4°C in an 
Eppendorf 5417R microfuge to pellet the DNA. The supernatant was removed and the 
DNA washed in 70% ethanol before being left to dry. The extracted DNA was then 
resuspended in 10pL ddH20.
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2.2.Z.7 DNA ligations
Ligations were performed in thin walled 0.5mL reaction tubes in a total volume of 
20pL. Reactions contained 1-2pL of purified vector, 7-1 OpL of purified insert, 1 x ligase 
buffer, 1-3 units of T4 DNA ligase (Promega, USA) and made up to volume with 
ddH20. Reactions were left either at room temperature for 2 hrs, or in the case of blunt- 
end ligations in a thermocycler. The thermocycler was run at 16°C for 1 min followed 
by 37°C for 1 min for 30 cycles and a final incubation at 22°C for 30 mins. In each 
case the ligation reaction was transformed into 200pL of competent XL1-B cells as 
described (section 2.2.1.4).
2.2.3.8 Colony characterisation using a radiolabelled probe
In the absence of X-Gal mediated selection, bacterial colonies could be screened for 
the incorporation of an inserted DNA fragment using a radiolabelled probe. This 
method was of particular use following blunt-end ligations where the insertion 
efficiency was usually low.
2.2.3.8.1 Colony transfer
Bacterial colonies were directly transferred onto Hybond-N+ nitrocellulose membranes 
(Amersham, UK) by placing membranes onto the LB-agar plates for 2 mins. Holes 
were punched in the membrane in an asymmetric pattern using a sterile needle. The 
position of the holes was marked on the Petri dish with a pen for the purpose of 
orientation at a later stage. The bacterial cells were lysed and the DNA denatured by 
immersing the nitrocellulose membranes in denaturing solution (1.5M NaCL, 0.5M 
NaOH) for 2 mins. The filters were then immersed in neutralisation solution (2M NaCL, 
1M Tris pH5.5) for 2 mins and washed in 2x SSC/0.1% SDS for 2 mins. The 
membranes were washed twice in 2 x SSC for 2 mins. Placing the membranes colony 
side up, they were cross-linked twice in a UV stratalinker (Stratagene, Netherlands).
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2.2.3.5.2 Radiolabelling DNA probes
Fragments of DNA were radiolabelled with a- [32P]-dCTP. DNA was digested (section
2.3.1.2) and run on a 1% agarose gel (section 2.2.3.5). The required DNA was then 
excised from the gel and purified with the GFX™ PCR and Gel Band Purification Kit 
(Amersham, UK) according to manufacturer’s instructions. The DNA was eluted in 
20pL TE buffer. To label the probe the ‘Ready-To-Go™ DNA labelling beads’ 
(Amersham, UK) were used as per the manufacturers instructions, using all of the 
eluted probe DNA in the reaction. The radiolabelled probe was then heated for 5 mins 
at 100°C and snap-cooled on ice for 2 mins before adding to the hybridisation solution.
2.2.3.8.3 Hybridisation
The nylon membranes were pre-hybridised for between 2-5 hrs at 65°C with 30mL of 
pre-hybridisation solution (6x SSC, 5x Denhardt’s reagent [Denhardt’s Reagent (100x): 
2% (w/v) bovine serum albumin, 2% Ficoll® (type 400), 2% (w/v) polyvinylpyrrolidone 
in ddH20], 0.5% (w/v) SDS in ddH20 containing 100pg/mL denatured herring sperm 
DNA). The volume of the pre-hybridisation solution was reduced to 5mL prior to adding 
a denatured probe. The probe for the appropriate DNA fragment was hybridised to the 
membranes overnight at 65°C. The membranes were washed twice for 10 mins in 
2xSSC/0.1% (w/v) SDS. The membranes were then wrapped in cling-film and exposed 
to X-ray film at -70°C. If necessary the membranes were washed further in 
0.5xSSC/0.1% (w/v) SDS and then 0.1xSSC/0.1% (w/v) SDS.
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2.2.4 Polymerase chain reaction (PCR)
The specific PCR amplification of a target DNA sequence was achieved using 
methodology essentially as described by Saiki et al (Saiki et al. 1985). Specific 
conditions are shown below and elsewhere in the text.
2.2.4.1 Standard PCR reaction.
The target DNA was added to the PCR reaction, which contained: 10x PFU or Taq 
buffer (Promega, USA), 40mM dNTPs, 50-1 OOng of each primer (Invitrogen, UK), 
2.5units of Taq or PFU polymerase (Promega) and the final volume was made up to 
50ptl. To prevent evaporation of the reaction of the mix during thermal cycling the 
reaction was overlaid with 50pJ of mineral oil. The PCR reactions were then put 
through different thermal cycles according to the primers used.
2.2.4.2 PCR of viral DNA
Due to the GC rich nature of HSV DNA, when it was used in a PCR then the GC-Rich 
PCR System (Roche, East Sussex, UK) was employed. This was used according to 
the manufacturer’s instructions in varying thermal cycles according to the primers 
used.
2.2.5 Preparation of cDNA
All solutions used in this process were treated with diethylpyrocarbonate (DEPC). RNA 
was prepared using Trizol reagent (Invitrogen, UK) according to the manufacturer’s 
instructions. RNA was dissolved in 25|J of DEPC H20.
First-strand cDNA synthesis was performed using Superscript II Reverse 
Transcriptase (Invitrogen, UK). RNA (1-5ng) was added to a tube with 150ng random 
primers (Invitrogen, UK), 40mM dNTP and was made up to 20pl with DEPC H20 . This 
mixture was then heated to 65°C for 5 mins and chilled on ice for 5 mins. Then 4ju.l 5x 
first-strand buffer (100mM HEPES pH 6.9, 2mM EDTA), 2pl 0.1 M DTT and 40U
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RNasin (Promega, US) were added and incubated at 42°C for 2 mins. 1pl of Reverse 
Transcriptase (Superscript II, Invitrogen, UK) was added and the reaction was 
incubated at 25°C for 10 mins, followed by 42°C for a further 50 mins. Finally the 
Reverse Transcriptase was denatured by incubation at 70°C for 15 mins. 10% of the 
cDNA was then added to a standard PCR reaction as described in section 2.2.4.1.
2.2.6 DNA sequencing
Where sequencing of DNA was necessary (e.g. after PCR) then this was carried out 
by the sequencing service, department of Biochemistry, University of Cambridge.
2.2.7 Viral DNA preparation
A well of a 6 well plate of virally infected cells at complete cytopathic effect (CPE) was 
harvested by adding 1ml of DNAzol (Helena Biosciences, Sunderland, UK). The DNA 
was precipitated by adding 0.5x volume of absolute ethanol and washed twice in 75% 
ethanol. Ethanol was removed and the DNA pellet dried for 5mins at room temperature 
(RT). The DNA was resuspended in 200pl of 8mM NaOH and incubated overnight at 
4°C on a rotating wheel. For neutralization, 23pl of 0.1 M HEPES were added and the 
DNA stored at -20°C.
2.2.8 Southern blotting
Southern blots (Southern 1975) were performed on viral DNA to determine that correct 
homologous recombination had occurred when producing recombinant HSV viruses.
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2.2.8.1 DNA preparation
A varying amount of DNA was digested with the appropriate enzymes and buffers in a 
total of 50pL overnight. The digested reactions were then run on a 1% TAE agarose 
gel until DNA fragments were well separated. The DNA was visualised on a UV 
transilluminator and photographed with a fluorescent ruler.
2.2.8.2 DNA transfer
The gel was left on the transilluminator for 2 mins and for further denaturation was 
then placed in denaturing solution (1.5M NaCL, 0.5M NaOH) for 45 mins. After rinsing 
briefly in H20, the gel was transferred to neutralising solution (2M NaCL, 1M Tris 
pH5.5) for at least 30 mins. The gel was then placed upside-down on a support 
covered in a layer of 3MM Whatman paper (Whatman, Maidstone, UK) which was 
used as a wick placed in a reservoir of 20x SSC (150mM NaCL, 15mM sodium citrate 
pH8.0). A piece of Hybond-N+ nylon membrane (Amersham, UK) cut to the same size 
as the gel was pre-soaked in the neutralising solution and then carefully placed on the 
gel ensuring that there were no air bubbles present. 10 pieces of 3MM Whatman 
paper, pre-soaked in 20x SSC were placed on top of the nylon membrane and a stack 
of dry paper towels was placed on top with a weight. The DNA was then transferred by 
capillary action from the gel to the nylon membrane overnight. The membrane was 
removed and washed in 6x SSC and then cross-linked twice using a UV stratalinker. 
The membrane was then air dried for 30 mins. The fixed membrane could then be 
stored at 4°C if required, prior to hybridisation.
2.2.8.3 Membrane analysis
Southern blot membrane analysis was performed using a radiolabelled probe 
designed to hybridise to the region of interest. The probe was labelled as previously 
described (section 2.2.3.8.2) and hybridisation was carried out as in section 2.2.3.8.3.
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2.3 TISSUE CULTURE
Tissue culture preparations were carried out under sterile conditions in a class II safety 
cabinet (Heraeus). Viral preparations were carried out under Health and Safety 
Category 2 Conditions. Tissue culture plastic ware was obtained from Nunc, and 
media and supplements were supplied by Gibco-BRL.
2.3.1 Mammalian cell lines
Dulbecco’s modified Eagle Medium (DMEM) supplemented with 10% foetal calf serum 
(FCS), 100 units/mL penicillin/streptomycin, 2mM L-glutamine and 5% (v/v) Tryptose 
Phosphate Broth is referred to as full growth media (FGM) and was used for culture of 
all cell lines unless specified. DMEM supplemented with 100-units/mL 
penicillin/streptomycin is referred to as serum free media (SFM).
2.3.1.1 Baby hamster kidney cells
Baby Hamster Kidney Cells (BHKs) (MacPherson and Stoker 1962) -  clone 21 were 
obtained from ECACC (number 85011433). Cells were passaged by washing in Hanks 
Balanced Salt Solution (HBSS) at room temperature and then incubated with a 
minimal volume of 10% (v/v) trypsin in versene at 37°C/5% C 0 2. An appropriate 
volume of FGM was added to neutralise the trypsin/versene and the cells were then 
divided accordingly into fresh FGM and cultured at 37°C/5% C 0 2.
2.3.1.2 27/12/M:4 cells
27/12/M:4 Cells (MAM49) are a stable cell line derived from BHK cells and have 
previously been described (Thomas et al. 1999b). The cells complement deletions or 
mutations in HSV-1 genes ICP4, ICP27 and VP16. Cells were cultured in FGM 
containing 800pg/mL of Neomycin and 750pg/mL of Zeocin (Cayla, France). Cells
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were passaged as for BHK cells (section 2.3.1.1). When MAM49 cells were grown for 
viral infection antibiotics were omitted.
2.3.1.3 ND7 cells
ND7 cells were created by fusion of mouse neuroblastoma cells (N18Tg2) with a rat 
post-mitotic neonatal dorsal root ganglion neuron (Wood et al. 1990). Cells were 
cultured in Leibovitz L15 media supplemented with 10% FCS, 100 units/mL 
penicillin/streptomycin, 0.35% (w/v) glucose, 2mM L-glutamine and 0.375% (w/v) 
sodium bicarbonate. Cells were passaged by removal of media and addition of 10mL 
fresh L15 supplemented media followed by gentle agitation of the flask to dislodge the 
cells. The suspended cells were then divided as required into fresh L15 supplemented 
media.
2.3.1.4 Vero cells
Vero cells are an African green monkey kidney cell line (ATCC number CCL81). Cells 
were cultured in FGM and passaged as for BHK cells (section 2.3.1.1).
2.3.1.5 HT1080 cells
HT1080 cells are a human fibrosarcoma cell line (ATCC number CL121). Cells were 
cultured in FGM and passaged as for BHK cells (section 2.3.1.1).
2.3.2 Cell line storage
Cells were trypsinised (section 2.3.1.1) and centrifuged at 1500rpm for 10 mins to 
pellet them. The pellet was then resuspended in freezing media A (DMEM 
supplemented with 20% FCS) followed by addition of an equal volume of freezing 
media B (DMEM supplemented with 40% FCS and 16% dimethylsulfoxide [DMSO]). 
Cells were aliquoted into 1.5mL cryovials and were maintained at -80°C  for 24 hours 
prior to storage in liquid nitrogen.
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When required, frozen cell stocks were rapidly thawed at 37°C and transferred 
immediately to 10mL of fresh FGM and pelleted by centrifugation at 1500rpm for 10 
mins in a Jouan CR422 centrifuge. The cell pellet was then resuspended in 6mL fresh 
FGM in a 25cm2 flask and incubated at 37°C/5% C 02.
2.3.3 Primary cultures
Adult mouse primary dorsal root ganglion (DRG) cultures were produced from either 
balb/c mice or balb/c SCID mice age >3 weeks. Two mice were used for one 12-well 
plate of culture.
2.3.3.1 Coating coverslips
25mm sterile coverslips were placed into a 12 well plate and covered with poly-DL- 
ornithine ((Sigma, UK), 100pg/mL in 0.15M boric acid) overnight. These were then 
washed 3 times with 1x PBS and covered with laminin ((Sigma, UK), 5pg/mL in 1x 
PBS) for 3-4 hours at 37°C.
2.3.3.2 Dissection and digestion of dorsal root ganglia
Mice were sacrificed using C 02 and all DRGs extracted and placed into HBSS. The 
ganglia were then cleaned of blood and excess nerve with fine forceps and scalpel 
and placed into 1.6mL DMEM. 400pL of collagenase ((Roche, UK), 1.25% in 1x PBS) 
and 40pL trypsin (2.5%) were added to the ganglia and incubated at 37°C for 2 hours, 
agitating every 20 mins until fluffy in appearance. Ganglia were then washed twice in 
excess DMEM containing 10% horse serum (Gibco, Paisley, UK) to inactivate the 
collagenase.
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2.3.3.3 Dispersion and plating of dorsal root ganglia
The ganglia were dispersed using Pasteur pipettes with diminishing diameter and then 
12mL DRG media added (DMEM + 10% Horse serum) and the ganglia plated out onto 
the pre-prepared coated coverslips (after removing the laminin) at 1ml_/well. After 24 
hours the media was changed to DRG media supplemented with 5pM cytosine 
arabinoside to kill all dividing non-neuronal cells. After 2 days the cultures were ready 
for viral infection.
2.3.4 Transient transfection assays
2.3.4.1 DNA transfections
Transfections were performed with plasmid DNA prepared by the ‘midi-prep’ method 
(section 2.2.22). The transfection method was based on the calcium phosphate- 
mediated method (Stow and Wilkie 1976). Cells were grown in 35mm wells until they 
were 80% confluent. Two tubes were set up labelled A and B. Tube A contained 31 pL 
2M CaCI2, 10pg plasmid DNA and 20pg herring sperm DNA (Sigma). Tube B 
contained 400pL HEBES transfection buffer. (140mM NaCI, 5mM KCI, 0.7mM 
Na2HP04, 5.5mM D-glucose, 20mM Hepes, pH 7.05 with NaOH). The contents of tube 
A were carefully mixed by gentle pipetting and then added slowly to tube B drop-wise 
with gentle mixing. The mixture was then left for 40 mins to allow the DNA to 
precipitate. Media was removed from the cell monolayer and the precipitated DNA 
mixture was then added and incubated for 30 mins. After this time, 1mL FGM was 
added to the cells. After a further incubation of 4-5 hours, the cells were DMSO 
shocked by removing the transfection/media from the cells and washing twice with 
FGM. 1mL of ice-cold 25% (v/v) DMSO in HEBES transfection buffer was added and
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left for 1.5 mins. The DMSO solution was removed and the cells washed twice with 
FGM. A final 2mL FGM was added to the cells before incubation at 37°C/5% C 0 2.
2.3.4.2 Detection of p-Galactosidase by X-Gal staining
Media was removed from the cells and then washed twice with 1x PBS. Cells were 
then fixed with 0.1% (v/v) glutaraldehyde in 1x PBS for 10 mins at room temperature. 
The cells were washed with 1 x PBS before the addition of X-Gal solution (5mM 
K3Fe(CN)6, 5mM K4Fe(CN)6.6H20, 1mM MgCI2l 150pg X-Gal dissolved in DMSO in 1x 
PBS). Cells were then incubated at 37°C until blue colour seen. The X-Gal stain was 
removed and cells washed twice in 1x PBS before addition of 70% (v/v) glycerol and 
storage at 4°C.
2.3.4.3 p-Galactosidase activity assay
To quantify the level of (3-galactosidase, the high-sensitivity (3-Galactosidase assay kit 
(Stratagene, Netherlands) was used as per the manufacturer’s instructions. Briefly, 
cells were washed with 1x PBS, lysis buffer added and the cells frozen at -20°C for 30 
mins. The cell lysates were then harvested and centrifuged to remove the cell debris. 
The supernatant was then used in a reaction with the substrate chlorophenol red-p-D- 
galactopyranoside (CPRG) and then assayed in triplicate using a Dynex Optiplex plate 
reader at 595nm. Occasionally the lysate required a 1:10 dilution before assay.
2.3.5 Virus construction and propagation
All HSV-1 recombinant vectors were derived from the 17syn+ HSV-1 strain isolated in 
Glasgow (Brown et al. 1973) and the 1764 strain (Coffin et al. 1996a). The latter strain 
refers to 17syn+ deleted for both copies of ICP34.5 (MacLean et al. 1991b) and an 
inactivating mutation (12bp linker insertion) in the C-terminal transactivation domain of 
VP16 -  /n1814 mutation (Ace etal. 1989). The VP16 deficiency was complemented for
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by the addition of hexamethylene bis-acetamide (HMBA) to the growth media, to a 
final concentration of 3mM. BHK or MAM49 cells were used for virus generation and 
propagation.
2.3.5.1 Homologous recombination transfections
Transfections were carried out as in section 2.3.4.1 except that 10-30pg of viral DNA 
(see section 2.2.7) was added to tube A and the transfection was left for 5-7 hours 
before DMSO shock. FGM containing 3mM Hexamethylene bisacetamide (HMBA) 
was added to the transfections at the final stage. The transfections were left for 3 -5  
days until complete cytopathic effect (CPE) was observed and were then harvested 
and freeze-thawed. The cells were then titred (see section 2.3.5.2) and the efficiency 
of recombination determined by assaying for recombinants having lost or gained a 
reporter gene.
2.Z.S.2 Viral plaque assay
Serial ten fold dilutions of a virus suspension (either harvested from homologous 
recombination or from a pure stock) were prepared in DMEM without FCS and plated 
onto 80% confluent 35mm wells of appropriate cells in a total volume of 500pl. The 
virus was allowed to adsorb for 60 mins at 37°C/5%C02 and then the monolayers were 
overlaid with 2mL of a 1:2 (v/v) mixture of 1.6% carboxymethylcellulose (CMC): FGM 
supplemented with 3mM HMBA. The cells were then incubated for a further 48 hours 
at 37°C/5% C 0 2 and the number of plaques were counted in order to determine the 
titre of the virus in plaque forming units (pfu)/mL.
Cells expressing green fluorescent protein (GFP) required no pre-treatment and were 
visualised directly under an inverted fluorescent microscope at a wavelength of 
520nm. Cells expressing 0-galactosidase were stained with X-Gal (section 2.3.4.2) 
prior to plaque counting. If the virus contained no reporter gene, the cells were fixed 
with glutaraldehyde (section 2.3.4.2) and 1mL of a 0.05% (w/v) crystal violet in 20%
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(v/v) ethanol solution added for 3 mins before washing, and then visualising of viral 
plaques.
2.3.5.3 Purification of viral recombinants by plaque selection
Titred transfection mixes were visualised by one of the methods described in section
2.3.5.2 and the identified plaques were picked from the cell monolayer using a P20 
Gilson micropipette (set at 3pl). Selected plaques were transferred into 100pl SFM and 
frozen at -80°C. The plaque suspension was thawed and 10pl and 90pl used to infect 
wells of a 6 well plate containing cells at 80% confluency in 500pL SFM per well. Cells 
were left for 1 hour at 37°C/5% C 02 and then overlaid with 2mL 1:2 (v/v) mixture of 
1.6% carboxymethylcellulose (CMC): FGM supplemented with 3mM HMBA. Cells 
were then incubated for a further 48 hours at 37°C/5%C02. The plaque purification 
process was repeated until a pure population was obtained. When this was achieved a 
single plaque was used to infect one well of a 6 well plate and incubated until CPE 
was detected. The whole well was then harvested and its titre determined (section
2.3.5.2). This was then used as a master stock (MS) for large-scale propagation of the 
recombinant virus.
2.3.5.4 High titre viral stock production
Approximately 300pl of MS was used to infect 90% confluent cells in 80cm2 flasks. 
Cells were infected with virus in SFM for 1 hour at 37°C/5%C02 after which cells were 
overlaid with FGM containing 3mM HMBA if necessary. Cells were harvested when 
complete CPE was observed. The virus was grown in 175cm2 flask until enough was 
obtained to infect 10 x 245mm2 plates of cells grown to 90% confluency. Each plate 
was infected with 5x106 pfu of virus stock suspension in a total volume of 50ml FGM 
supplemented with HMBA. Cells were harvested by freezing at -80°C, followed by 
thawing and pooling of the cell suspensions. Cells were centrifuged at 3500rpm for 45 
mins to remove cell debris. To pellet the virus particles, the supernatant was spun at 
12000rpm in a Sorvall RC 26 Plus Centrifuge using a SLA-1500 rotor for 2 hours at
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4°C. The supernatant was removed and a small volume of SFM media added (50|jl 
per 250ml cell suspension). The virus pellet was resuspended by shaking on an orbital 
shaker overnight at 4°C. 25pl and 50pl aliquots of the resuspended virus were stored 
in liquid nitrogen. The titre of the resuspended virus was then determined (section
2.3.5.2).
2.3.S.4.1 Filtration of viral stocks
If the virus in use was a replication incompetent virus it was filtered during high-titre 
production to remove complementing proteins present in the cell suspensions. This 
was carried out after removal of the cell debris and was performed using a 0.65 + 0.45 
pM progressive filter, (Sartorius, Germany) attached to a Watson-Marlow pump. The 
filtered supernatant was then centrifuged at 12000rpm for 2 hours in a Sorvall RC 26 
plus centrifuge using a SI_A-1500 rotor and resuspended as described (section 
2.3.5.4).
2.3.6 Growth curves
80% confluent 12-well plates of BHK cells were infected at an MOI of 0.1 in a final 
volume of 250pl of SFM. Virus was allowed to adsorb for 30-60 mins at 37°C/5%C02 
and then the monolayers were overlaid with 500pl of FGM (supplemented with 3mM 
HMBA if necessary). Cells were harvested at 0, 4, 7, 22, 30 and 51 hours post­
infection. Harvested samples were freeze-thawed to disrupt the cells and the yield of 
the virus was measured by plaque assay (section 2.3.5.2).
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2.4 IN VIVO WORK
All experiments were carried out in accordance with the UK Animal Scientific 
Procedures Act 1986.
Balb/C mice were obtained from Harlan Laboratories (Oxon, UK). Balb/C SCID mice 
were obtained from breeding colonies within the Department of Biological Services, 
UCL. SCID mice are homozygous for the severe combined immune deficiency 
spontaneous mutation (Prkdcso,d, commonly referred as SCID) and are characterised 
by an absence of functional T and B cells.
2.4.1 Footpad delivery
Groups of three or ten mice were anaesthetised by fluothane inhalation and inoculated 
in the left rear footpad (Cook and Stevens 1973a; Stevens and Cook 1971a) with 20pl 
of a high titre stock (section 2.3.5.4) of recombinant vector, at the desired dose. At 
various times post-inoculation the mice were sacrificed and the ipsilateral lumbar DRG 
(L3-L6) were removed and reporter gene expression determined (sections 2.4.1.1 and
2.4.1.2).
2.4.1.1 Detection of p-Galactosidase activity in extracted DRG
DRG dissected from mice were placed in 1x PBS. The DRG were then fixed with 4% 
(w/v) paraformaldehyde (PFA) in 1x PBS for 1 hour on ice. The DRG were then 
washed 3 times with 1x PBS for 15 mins each wash. The DRG were then placed in 
100pl of DRG X-Gal solution (5mM K3Fe(CN)6, 5mM K4Fe(CN)6.6H20 , 1mM MgCI2, 
0.02% (w/v) sodium deoxycholate, 0.02% (v/v) NP-40 and 40mg/mL X-Gal in DMSO, 
in 1x PBS) and incubated at 37°C overnight. The X-Gal solution was removed and the 
DRG placed in 70% (v/v) glycerol and stored at 4°C prior to photography. DRG to be
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photographed were mounted in 1x PBS on a glass slide and coverslipped. 
Photographs were taken at 10x magnification on a Zeiss Axiophot microscope.
2.4.1.2 Detection of GFP in extracted DRG
DRG dissected from mice were placed in 1x PBS. The DRG were then fixed with 4% 
(v/v) PFA in 1x PBS for 1 hour, on ice. The DRG were then washed 3 times with 1x 
PBS for 15 mins each wash. DRG to be photographed were mounted in 1x PBS on a 
glass slide and coverslipped. GFP expression was then visualised under fluorescent 
light (520 nm) at 10x magnification and photographed (Zeiss Axiophot microscope). 
When dual expression of GFP and /3-Gal was to be assessed, GFP fluorescence was 
examined prior to X-Gal staining as otherwise /3-Gal masked the GFP fluorescence.
2.4.2 Stereotaxic injections
For all CNS injections a Kopf stereotaxic frame (dual small animal stereotaxic, Kopf 
Instruments, USA) was used and coordinates established according to a stereotaxic 
mouse brain atlas (Franklin and Paxinos 1997). The head of the anaesthetised animal 
was positioned into the frame, and a sagittal incision was made to expose the skull. 
Tissue was removed and bregma and lambda points marked. Bregma was defined as 
the point of intersection of the sagittal suture with the curve of best fit along the coronal 
suture. When the two sides of the coronal suture met the sagittal suture at different 
points, bregma usually falls midway between the two junctions. The incisor bar was 
adjusted until the heights of lambda and bregma were equal (flat-skull position). The 
tip of the needle was positioned at Bregma, the appropriate anterior-posterior and 
medial-lateral coordinates calculated and the injection site marked. A hole was made 
through the skull with a needle without damaging dura. The injection needle was 
lowered until the tip just touched the tissue surface. The dorsal-ventral coordinates 
were calculated and the needle accordingly lowered. Injections were carried out using
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an automatic micro injector (World Precision Instruments, USA) with a flow rate set at 
0.5-1 |jL/min. Following injection, the needle was left in place for an additional 5 mins to 
allow the injectate to diffuse from the needle tip. The needle was then removed within 
3mins. The wound was closed using metal clips and the animal allowed to recover. At 
various times post-inoculation the mice were sacrificed, perfused with ice-cold 4% 
(w/v) PFA and the brains removed. The brains were post-fixed for 1 hour in 4% PFA 
and then washed in 1x PBS.
2.4.2.1 Detection of p-Galactosidase activity in extracted brains
Whole brains were set in 3% agarose using peel-away agarose moulds (Agar 
Scientific, Cambs., UK), and then mounted with superglue onto a vibrating microtome 
(Campden Instruments, Loughborough, UK). Sections were taken from the injected 
side of the brain of 200pM thickness and then placed into X-gal tissue stain (see 
section 2.4.1.1). Sections were incubated overnight at 37°C to allow for colour 
development. Sections were then washed in 1x PBS and stored in 70% (v/v) glycerol 
until photographed.
2.5 STATISTICAL ANALYSIS
Statistical analysis was performed using the appropriate statistical test. Statistical 
comparisons were made by ANOVA when more than three groups were involved. 
Data were expressed as means ± standard error of the means (SEM). All statistics 
were performed using the Prism software package Version 4.03 (Graphpad Software 
Inc, CA, USA).
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CHAPTER 3:
CONSTRUCTION AND TESTING OF HSV1 
VECTORS CONTAINING LATP2 DELETION 
CONSTRUCTS (I)
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3.1 INTRODUCTION
Long-term transgene expression from HSV1 vectors has been achieved by a number 
of different groups as discussed in chapter 1 (Andersen et al. 1992; Berthomme et al. 
2000; Bloom et al. 1994; Bloom et al. 1995; Carpenter and Stevens 1996; 
Chattopadhyay et al. 2005; Dobson et al. 1989; Dobson et al. 1990; Goins et al. 1994; 
Goins etal. 1999; Ho and Mocarski 1989; Lachmann and Efstathiou 1997; Lokensgard 
et al. 1994; Lokensgard et al. 1997; Marshall et al. 2000; Perez et al. 2004; Puskovic 
et al. 2004). It has been shown that the region downstream of the LAP2 promoter, the 
long-term expression element (LTE), is required to maintain expression from the LAP1 
promoter during latency (Berthomme et al. 2000; Lachmann and Efstathiou 1997; 
Lokensgard etal. 1997).
Latency associated transcript promoter 2 (LATP2) is the 1.35kb stretch downstream of 
the LAP1 promoter, encompassing the LAP2 promoter and the LTE (nt 118866 to 
120219). It contains promoter, enhancer and long-term expression elements, the latter 
two of which can work in a bi-directional manner. It has been used successfully to 
confer long-term expression on the LAP1 promoter from the gC locus (Berthomme et 
al. 2000; Lokensgard et al. 1997) and the UL43 locus (Palmer et al. 2000). The LATP2 
region and its relationship to the rest of the genome are shown in figure 3-1.
The bi-directional function of LATP2 has been exploited in the previously described 
vector from our laboratory, 1764/UL43/pR20.9. See figure 3-2 (Palmer et al. 2000). 
This vector contains a cassette with the LATP2 region between LAP1 and the MMLV 
LTR driving genes for lacZ and GFP, respectively. When placed in the non-LAT UL43 
locus, within a replication competent viral backbone (1764), this arrangement of 
LATP2 and promoters has been shown to give transgene expression for at least six 
months post-infection in the mouse PNS (unpublished results). The fact that this vector 
can drive expression of two exogenous genes means that it has the potential to be a
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useful tool for a number of research and gene therapy applications in the nervous 
system, where delivery of more than one therapeutic gene is required.
TATA
LATP2
118866 119499 120219118439
Figure 3-1 Diagram of the LATP2 region and the surrounding genome
Numbering refers to nucleotide positions based on the published 17syn+ 
genomic sequence.(McGeoch et al. 1986; McGeoch et al. 1988; McGeoch et 
al. 1991; Perry and McGeoch 1988). UL = unique long region. Us = unique 
short region.
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ICP34.5 ICP34.5
<   >  >
LacZ la p i LATP2 MMLV aGFP
LTR
Figure 3-2 Schematic diagram of the structure of 1764/UL43/pR20.9
The deletions in the backbone virus are shown along with the site of insertion 
of the cassette into the virus (UL43 gene). Arrows show the orientation of the 
promoter elements in the cassette. RL & Rs = Long and short repeat regions. 
UL & Us = Long and short unique regions.
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An important aspect of the development of HSV-based vectors for long-term neuronal 
delivery is the identification and characterisation of promoter and regulatory elements 
that can drive the stable long-term expression of foreign genes during neuronal 
latency. Although the LATP2 region has been shown to be required for long-term 
expression, it has not been fully characterised, although since this project began, other 
groups have attempted to do this (Berthomme etal. 2001). Identifying which regions of 
LATP2 contain regulatory elements could lead to optimal long-term expression from 
this region and thus improved gene therapy vectors.
Therefore the initial aim of this thesis was to characterise the LATP2 region by 
creating a series of deletion mutants based on the 1764/UL43/pR20.9 virus and 
comparing the expression profiles of each by examining levels of GFP and lacZ 
expression at lytic and latent times.
3.2 IDENTIFICATION OF POTENTIAL BINDING SITES WITHIN 
LATP2
It is already known that the LAP2 promoter contains potential c/s-acting elements that 
may be responsible for modulating the promoter activity. These include an Sp1 site 
and putative AP2 and E2F sites (Goins et al. 1994). LAP2 also contains CT rich and 
polyT elements that bind transactivating factors known to regulate cellular 
housekeeping gene promoters.
The program TFSEARCH (Heinemeyer et al. 1998), was used to search the whole 
LATP2 sequence (nt 118869-120219 from HSV1 genbank accession number X14112) 
for other possible transcription factor (TF) binding sites. The results are shown in 
figure 3-3.
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A number of consensus elements for transcription factors were identified, most 
abundantly for AML-1 a and GATA. AML-1 a is known to be a transcriptional activator 
and binds to enhancer motifs (Meyers et al. 1993) whilst GATA TFs are transcriptional 
activators (Merika and Orkin 1993). Other putative binding sites for TFs include p300 
which possesses histone acetyltransferase activity, which usually activates 
transcription (Ogryzko et al. 1996) but can also act as a co-repressor (Guidez et al. 
2005); MZF1 which has been shown to be a transcriptional repressor (Gaboli et al. 
2001; Morris et al. 1994) and ZID which is also thought to be involved in transcriptional 
repression by interacting with histone deacetylases and Sp1.
This suggests that the region contains both positive and negative regulatory elements 
and as such by creating deletion mutants of the region it will hopefully be possible to 
identify where the strongest repressing or activating elements are located.
102
Chapter 3 LATP2 deletion vectors (!)
|-------► Start of 5 'half LATP2/LAP2
118869 c cggggcggcc aaggggcgtc ggcgacatcc tccccctaag cgccggccgg
118921 ccgctggtct gttttttcgt tttccccgtt tcgggggtgg tgggggttgc ggtjtctgtt
118981 tctttaaccc gtctggggtg tttttcgttc cgtcgccgga atgtttcgtt cgtctgtccc
I_______1
119041 ctjeacggggc gaaggccgcg tacggcccgg gacgaggggc ccccgaccgc ggcggtccgg 
i ►Start of Mid LATP2
119101 gccccgtccg gacccgctcg ccggcacgcg acgcgaaaaa ggccccccgg aggcttttcc
119161 gggttcccgg cccggggcct gagatgaaca ctcggggtta :cgccaacgg c :ggcccccg
119221 tggcggcccg gcccggggcc ccggcggacc caaggggccc cggcccgggg ccccacaacg 
119281 gcccggcgca tgcgc|tgtgg ttjtttttttc ctcggtgttc tgccgggctc catcgccfttt 
119341 cctgttctcg cttdtccccc ccCccttctt cacccccagt accctcctcc ctcccttcct
119401 cccccgttat cccactdgtc gagggcgccc cggtgtcgtt caacaaagac gccgcgtttc 
Start of 3' half /end of 5' half LATP2/LAP2 |— -►
119461 caggtaggtt agacacctgc ttctccccaa tagagggggg ggacccaaac gacagggggc
119521 gccccagagg ctaaggtcgg ccacgccact cgcgggtggg ctcgtgttac agcacaccag
119581 cccgttcttt tccccccctc ccacccttag tcagactctg ttacttaccc gtccga|ccac|
End of Mid LATP2
119641 caactgcccc ctta :ctaag ggccggctgg aagaccgcca gggggtcggc cggtgtcgct
119701 gtaacccccc acgccaatga cccacgtact ccaagaaggc atgtgtccca ccccgcctct
119761 gtttttgtgc ctggctctct atgcttgggt cttactgcct ggggpggggg agtgcggcgg 
119821 agggggggtg tggaaggaaa tgcacggcgc gtgtgtaccc cccctaaagt tgttcctaaa
119881 gc^aggatac ggaggagtgg cgggtgccgg gggaccgggg tgatctctgg cacgcggggg 
119941 tgggaagggt cgggggaggg ggggatggag taccggccca cctggccgcg cgggtgcgcg 
120001 tgcctttgca caccaacccc acgtcccccg gcggtctcta agaagcaccg ccccccctcc
120061 ttcataccac cgagcatgcc tgggtgtggg ttggtaacca acacgcccat cccctcgtct
120121 cctgtgattc tctggctgc a ccgcabtctt gttttctaac tatgttcctg tttctgtctc]
------------  ^  | End of 3' half LATPz
120181 cccccccccc acccctccgc cccacccccc aacacccac
Figure 3-3
Key:
Sequence of LATP2 showing putative TF binding sites.
TF binding sites with a score of >90 are shown from a search using the 
TFSEARCH program. The areas of LATP2 used for cloning are also marked.
AML-la MZF1
GATA-1 ZID
AhR/Ar
Spl
v-Myb
p300
c-Myb
103
Chapter 3 LATP2 deletion vectors (I)
3.3 LATP2 DELETION PLASMIDS
A series of plasmids was constructed based on the pR20.9 plasmid with various 
deletions of the LATP2 region (figure 3-4). The first contained the 3’ half of LATP2, 
which removes the LAP2 promoter. The second contained the mid section of LATP2 
with regions from both the 3’ and 5’ ends deleted. The third contained the 5’ half of 
LATP2, equating to the LAP2 promoter only. A fourth plasmid was created by 
removing the LATP2 region from pR20.9 completely. Details of construction are 
provided below.
The reporter genes used in this study were green fluorescent protein (GFP) and iacZ. 
The IacZ gene encodes the bacterial E. coli enzyme IacZ (p-Gal), which forms a blue 
intracellular precipitate upon incubation with “X-Gal” substrate. This reporter gene is 
commonly used to detect gene expression in neural tissue (Sanchez-Ramos et al. 
2000), and elsewhere. GFP use is also widespread. GFP is very stable, relatively non­
toxic and allows direct detection of gene expression. Each of these properties makes 
GFP a very useful marker gene (Tsien 1998). Zhang and co-workers developed an 
enhanced GFP protein (eGFP) (Zhang et al. 1996). This version gives enhanced 
fluorescence compared to wild type GFP and is widely used to detect gene transfer in 
mammalian systems. The eGFP version from pEGFPNI (Clontech) was used 
throughout this thesis.
3.3.1 Method of Construction
pR20.9 was digested with KpnMNs'A to remove the LAP1/LATP2/MMLV/GFP 
fragment. LAP1 was digested from pP1/acZSrf with Kpn'\/Nsrt and re-ligated into the 
digested pR20.9 plasmid.
An oligonucleotide was then ligated after LAP1, to allow reinsertion of MMLV & GFP 
(from pJ4GFP (Morgenstern and Land 1990) by digestion with NsiWT4/Nhe'\):
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Nsil compatible
Xhol — —  Soe/ Nhel Hindlll ......
Strand 1 - 5’ CTCGAGTCCGGACTAGTGCTAGCTGACAAGCTTTGCA 3’
Strand 2 - 5 ’ AAGCTTGTCAGCTAGCACTAGTCCGGACTCGAGTGCA 3’
The LATP2 deletion fragments were all digested from pP2BSK (M. Robinson) as 
follows: -
(1) PpuM'l -  Spe1 (HSV nt 119502 - 120219) (3’LATP2)
(2) BspE^ -  Bbsl (HSV nt 119107 -  119677) (Mid LATP2)
(3) Xho^ -  PpuMl (HSV nt 118866 -  119502) (5’ LATP2)
(4) No LATP2
These were then ligated into the cassette at the oligonucleotide by digestion with 
appropriate enzymes to give the series of LATP2 deletion plasmids (Figure 3-4).
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P lasm id
N a m e
+1 +282 +678 +854 +1411
Xho1 BspE1 PpuM1 Bbs1 Spe1
I I I
p G E M 5- LAP.1 LAIE2. MMIV | 3K3M— pR20.9
Xba1 Xho1
1---------------L-. 3' LA TP 2 . . 1 .S Z B B - p1
1-------E Mid LA TP2 ^ -------------- 1 p2
r" 5’latp2 "E---------------E 1 ___ p3
^ ----------- 1------------------------------ 1 1 —
r w
P4
Figure 3-4 Schematic of LATP2 deletion cassettes
Restriction sites used to clone LATP2 fragments from pP2BSK are shown 
along with numbering relative to the start of LATP2 in the same plasmid. Other 
restriction sites shown were used in restriction digest analysis (NB Diagram not 
to scale).
Plasmid structures were confirmed by restriction digest analysis using Xba1 or Xho1. 
PCR was also carried out to confirm that the correct fragments of LATP2 were 
present. Primers exclusive to each section of LATP2 were used in PCR reactions on 
all five plasmids as shown in Table 3-1 and Figure 3-5.
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Region
of
LATP2
Forward Primer Reverse Primer
3’ half 
(P1)
AP2-1F1
CCCTAAAGTTGTTCCTAAAGC
AP2-1R1
AGGGGATGGGCGTGTTGGTTA
Mid
section
(P2)
AP2-2F
TT AT CCCACT CGT CGAGGGC
AP2-2R
AGAACGGGCTGGTGTGCTGTAA
5’ half
(p3)
AP2-3F
TCGGCGACATCCTCCCCCTAA
_____  _______
AP2-3R
G AAACATT CCGGCGACGG AA
Table 3-1 Primers used in PCR reactions for LATP2 deletion fragments
M 1 2 3 4 5 M a.
254bp
95°C -  3 mins x1 cycle
x30 cycles 
72°C -  10 mins x1 cycle
95°C -  1 min “I 
58°C - 1  min 
72°C -  1 min J
1 2 3 4 5 M
181 bp
95°C -  3 mins x1 cycle
95°C -  1 min “ I
54°C -  1 min x30 cycles
72°C -  1 min J
72°C -  10 mins x1 cycle
1 2 3 4 5 M
139bp
95°C -3m ins x1 cycle
95°C -  1 min "
57°C -  1 min x30 cycles 
72°C -  1 min -
72°C -  10 mins x1 cycle
Figure 3-5 Gel photos showing PCRs on all five plasmid constructs with primers for 
each section of LATP2 and the respective PCR program used.
a - Primers for 3’ half LATP2. b - Primers for mid LATP2. c - Primers for 5’ half 
LATP2. (M = Marker, 1 = p1, 2 = p2, 3 = p3, 4 = p4, 5 = pR20.9)
107
Chapter 3 LATP2 deletion vectors (I)
The cassettes were then excised from the pGEM5 (Promega) backbone with Srf1 and 
ligated into the plasmid p35mod at the unique site A/s/1. p35mod contains a 5.1Kb 
BamM/EcoR1 fragment of HSV1 (nt 91619-96751), encompassing the UL43 gene and 
regions flanking UL43, inserted into pGEM2 (Promega). Insertion into the Nsi1 site in 
the UL43 gene (nt 94911) causes inactivation of the gene. Use of this plasmid will 
allow recombination of the cassettes into the UL43 gene of HSV1.
Because the insertion into p35mod can occur in either orientation due to the double- 
blunt digestion and ligation necessary, restriction digests of the resulting plasmids 
were carried out firstly to check that the insertion had taken place and secondly to 
identify in which orientation each cassette was relative to UL43. Figure 3-6 shows the 
structure of the cassettes in UL43 and the restriction digests by Xba*\ and Age 1.
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Plasmid
Name
pR 20.9
UL43
p1 UL43
p2 UL43
p3 UL43
p4 UL43
a.
2 0 0 0 b p
1650bp ^  
1000bp —
b.
Figure 3-6 Structure of the LATP2 deletion cassettes in UL43 flanking regions
a. Diagram showing the structure of the different plasmids and the 
restriction sites used for analysis. The position of the Age 1 site differs between 
plasmids as the cassettes were inserted into the UL43 region by double-blunt 
ligation.
b. Gel photo of restriction digests using Xba 1 and Age 1 to show 
orientation of the cassettes. (M = Marker. 1 = p1/UL43, 2 = p2/UL43, 3 = 
p3/UL43, 4 = p4/U|_43, 5 = pR20.9/UL43) It can be seen that cassettes 1, 2 and 
3 are in the opposite orientation to cassettes 4 and 5.
UL43 
Flanking
  ___________________ Region
m m i v  [ T & f f f S ]  i -LAT.P2
Flanking 2040bp 2200bpRegion
1879bp 
]  Mid LATP2
1985bp
1200bp
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As the cassettes were to be inserted into HSV1 in the UL43 gene by homologous 
recombination, the different orientations of the cassettes within the plasmids would 
also result in them being in differing orientations within the virus. It was not thought 
that this would affect the gene expression from within the cassettes, as UL43 and the 
surrounding genome are quiescent during latency, therefore any transgene expression 
seen should be influenced by elements within the cassette only, regardless of 
orientation in the virus.
3.4 IN VITRO TESTING OF PLASMID CONSTRUCTS
Following construction, the plasmids were tested in transient transfection assays to 
determine the levels of expression of the marker genes. These were carried out in 
BHK cells (fibroblast) and ND7 cells (neuronal).
5jig of each plasmid was transfected into each cell line (n=4). In 3 sets of the 
transfections the cells were harvested after 48 hours and the level of IacZ expression 
determined using the high-sensitivity (3-Galactosidase assay kit (Stratagene), (i.e. the 
results of 9 individual transfections). The level of expression for each plasmid was 
expressed as a percentage of the total activity of pR20.9/UL43. The results are shown 
in figure 3-7.
The fourth set of transfections was examined after 48 hours for GFP expression under 
a fluorescence microscope in order to visualise this expression. The levels of GFP 
were not quantified due to inaccuracies in counting GFP positive neurons under a 
microscope. Examples of GFP expression in the transfected cells are shown in figure 
3-8a-b.
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£
>
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o<Arejo
<o
2ore
re
9>
CO.
250 -
mock p1/UL43 p2/UL43 p3/UL43 p4/UL43 pR20.9/UL43
transfected (3' LATP2) (mid LATP2) (5' LATP2) (no LATP2) (full LATP2)
Plasm id
a. BHK
aS 300
■f 250
8 200
% 150
S 100
mock p1 AJL43 p2/UL43 p3/UL43 p4/UL43 pR20.9/UL43
transfected (3'LATP2) (mid LATP2) (5'LATP2) (no LATP2) (full LATP2)
Plasmid
b. ND7
Figure 3-7 LacZ activity of LATP2 deletion plasmids In Vitro.
5pg plasmid was transfected into BHK cells (a) and ND7 cells (b). Data is 
represented as the % IacZ activity compared to that given by pR20.9/UL43. 
The graphs depict average values of 3 transfection wells and the error bars are 
shown as SEM. (* - p<0.05, ** - p<0.01)
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Figure 3-8a
Mock
T ransfected
P1/UL43
p2/UL43
P3/UL43
P4/UL43
pR20.9/UL43
GFP expression from plasmids in BHK cells.
Cells were transfected with 5pg each plasmid and after 48 hours visualised for 
GFP expression. The photographs are representative regions of transfections 
used for the graphs in figure 3-7.
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Figure 3-8b
Mock
Transfected
p1/UL43
p2/UL43
P3/UL43
P4/UL43
pR20.9/UL43
GFP expression from plasmids in ND7 cells.
Cells were transfected with 5^g each plasmid and after 48 hours visualised for 
GFP expression. The photographs are representative regions of transfections 
used for the graphs in figure 3-7.
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The results of the IacZ quantification show the effect of deletions of the LATP2 region 
on IacZ expression from plasmid constructs in vitro. The effect of LATP2 in this 
arrangement would be expected to be that of an enhancer on LAP1 promoting IacZ 
expression.
Interestingly, p4/UL43, the plasmid containing no LATP2, seems to give a similar (in 
BHK cells) or significantly higher (in ND7 cells, p<0.01) level of IacZ expression 
compared to pR20.9/UL43, containing the whole of LATP2. When only the 5’ half of 
LATP2 (p3/UL43) is present, it appears to reduce IacZ expression from LAP1 
significantly (p<0.05). It is almost reduced to background levels in both cell types. This 
could suggest that there is a repressive element in this region of LATP2. Removing 
this 5’ region, as is the case in plasmid p1/UL43, is not sufficient to alleviate this 
repression fully, particularly in ND7s where the level of IacZ activity is significantly 
(p<0.05) lower compared to the plasmid without LATP2 (compare p1/UL43 and 
p4/UL43). This suggests that there is a repressive element in the 3’ half of LATP2 also. 
These repressive elements can perhaps be further localised by looking at the level of 
IacZ expression in plasmid p2/UL43. This plasmid has regions from both ends of 
LATP2 deleted which seems to remove the repression and increase enhancer activity, 
allowing IacZ expression above that from the full LATP2 and approximately to that of 
the plasmid containing no LATP2 (p4/UL43).
The results from the plasmid with no LATP2 are somewhat surprising, as similar 
studies have shown that plasmids containing full LATP2 regions linked to LAP1 give 
much higher (4 -  5x) expression of IacZ than those without LATP2 (Berthomme et al. 
2000; Berthomme et al. 2001). This group also showed that a plasmid containing the 
5’ half of the LTE gave similar IacZ expression to that of a plasmid containing the 
whole LATP2 region. However, in both these cases, the LATP2 region was placed 
downstream of LAP1, between LAP1 and the IacZ gene, so as to preserve the 
arrangement of the LAT region to that of the native virus. This LAT promoter
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arrangement and the fact that the plasmids used here also contain the MMLV LTR 
probably accounts for the difference in results seen.
3.5 VECTOR CONSTRUCTION
Viral vectors were produced using the 1764 virus backbone, as this is the virus that 
was used previously to insert the pR20.9/UL43 cassette into for in vivo testing and 
allows long-term expression in the PNS. The 1764 viral mutant is deleted for the 
neurovirulence factor ICP34.5 and has an inactivated VP16 gene (see section 1.1.4 
and figure 3-2), therefore having reduced toxicity compared to wild-type HSV1. This 
vector has previously been shown to infect the PNS efficiently in animal models (Coffin 
et al. 1996b; Palmer et al. 2000). The recombinant vector does not need to be grown 
on a complementing cell line, as ICP34.5 is non-essential for replication in cell culture. 
The VP16 mutation can be complemented for by addition of HMBA to the media (Ace 
etal. 1988).
The UL43 gene has been shown to be a suitable insertion site for the expression 
cassettes from 1764. UL43 has no known function, but contains multiple hydrophobic 
stretches and is predicted to be a membrane channel protein (Carter et al. 1996). UL43 
is not required for replication of the virus, nor does it affect the growth characteristics 
of the virus (MacLean et al. 1991a). The use of an insertion site outside of the LAT 
region assures that the virus establishes a normal latent infection by producing LATs. 
Deletion of certain regions of the LAT region may otherwise alter the ability to establish 
latency otherwise by altering LAT production as discussed in chapter 1, section 
1.1.2.4.2 (Thompson and Sawtell 1997).
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The four LATP2 deletion plasmids were linearised with Xmn 1 and co-transfected with 
1764 viral DNA (see figure 3-9). Recombinant vectors containing the cassettes were 
identified by gain of eGFP and IacZ marker genes and plaque purified. Insertion of the 
cassettes was confirmed by Southern blot analysis (see figure 3-10).
ICP34.5 ICP34.5
Ul43 VP16
1764
Viral
DNA
Plasmid
DNAUl43
Flanking
Regions
Ul43
Flanking
Regions
Figure 3-9 Homologous recombination to produce recombinant HSV vectors
Plasmid DNA was co-transfected with 1764 viral DNA into BHK cells. During 
lytic replication, homologous recombination occurs between the UL43 flanking 
regions present in both plasmid and viral DNA.
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4577bp
Non Not1 4460bp Not1I
1764 — L "  T l i AP1 czz . A L A .IP 2 ! M M L V  r
UL43
Probe
M +' 1 2 3 4 5
4 4 6 0 -
45 7 7 b p
Figure 3-10 Southern Blot analysis of Viral Recombinants
Viral DNA was digested with A/of1 and probed for the IacZ gene. The two A/oM 
sites in UL43 are of an almost equal distance either side of the inserted 
cassettes such that either orientation of cassette in the virus gives a similar 
size band.
(M = 1Kb+ Marker, + = Positive plasmid control, 1 = 1764/UL43/1, 2 = 
1764/UL43/2, 3 = 1764/UL43/3, 4 = 1764/UL43/4, 5 = 1764/UL43/20.9)
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3.6 IN VITRO TESTING OF RECOMBINANT VECTORS
3.6.1 Viral plaque characteristics
During purification of the viral vectors it was noted that the plaque phenotype of all of 
the LATP2 deletion mutants was similar to that of the 1764/UL43/20.9 virus as would 
be expected. It had been seen with previous use of this virus in our laboratory, (Palmer 
et al. 2000) that the IacZ expression in vitro was weaker than with a similar virus in 
which the LATP2 region was placed in a back-to-back fashion with the RSV and CMV 
promoters in place of LAP1 and MMLV LTR respectively. Figure 3-11 shows the 
differences in phenotype between these viruses (R. Branston, unpublished data). It 
was suggested that it could be a result of viral protein repression on LAP1, only 
present in 1764/UL43/20.9, as GFP expression from both viruses is similar and during 
transient transfection of the corresponding plasmids, IacZ expression is just as strong 
in both. Furthermore, when the 1764/UL43/20.9 virus is plated on BHK cells together 
with acyclovir preventing replication, X-Gal staining of transduced cells is strong (figure 
3-12). It is known that the ICP4 protein down-regulates LAP1 during productive 
infection, by binding to the ICP4 binding motif in the cap site (Batchelor et al. 1994) 
and it is thus possible that this functions to dampen LAP1 in the 1764/UL43/20.9 virus 
in vitro. Nevertheless, IacZ expression from 1764/UL43/20.9 in latently infected 
neurons in vivo is known to be strong (Palmer et al. 2000), perhaps due to an absence 
of ICP4 at this time.
Figure 3-12 shows the LATP2 deletion virus plaques expressing IacZ and GFP. It can 
be seen that all the LATP2 deletion viruses have the same phenotype as 
1764/Ul43/20.9, with IacZ expression being repressed in the same manner. GFP 
expression appears to be similar between all viruses. The relief from repression given 
by acyclovir on IacZ expression is also illustrated.
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LacZ GFP
4
1764/Ul43/20.9
. ^ J |
1764/Ul43/20.5
Figure 3-11 Plaque phenotype of two replication competent vectors.
Each vector contains the central LATP2 region in a back-to-back orientation 
with either LAP1 (20.9) or RSV (20.5) driving IacZ expression and MMLV LTR 
(20.9) or CMV (20.5) driving eGFP expression.
(Photographs courtesy of Dr. R. Branston.)
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- acyclovir + acyclovir
LacZ GFP LacZ GFP
1764/UL43/1
1 764/Ul43/2
1764/Ul43/3
1764/Ul43/4
, . i . ‘  y
11 ■ 7  •-
1764/Ul43/20.9
Figure 3-12 LATP2 deletion virus plaques showing IacZ and GFP expression
BHK cells were infected with virus + or - acyclovir and left for 48 hours. The 
GFP expression was then photographed before staining with X-Gal to visualise 
and photograph IacZ expression. Note that addition of acyclovir inhibits 
replication and thus plaque formation.
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3.6.2 Growth Curves
The recombinant viruses would be expected to behave in vitro similarly to their 
parental counterpart since they contain just an insertion of a cassette into UL43, whilst 
the rest of the viral genome remains unchanged. To confirm this, the recombinant 
viruses’ growth kinetics were compared to the parent virus, 1764, in a growth curve 
experiment, which showed them to be very similar (Figure 3-13).
1.00E+08
1764/UL43/1
1764/UL43/2
1764/UL43/3
1764/UL43/4
1764/UL43/20.9
1764
1.00E+07 ■
~  1.00E+06 -
*  1.00E+05
1.00E+04 -
1.00E+03 *
1.00E+02
Time post infection (hrs)
Figure 3-13 Growth Curves of the LATP2 deletion viruses
Growth Curves were carried out at an MOI of 0.1 as described in Materials and 
Methods (2.3.6).
N.B. The drop in titre between infection and 10 hours reflects virus entry into 
the cells.
Before testing the activity of the LATP2 deletion vectors further, high titre stocks were 
prepared (see 2.3.5.4), along with a stock of the 1764/UL43/20.9 virus for use as a 
control.
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3.6.3 Infection of cell lines
In order to determine the level of reporter gene expression occurring during lytic 
infection of non-neuronal BHK cells and neuronal ND7 cells, these two cell lines were 
infected with the viruses. 3 different MOIs were used for infection -  0.1, 1 and 5. In 
BHK cells, infections at an MOI of 1 or 5 caused considerable cell lysis, resulting in 
very low levels of measurable lacZ expression (data not shown). In ND7 cells, 
infections at an MOI of 0.1 resulted in inadequate infection of cells, also leading to 
non-quantifiable levels of lacZ and therefore no data. These differences between cell- 
types are due to the fact that the 1764 viruses can replicate in BHK cells, and spread 
from cell to cell, whereas in ND7 cells, very few, or no immediate early (IE) genes are 
expressed preventing viral replication (Wheatley etal. 1990; Wheatley etal. 1991).
Four infections were carried out at each MOI for each virus. For 3 sets of the 
infections, whole wells of cells were harvested after 48 hours and the level of lacZ 
expression determined using the high-sensitivity p-Galactosidase assay kit 
(Stratagene). The level of expression for each virus was expressed as a percentage of 
the total activity of 1764/UL43/20.9. The results are shown in figure 3-14.
The levels of GFP were assessed by visualisation only. The fourth set of infections 
were examined after 48 hours for eGFP expression under a fluorescent microscope 
and photographed. Examples of GFP expression in the infected cells are shown in 
figure 3-15.
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Figure 3-14 In vitro (3-galactosidase assays.
BHKs (a) and ND7s (b, c) were infected with virus at different MOIs and left for 
48 hours before assay. (Graph c, no data for 1764/UL43/2). Negative control = 
1764 virus. (* - p<0.01, ** - p<0.001)
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1764/U L43/1
1764/UL43/2
1764/U L43/3
1764/U L43/4
1764/UL43/20.9
Negative
Figure 3-15a BHK cells infected at MOI = 0.1
BHKs were infected with virus and left for 48 hours before visualising GFP by fluorescence 
microscopy. Negative control is 1764 virus.
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Figure 3-15b
1764/U L43/1
1764/U L43/2
1764/U L43/3
1764/U L43/4
1764/UL43/20.9
Negative
ND7 cells infected at MOI = 1
ND7s were infected with virus and left for 48 hours before visualising GFP by 
fluorescence microscopy.
126
Chapter 3
Figure 3-15c ND7 cells infected at MOI = 5
ND7s were infected with virus and left 
fluorescence microscopy.
LATP2 deletion vectors (!)
1764/U L43/1
1764/U L43/2
1764/U L43/3
1764/U L43/4
1764/U L43/20.9
Negative
48 hours before visualising GFP by
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These results show that the 1764/UL43/20.9 virus has a higher level of lacZ expression 
than any of the other viruses (p<0.001) in BHK cells, all of which do not give more 
expression than background levels. However, in neuronal ND7 cells, at an MOI of 1, 
1764/UL43/1 (right half LATP2), 1764/11,43/2 (mid LATP2) and 1764/UL43/20.9 all give 
significantly higher (p<0.001 -  p<0.01) lacZ activity than background levels. This 
appears to be true at the higher MOI of 5 also, although as the data for the mid LATP2 
virus is missing due to loss of two sets of infections, this is not conclusive.
In a similar study, viruses with deletions of more or less the same sections of LATP2 
gave the most expression of lacZ when the full-length region was present in BHK and 
ND7 cells, with the other deletion viruses giving 2.5 -  4 times less expression 
depending on cell type (Berthomme et al. 2001). In that study, the viruses contained 
LATP2 fragments in the natural orientation and position with respect to LAP1; which 
differs from the work described here, where the LATP2 fragments are in the reverse 
orientation and position with respect to the natural orientation of LAP1. Therefore the 
lacZ expression seen by the other group could be a function of promoter activity from 
LAP2 within the LATP2 region, whereas the expression seen in the results described 
above can only come from the LAP1 promoter, with LATP2 acting as an enhancer.
The fact that the two sets of results (those presented here and those of Berthomme et 
al) seem to concur in BHK cells, in both cases the whole of LATP2 being required for 
optimum transgene expression, shows that during the lytic cycle in BHK cells in 
culture, most activity comes from the LAP1 promoter, with elements across the whole 
of LATP2 being required for maximal enhancer activity. As mentioned, when LATP2 is 
in its natural position, promoter and enhancer activity could both affect lacZ expression 
in the vectors. Direct comparison of absolute lacZ expression levels between the two 
sets of viruses would need to be looked at in order to confirm this.
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In neuronal ND7 ceils, the results obtained differ. Berthomme et al found that the virus 
infections gave the same pattern of results as in BHK cells, however the data above 
differs in the two cell types. This could be due to the low lacZ expression levels from 
these viruses in vitro, as discussed previously, such that because they are below the 
detectable range of the assay in some viruses, the differences are just not being seen.
The use of cell lines may not be an ideal method to study the efficiency of 
transcriptional regulation in some cases. Cell lines may not represent the cellular 
environment in vivo, probably not containing the transcription factors present in the cell 
in vivo and may not therefore be physiologically relevant for the study of HSV latency.
3.7 IN VIVO TESTING OF RECOMBINANT VECTORS
To investigate the activity of LATP2 in the viruses described further, in vivo 
experiments were carried out. 1764/UL43/20.9 has previously been shown to give 
higher levels of lacZ expression in vivo than that observed in vitro (Palmer et al. 2000), 
so it was thought likely that the LATP2 deletion viruses would show a similar 
expression pattern.
3.7.1 Testing in the PNS
The use of the footpad inoculation model for examination of expression from LAT 
promoters has been well documented (Cook and Stevens 1973b; Stevens and Cook 
1971b) (see section 2.4.1). 3-week-old Balb/C or Balb/C-SCID mice were injected in 
the left footpad with 20^iL of each virus at a titre of 1 x 108 pfu/mL (Total virus injected 
= 5 x 106 pfu). The dorsal root ganglia from the lumbar region ipsilateral to the injection 
site were removed after 3 days (Balb/C) and 1 month (Balb/C-SCID). These time- 
points correspond to acute infection and latent infection. DRG were post-fixed and
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stained with X-Gal. LacZ positive neurons from DRG at positions L3-L6 were then 
counted.
Initially, 3 mice per virus, per time-point were inoculated and DRG processed. 
However, it was found that there was great variability in the results (data not shown) 
using this number of animals per group, so the experiments were repeated with 10 
mice per time-point.
The method of measuring lacZ activity in whole ganglia has been investigated before 
in our laboratory. It has previously been attempted to measure lacZ expression from a 
virus with a 1764 backbone by chlorophenolred-fc-D-galactopyranoside (CPRG) assay. 
This was met without success even at lytic time-points due to the relatively low level of 
expression. Dobson et al. (Dobson et al. 1995) were able to do this at early time-points 
using a wild-type KOS-based virus, but this did not give enough expression during 
latency to allow quantification by CPRG assay. Dobson et al counted lacZ expressing- 
neurons at lytic times as well as measuring by CPRG and showed that the two results 
obtained tallied. Therefore it is reasonable to count /acZ-positive neurons in DRGs as 
a measure of promoter activity.
On examining the stained ganglia, it was observed that two populations of lacZ -  
positive neurons were present; darkly stained and lightly stained. Those that were 
darkly stained were often associated with stained axons highlighting the tracking of the 
virus from the footpad to the ganglia. The more lightly stained neurons often had a 
‘speckled’ appearance as observed by others previously (Dobson et al. 1990; Ho and 
Mocarski 1989). The two different populations might correspond to unequal amounts 
of virus reaching the neurons of the ganglia from the footpad. Not all neurons will 
receive the same amount of virus during footpad injection. In order to improve the 
recording of lacZ expression and obtain a more meaningful, semi-quantitative result, a 
score was given to each neuron counted -  1 for a lightly stained neuron and 2 for a
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darkly stained neuron, where there was obviously greater transgene expression. 
Results are therefore shown as a weighted lacZ ‘score’ to represent the expression 
level.
3.7.1.1 LATP2 activity 3 days post-injection
Results for 3 days post-injection (p.i.) are shown in table 3-2 and figure 3-16. Selected 
ganglia from each virus-set are shown in figure 3-17.
The results of the lacZ quantification show the effect of deletions of the LATP2 region 
on lacZ expression in vivo at 3 days p.i. Deleting either the 5’ or 3’ half of LATP2 
(viruses 1764/UL43/1 and 1764/UL43/3) reduces lacZ expression significantly 
(p<0.001) compared to that from 1764/UL43/4 (i.e. expression from just LAP1). 
Expression levels of lacZ from the virus 1764/UL43/20.9 and the virus with the mid­
section of LATP2 (1764/Ul43/2) are similar to that without LATP2 (1764/UL43/4). 
There does not appear to be much enhancer activity at all at this time from LATP2. 
This would also suggest that there are repressive elements in both halves of the 
LATP2 promoter; the action of which are only underlined when the other half is not 
present. When neither, both, or fragments of both halves are present, the repression is 
not seen. Perhaps a mechanism exists in the region in which a mirroring effect occurs, 
active and repressive elements in each balancing out the activity of each half when 
both are present. The fact that the repression is not seen when the extreme ends of 
LATP2 are removed as in virus 1764/UL43/2 perhaps points to the repressive elements 
being located in these regions.
Although the GFP expression was not quantified, examining the DRGs under 
fluorescent light shows the general level of this reporter gene activity at 3 days p.i. The 
most notable observation is that levels of lacZ and GFP activity are similar in the 
DRGs (N.B. Figure 3-17 only shows 1 DRG out of up to 40 extracted for each virus).
131
Chapter 3 LATP2 deletion vectors (!)
VIRUS PALE
NEURONS
DARK
NEURONS
TOTAL SCORE S.E.M.
1764/Ul43/1 
(3’ HALF LATP2)
27.8 24.6 77 7.34
1764/Ul43/2 
(MID LATP2)
47 51.1 149.2 16.40
1764/Ul43/3 
(5’ HALF LATP2)
27.7 4.8 37.3 3.17
1764/U l43/4 
(NO LATP2)
42.6 49.5 141.6 14.93
1764/Ul43/20.9 
(FULL LATP2)
44 60.7 165.4 10.65
Table 3-2 Averaged counts of /acZ-positive neurons 3 days p.i.
LacZ positive neurons were recorded per animal, and scored according to 
whether staining for lacZ was pale or dark (n=10).
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Figure 3-16 LacZ expression from LATP2-deletion viruses 3 days post-injection in 
Balb/C mice
Weighted /acZ-positive neuron scores give a semi-quantitative measure of lacZ 
expression from the LATP2 deletion viruses.
*-p<0.01,**-p<0.001.
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LacZ GFP
1764/UL43/1
1764/UL43/2
1764/UL43/3
1764/UL43/4
1764/UL43/20.9
DRGs 3 days post-injectionRepresentative 
m
vrt f ,
Light, punctate 
staining
Dark staining
b. Example of the two populations of stained neurons
Figure 3-17 Photographs of lacZ and GFP expression from LATP2-deletion viruses 3 
days post-injection in Balb/C mice
a. Selected examples of ganglia from animals 3 days 
post-injection showing GFP and lacZ expression.
b. Magnified DRG showing the two types of staining 
seen: paler, punctate staining and darker staining.
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3.7.1.2 LATP2 activity 1 month post-injection
Results for lacZ expression at 1-month p.i. are shown in table 3-3 and figure 3-18. 
Selected ganglia are shown in figure 3-19.
These results demonstrate that the level of expression of lacZ at 1 month is much 
lower (up to 12 times) than at 3 days. As SCID mice were used for the 1-month time- 
point, immune clearance of the viruses should not be playing a large part in the 
reduction in lacZ expression. Furthermore, previously the 1764/UL43/20.9 virus was 
shown to have the same number of LAT-positive cells as /acZ-positive cells during 
latency in vivo by in situ hybridisation (Palmer et al. 2000). Thus the reduced 
expression is not due to promoter inactivation within the cassette. It has been shown 
previously that the number of LATs expressed during latency is less than would be 
expected from the number of viral genomes present (Mehta et al. 1995; Ramakrishnan 
et al. 1994). This could be responsible for the observed reduction in expression of 
transgene between lytic and latent time-points.
The results of the lacZ quantification show the effect of deletions of the LATP2 region 
on lacZ expression in vivo at 1-month p.i. As at 3 days p.i., expression from the virus 
containing only the 5’ half of LATP2 (1764/UL43/3) is significantly lower (p<0.001) than 
that from the virus containing no LATP2 region. The virus without LATP2 
(1764/Ul43/4) gives significantly higher levels of lacZ expression (p<0.001) than that 
with the full LATP2.
These results suggest that there is a repressive element within the 5’ half of LATP2 
acting at latent time-points. It is probably located within the DNA upstream of that 
present in 1764/UL43/2 (the mid section), as this virus gives a similar level of lacZ 
expression to that of the virus containing no LATP2. As the full LATP2 also contains 
this potentially repressive region and yet allows almost as much expression as the mid 
LATP2, there must be other elements also present to balance this repression.
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The low expression level of lacZ from the virus containing the 5’ half of LATP2 is 
interesting as this result does not concur with that seen by (Berthomme et al. 2001). 
This region alone in their virus was sufficient to give as much long-term expression as 
the whole region. The disparity between the two results can probably be explained by 
the difference in arrangement, orientation and location of LAT promoters/enhancer 
within the virus. The long-term activity seen from LATP2 when in the same orientation 
as LAP1 in that study appears to be abrogated when in the reverse direction as seen 
here.
Perhaps the most surprising result is that of lacZ expression levels from the virus 
without any LATP2 (1764/UL43/4). Others have found that expression from LAP1 is 
very low or non-existent at latent time-points without some part of the LATP2 region 
present (Berthomme et al. 2000; 2001; Coffin et al. 1996b; Lokensgard et al. 1994; 
Lokensgard et al. 1997; Margolis et al. 1993). This must be contributed to the 
presence of the MMLV LTR in 1764/UL43/4. As previously mentioned (section 1.1.3), 
the MMLV LTR has been shown to be capable of long-term expression of a transgene 
when linked to LAP1 (Carpenter and Stevens 1996; Dobson etal. 1990; Lokensgard et 
al. 1994). In the work presented here, the MMLV LTR is in the reverse orientation to 
LAP1, acting as an enhancer.
The presence of LATP2 in addition to the MMLV LTR has no advantage in these 
vectors; indeed it appears to be causing repression of this activity by MMLV LTR in 
varying degrees depending on which part is present. Thus the effects of the MMLV 
LTR promoter may be obscuring those of LATP2 on LAP1.
In figure 3-18, the examples of DRGs expressing GFP demonstrate that the same 
virus, without LATP2, that has the most lacZ expression also has the most GFP 
expression during latency, suggesting that any effect of the MMLV LTR on transgene 
expression is bi-directional, with promoter and enhancer activity.
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VIRUS PALE
NEURONS
DARK
NEURONS
TOTAL SCORE S.E.M.
1764/Ul43/1 
(3’ HALF LATP2)
15.9 0.3 16.5 1.86
1764/U l43/2 
(MID LATP2)
22.7 1 24.7 3.07
1764/Ul43/3 
(5’ HALF LATP2)
2.5 0.1 2.7 0.60
1764/U l43/4 
(NO LATP2)
25.9 2.8 31.5 2.75
1764/Ul43/20.9
(FULL LATP2)
11.3 1.6 14.5 3.40
Table 3-3 Averaged counts of /acZ-positive neurons 1 month p.i.
LacZ positive neurons were recorded per animal, and scored according to 
whether staining for lacZ was pale or dark (n=10).
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Figure 3-18 LacZ expression from LATP2-deletion viruses 1 month post-injection in 
Balb/C SCID mice
Weighted /acZ-positive neuron scores give a semi-quantitative measure of lacZ 
expression from the LATP2 deletion viruses.
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LacZ GFP
1764/U L43/1
1764/U L43/2
1764/U L43/3
1764/U L43/4
1764/UL43/20.9
Figure 3-19 Representative ganglia from Balb/C SCID mice 1 month post-injection
showing lacZ and GFP expression.
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3.7 DISCUSSION
The LATP2 region of HSV1 has been shown to contain promoter, enhancer and long­
term expression capabilities as well as the ability to confer long-term expression onto 
neighbouring exogenous promoters (Berthomme et al. 2000; Lachmann and Efstathiou 
1997; Lokensgard etal. 1997; Palmer et al. 2000).
This chapter aimed to identify active or repressive elements of the LATP2 region within 
the context of a vector containing a cassette wherein LATP2 confers long-term activity 
on two promoters in a back-to-back fashion -  1764/UL43/20.9 (Palmer et al. 2000). 
Deletion mutagenesis of the LATP2 region was carried out to create vectors based on 
1764/UL43/20.9.
The expression profiles of the plasmids and viruses appeared to be consistent, 
irrespective of the cells infected, illustrating a non cell-type specific enhancer activity. 
This was also reported by a group studying this region (Berthomme et al. 2000).
The results show that in the vectors studied, LATP2 contains repressive elements, 
which in plasmid transfections in vitro and viral infections in vivo, both lytic and latent, 
seem to be located in the first 242 base pairs of the region. Looking at the putative TF 
binding sites for LATP2 in section 3.2, a candidate for causing repression of the virus 
is the transcription factor MZF1.
In plasmid transfections and in vivo infections, the 3’ half of LATP2 also appears to 
contain a repressive element, potentially within the last 720 base pairs. Potential 
transcriptional repressors of this region are MZF1 again and also p300, which can act 
as a repressor or activator depending on the environment. Of course these TFs are 
not necessarily present in the cellular environment in which these viruses were tested 
and further work beyond the scope of this thesis would be required to investigate the 
relevance of this.
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The plasmid and virus with LATP2 completely deleted consistently gave similar or 
higher transgene expression than the plasmid and virus containing the full LATP2 
region, in all situations studied except for lytic infections in vitro. The in vitro assays 
were not very conclusive however, due to the low expression afforded from most of the 
viruses when used to infect BHK cells and the low infection achieved in the ND7 cells. 
Differences in LAT promoter expression in different cell lines in vitro and in vivo has 
been observed before (Dobson et al. 1995). This group made deletions of LAP1 and 
commented that the differences seen in activity from the different constructs and 
viruses in different situations was probably due to the fact that the kinds and quantities 
of transcription factors present would vary depending on the cellular environment.
A possible reason that in some situations tested, the highest lacZ expression levels 
were seen when LATP2 was removed is that this configuration places the MMLV LTR 
closer to LAP1 than in any other plasmid/virus. The MMLV LTR is an enhancer and 
often increasing the proximity to the promoter results in increased promoter activity.
The presence of the MMLV LTR in these vectors obviously has an effect on lacZ 
expression from LAP1 and appears to be repressed by the presence of certain 
elements within LATP2. In light of this, the vector 1764/UL43/20.9 could perhaps be 
improved for long-term expression of two transgenes by actually deleting LATP2 
completely, as the MMLV LTR has its own enhancer and ability to confer long-term 
expression on exogenous promoters (Carpenter and Stevens 1996; Dobson et al. 
1990; Laimins et al. 1984; Lokensgard et al. 1994) and the presence of both appears 
to be unnecessary.
However, as this thesis is focussed on characterising LATP2, it is clear that the 
presence of the MMLV LTR in these vectors is not ideal. As the MMLV LTR contains 
an enhancer itself, it is obscuring the effects of the enhancer activity of LATP2, making 
it difficult to assess purely the effects of LATP2 on transgene expression.
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CHAPTER 4:
CONSTRUCTION AND TESTING OF HSV1 
VECTORS CONTAINING LATP2 DELETION 
CONSTRUCTS (II)
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4.1 INTRODUCTION
In Chapter 3, it was shown that LATP2 deletion viruses based on 1764/UL43/20.9 gave 
varying levels of transgene expression. The presence of the MMLV LTR 
promoter/enhancer in the viruses also conferred activity onto the LAP1 promoter and 
confused the results. To assess the effect of LATP2 alone on expression from LAP1, a 
second set of LATP2 deletion viruses was created, without the MMLV LTR and GFP 
region of the expression cassette.
To characterise the LATP2 region further, it was thought appropriate to also create a 
third set of LATP2 deletion viruses, in which LATP2 is placed in the same orientation 
as LAP1. This should enable the directionality of LATP2 to be studied, which is 
relevant to the starting vector, 1764/UL43/20.9, in which LATP2 is exerting activity in 
both directions and in which it was not possible to quantify the activity of LATP2 on 
GFP expression due to the presence of the MMLV LTR (chapter 3).
It is known that the ICP4 protein negatively regulates the LAP2 promoter contained 
within LATP2 in vitro (Goins et al. 1994). The repression was shown not to be due to 
the direct binding of ICP4 to LAP2, as is the case with LAP1 (Batchelor et al. 1994), as 
LAP2 does not contain an obvious binding site for the protein. It was suggested that 
the repression might occur via the interaction of ICP4 with pre-initiation complex 
transcription factors. In order to investigate this further and see whether it affected 
enhancer activity of LATP2, the region identified by Goins et al. (Goins et al. 1994) as 
being repressed by ICP4 in LAP2, was removed from the 5’ half of LATP2 (equating to 
LAP2) and the full LATP2. These LATP2 deletion fragments were then used to create 
a further four viruses, the fragments being placed in both orientations with respect to 
LAP1 within the expression cassette.
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4.2 LATP2 DELETION PLASMIDS
4.2.1 Series 2 plasmids- LATP2 in the opposite orientation to 
LAP1
A series of seven LATP2 deletion plasmids were created based on those described in 
the previous chapter, but lacking the MMLV LTR and GFP. The same deletion 
fragments of LATP2 were used, as well as two additional ones, the 5’ half minus the 
‘ICP4 responsive region’ (these are referred to as AICP4 throughout the chapter) and 
the full LATP2 minus the ‘ICP4 responsive region’. Details of construction are provided 
below.
4.2.1.1 Method of construction
pR20.9 was digested with Kpn1/Nsi1 to remove the LAP1/LATP2/MMLV/GFP 
fragment. LAP1 was digested from pP1/acZSrf with Kpn1/Nsi1 and religated into the 
digested pR20.9 plasmid.
An oligonucleotide was then ligated after LAP1, to allow reinsertion of LATP2. This 
was the same as that described in section 3.2.1.
The LATP2 deletion fragments were all digested from pP2BSK (M. Robinson) as 
follows: -
(1) PpuM1 -  Spe1 (HSV nt 119502 - 120219)
(2) BspE1 -  Bbs1 (HSV nt 119107 -  119677)
(3) Xho1 -  PpuM1 (HSV nt 118866 -  119502)
(4) No LATP2
(5) Xho1 -  Spe1 (HSV nt 118866 -  120219)
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The AICP4 LATP2 fragments were created by removing nucleotides 119420 -  119502 
as follows: The 5’ half of LATP2 was digested with TaqlfTA pol to remove the last 
82bp. The full LATP2 had the ICP4 region removed by PCR from each half of LATP2 
(excluding the AICP4 region). The following primers were used in a standard PCR 
reaction of 30 cycles:
(3’ half) Primer ‘FOR’: 5’ GAATTCGGACCCAAACGACAGGGGGCG 
(5’ half) Primer ‘REV’: 5’ CTTAAGACGAGTGGGATAACGGG
The product of primer ‘FOR’ was cut with Xba1 and inserted into pBluescript. The 
product of primer ‘REV’ was cut with Xho1 and inserted into the plasmid above by 
digesting the pBluescript + 3’ half LATP2 fragment with EcoR1/T4/Xho1 and then 
ligating the two. This removed the same 82bp section of DNA from the centre of 
LATP2. The final cloned product structure was confirmed by sequencing.
These deletion fragments were then ligated into the cassette at the oligonucleotide by 
digestion with appropriate enzymes to give the series of LATP2 deletion plasmids 
(Figure 4-1).
4.2.2 Series 3 plasmids -  LATP2 in the same orientation as 
LAP1
A third series of six LATP2 deletion plasmids were created, using the identical 
fragments to those in series 2, but inserted into the cassette in the opposite
orientation, such that the LATP2 fragments were in the same orientation as LAP1. The
plasmid without LATP2 is the same for both series (p4a). The series of plasmids 
created is shown in figure 4-1.
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Figure 4-1 Schematic representation of LATP2 deletion cassettes
Restriction sites used to clone LATP2 fragments from pP2BSK are shown 
along with numbering relative to the start of LATP2 in the same plasmid. The 
brown block indicates the ICP4 responsive region removed. Both series of 
deletion cassettes are shown, the arrows denoting the orientation of LATP2, 
LAP1 and MMLV.
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4.2.3 Analysis of plasmids
Plasmid structures were checked by restriction digest analysis using Notl and either 
BspE^l, Bbs'l or PpuM'l as appropriate.
PCR was also carried out to check that the correct fragments of LATP2 were present. 
Primers exclusive to each section of LATP2 were used in PCR reactions on all seven 
plasmids as in the previous chapter. Primer sequences are as in chapter 3; shown in 
Table 3-1. Results for both series 2 and 3 plasmids are shown in figure 4-2.
95°C -  3 mins x1 cycle
95°C -1  min -i
57°C -1  min x30 cycles
72*C -1  min
72*C -1 0  mins x1 cycle
139bp
139bp
d . 1 2 3 4 5 6 7
b . M - 1  2 3 4 5 6 7 8
95*C -  3 mins 
95°C -1  min
x1 cycle 
| x30 cycles 
72'C-10mins x1 cycle
54°C -1  min 
72*C-1 min
-181 bp 181bp-
C. M -  1 2 3 4 5 6 7 8  M 950C -  3 mins x1 cycle 
95'C - 1  min -|
58°C -1  min 
72*C - 1  min 
72*C -1 0  mins x1 cycle
x30 cycles
254bp
254bp
M - 1 2 3 4 5 6 7
Figure 4-2 Gel photos showing PCRs on all seven plasmid constructs with primers 
for each section of LATP2 and the respective PCR program used.
a & d Primers for 5’ half LATP2. b & e Primers for mid LATP2. 
c & f Primers for 3’ half LATP2.
a b & c Series 2 Plasmids M = Marker, 1 = p1a, 2 = p2a, 3 = p3a, 4 = p4a, 5 = 
p5a, 6 = p3b, 7 = p5b, 8 = pR20.9.
d e & f. Series 3 Plasmids M = Marker, 1 = p1c, 2 = p2c, 3 = p3c, 4 = p4a, 5 = 
p5c, 6 = p3d, 7 = p5d, 8 = pR20.9
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The cassettes were then excised from the pGEM5 (Promega) backbone with Srf1 and 
ligated into the plasmid p35mod at the unique site A/s/1 as in section 3.2.1.
Because the insertion into p35mod can occur in either orientation due to the double- 
blunt digestion and ligation necessary, restriction digests of the resulting plasmids 
were carried out firstly to check that the insertion had taken place and secondly to 
identify which orientation each cassette was in relative to UL43. Figure 4-3, table 4-1 
and figure 4-4 show the structure of the cassettes in UL43 and the restriction digests 
by Not1.
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Not1.
--------------- » N o t 1 N o ? r -  x — ► N,ot1
P35 — I----------- I LA P..1— 3’ LATP2 3
mod -----------
Not
I *
<--- x --------► A /|»
- i -------------J L______1 Mid LATP2 J
Plasmid
Name
p1a,c Ul43
p2a,c Ul43
Notl >Not1
UL43
Flanking
Region
Not1 Nqt1
Not1 >A/<
p3a,b,c,d
Ul43
p4a Ul43
Ul 43 Flanking 
Region
Ul43
= 270bp
Figure 4-3 Schematic representation of the cassettes in the UL43 flanking regions
NB. The distance between the cassette and the first Not1 site in UL43 is either 
315bp or 432bp on either side of the cassette, depending on orientation of the 
cassette within UL43.
Plasmid Name Size of x in orientation A Size of x in orientation B
p1a,c 1448 1565
p2a,c 1287 1404
p3a,c 1393 1510
p4a 715 832
p5a,c 2126 2243
p3b,d 1205 1322
p5b/d 2044 2161
Table 4-1 Difference in size of fragment ‘x’ depending on the orientation of each 
cassette.
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2000bp
1650bp
1000bp
2000bp ^
1650bp 
1000bp —
Figure 4-4 Digestion with Not1 of the cassettes in UL43 flanking regions.
a. Gel photo of digests of series 2 plasmids with Not1.
M = 1kb+ ladder; 1 = p1a/U L43; 2 = p2a/U L43; 3 = p3a/U L43; 4 = p4a/U L43; 5 = 
p5a/U L43; 6 = p3b/UL43; 7 = p5b/UL43.
b. Gel photo of digests of series 3 plasmids with Not1.
M = 1 kb+ ladder; 1 = p1c/UL43; 2 = p2c/UL43; 3 = p3c/UL43; 4 = p4a/U L43; 5 = 
p5c/UL43; 6 = p3d/UL43; 7 = p5d/UL43.
From Figures 4-3 and 4-4, it can be seen that the plasmids have ligated into the UL43 
flanking region plasmid (p35mod) in different orientations. p2a/UL43, p4a/UL43,
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p5a/UL43, p3b/UL43, p5b/UL43, p1c/UL43, p5c/UL43 and p5d/UL43 are all in orientation 
‘A’. p1a/UL43, p3a/UL43, p2c/UL43, p3c/UL43 and p5d/UL43 are all in orientation ‘B’.
As in the previous chapter, the cassettes were to be inserted into HSV1 in the UL43 
gene by homologous recombination. The different orientations of the cassettes within 
the plasmids would also result in them being in differing orientations within the virus. 
As stated before, it was not thought that this would affect the gene expression from 
within the cassettes.
4.3 IN VITRO TESTING OF PLASMID CONSTRUCTS
Following construction, the plasmids were tested in transient transfection assays to 
determine the levels of expression of the marker genes. These were carried out in 
BHK cells (fibroblast) and ND7 cells (neuronal).
5pg of each plasmid was transfected into each cell line, in quadruplicate. In 3 sets of 
the transfections, the cells were harvested after 48 hours and the level of lacZ 
expression determined using the high-sensitivity p-Galactosidase assay kit 
(Stratagene). The level of expression for each plasmid was expressed as a 
percentage of the total activity of p5a/UL43 (with full LATP2) for series 2 plasmids, or 
p5c/UL43 (again with full LATP2) for series 3 plasmids. The results are shown in figure 
4-5.
The fourth set of transfections was examined after 48 hours, through staining with X- 
Gal in order to visualise lacZ expression. Examples of lacZ expression in the 
transfected cells are shown in figure 4-6a-d.
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^  400
e  350
I
LATP2 Orientation
I Opposite to LAP1 (series 2) 
I Same as LAP1 (series 3)
mock pla, p1c p2a, p2c p3a, p3c p4a p5a, p5c p3b, p3d p5b, p5d pR20.9 
transfected (3 LATF2) (MdLATF2) (5 LATP2) (No LATF2) (FU LATF2) (5 LATR2 (Full LATR2 (CONTROL)
(no CR (no CR 
region)) region))
Plasmid
a. BHK Cells
1200
? 1000
* *
800 -
600 -
400
200 -
mock p1a, p1c p2a, p2c p3a, p3c p4a p5a, p5c p3b, p3d p5b, p5d pR20.9
trensfected (3' LATR2) (Md LATF2) (5' LATR2) (NoLATF2)(FUI LATP2) (S LATP2 (Fud LATF2 (OONTROL)
(no ICR (no ICR 
region)) region))
Plasmid
LATP2 Orientation
I Opposite to LAP1 (series 2) 
I Same as LAP1 (series 3)
b. ND7 Cells
Figure 4-5 LacZ activity of series 2 & 3 LATP2 deletion plasmids in vitro.
5pg plasmid was transfected into BHK cells (a) and ND7 cells (b). Data is 
represented as the % lacZ activity compared to that given by p5a/U L43 (series 
2) or p5c/UL43 (series 3). The graphs depict average values of 3 transfections 
and the error bars are shown as SEM. (* - p<0.01, ** - p<0.001).
NB. p4a and pR20.9 are the sam e for both sets of plasmids, i.e. the 
directionality in the legend does not apply.
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Mock
T ransfected
p1a/UL43 p3b/UL43
p2a/UL43 p5b/UL43
p3a/UL43 p20.9/UL43
p4a/UL43
p5a/UL43
Figure 4-6a Photographs of transient transfections in BHK cells -  series 2 plasmids
5pg of each plasmid was transfected into BHK cells, left for 48 hours and then 
stained with X-Gal to visualise lacZ expression.
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Figure 4-6b Photographs of transient transfections in BHK cells -  series 3 plasmids
5pg of each plasmid was transfected into BHK cells, left for 48 hours and then 
stained with X-Gal to visualise lacZ expression.
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' . -  -
-  ‘  • - V  • '
  . 12-1
Mock
T ransfected
p1a/UL43 p3b/UL43
p2a/UL43 p5b/UL43
p3a/UL43 p20.9/UL43
p4a/UL43
p5a/UL43
Figure 4-6c Photographs of transient transfections in ND7 cells -  series 2 plasmids
5pg of each plasmid was transfected into ND7 cells, left for 48 hours and then 
stained with X-Gal to visualise lacZ expression.
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Mock
T ransfected
p1c/UL43 p3d/UL43
p2c/UL43 p5d/UL43
p3c/UL43 p20.9/UL43
p4a/UL43
p5c/UL43
Figure 4-6d Photographs of transient transfections in ND7 cells -  series 3 plasmids
5pg of each plasmid was transfected into ND7 cells, left for 48 hours and then 
stained with X-Gal to visualise lacZ expression.
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The results of the lacZ quantification show the effect of deletions of the LATP2 region 
on lacZ expression from the plasmid constructs in vitro.
Although it is not possible to directly compare the expression levels between the two 
sets of plasmids, as the experiments were carried out at different times, the two series 
of plasmids seem to have a similar level of expression to each other. The apparent 
higher expression levels from the series 3 plasmids seen in the photographs in figure 
4-6b compared to that from series 2 in figure 4-6a are due to differences in 
transfection efficiency between the two experiments. The fact that the control in both 
experiments is similar in terms of percentage activity confirms this (Figure 4-5a). This 
demonstrates the reason why the absolute lacZ expression values are not plotted, but 
displayed in relative terms.
The series 2 plasmids give a similar pattern of expression in both BHK and ND7 cells. 
However, the series 3 plasmids give a markedly different pattern of expression in BHK 
and ND7 cells. This must be due to the orientation of the region.
4.3.1 The effect of LATP2 deletions on lacZ expression within 
the series of plasmids
4.3.1.1 Series 2 plasmids -  LATP2 in the opposite orientation to LAP1
(Paler green bars in figure 4-5)
Figure 4-5 shows that in both BHK and ND7 cells, deleting both ends of LATP2 
reduces lacZ expression to background levels when it is in the opposite orientation to 
l_AP1 (p2a/UL43), even below the level given by LAP1 alone (compare with p4a/UL43). 
Removing the ICP4 responsive region from 5’LATP2 abrogates enhancer activity 
(p3b/UL43) and actually represses in ND7 cells. This is not seen however when it is 
removed from the full LATP2. All other deletions do not significantly alter lacZ
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expression as compared to that when the full LATP2 is present. The control plasmid 
pR20.9 gives significantly higher (p<0.001 in BHKs, p<0.05 -  0.001 in ND7s) lacZ 
expression than any of the others, showing the effect of the MMLV LTR in the 
cassette.
4.3.1.2 Series 3 plasmids -  LATP2 in the same orientation to LAP1
(Darker green bars in figure 4-5)
Deleting the ICP4 responsive region from the 5’ half of LATP2 gives a significant 
(p<0.001) increase in lacZ expression compared to all other plasmids (except 
pR20.9/UL43) when in the same orientation as LAP1 in BHK cells, but not ND7 cells. 
This increase in expression is not seen when the same region is deleted from the full 
LATP2 in BHK cells, but is in ND7 cells. As ICP4 is not present in the transfection 
experiments, this effect must be due to deletion of a differently repressive element at 
this location. The mid section of LATP2 also allows increased lacZ expression when in 
ND7 cells compared to that from the whole LATP2 (p<0.001). This would suggest that 
a repressor, active in neuronal cells, has been removed from this section of LATP2. 
However, this same reprieve from repression might be expected in either the plasmid 
with the 5’ half of LATP2 or the 3’ half. The fact that although a certain increase in 
expression is seen with both of these plasmids compared to the full LATP2-containing 
plasmid, but not to the same extent suggests that there are possibly repressive 
elements in each end of LATP2.
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4.3.2 The effect of orientation of LATP2 deletions on lacZ 
expression
In the transfections carried out in BHK cells (figure 4-5a), differences between the 
LATP2 fragments in different orientations are only seen in the mid section of LATP2 
and the 5’ LATP2AICP4 fragment. Both of these LATP2 fragments allow barely any 
transgene expression from LAP1 when placed in the opposite orientation to LAP1, but 
when in the same orientation are capable of enhancing expression at least as well as 
the full LATP2 region. Therefore these two fragments of LATP2 must be missing an 
element essential for enhancer activity when in the opposite orientation to LAP1. The 
effect of ICP4 in these experiments is obviously irrelevant as there is none present, 
therefore this stretch of DNA in the 5’ LATP2 fragment must also code for a 
recognition element essential for LATP2 activity. The fact that when this is deleted 
from the full LATP2, expression from LAP1 is still allowed suggests that this element 
must work in concert with another not present in the 5’ half and perhaps not in the mid­
section. It is a little strange that there is directionality in these elements, as classic 
enhancers are orientation independent. LATP2 may contain a complicated enhancer 
that requires a number of elements to work optimally.
The same effect of orientation is also seen with these two plasmids in ND7 cells, to a 
greater extent with the mid fragment of LATP2 and to a lesser extent with the 5’ 
LATP2AICP4 fragment, again pointing to neuronal-responsive elements being present 
in these LATP2 fragments. The biggest difference in orientation effect between BHK 
and ND7 cells is that of the full LATP2AICP4. This region in either orientation allows 
similar expression levels of lacZ to the full LATP2 in BHK cells, however in ND7 cells, 
placing the full LATP2AICP4 in the same orientation as LAP1 gives a significant 
(p<0.001) increase in lacZ expression over that from the full LATP2. If there is a 
repressor of LATP2 activity within the stretch of DNA deleted then it is neuronal- 
specific.
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A summary of the results from the in vitro transfection experiments is given as follows:
• All LATP2 fragments contain some enhancer activity, but this is in some cases 
directional.
• Directionality is most noticeable for the mid LATP2, 5’ LATP2AICP4 and full 
LATP2AICP4 fragments.
• Mid LATP2 and 5’I_ATP2AICP4 are repressive in the opposite of their natural 
orientation with respect to I.AP1, but enhance considerably in the natural 
orientation.
• Deleting the ICP4 responsive region considerably boosts expression in the 
correct orientation; however, these effects are variable between BHK and ND7 
cells.
• It appears that central regions of l_ATP2 have most enhancer functions, but 
that these may be counterbalanced by repressive elements at either end.
The fact that the activity of some fragments of LATP2 appears to differ whether in 
fibroblasts or neuronal-derived cells is perhaps not surprising as the natural host for 
HSV1 is neurons. As stated before however, even in vitro neuronal systems do not 
contain all of the factors present in vivo. Therefore the effect of the LATP2 deletions 
was hoped to become clearer when in the context of the animal model.
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4.4 VECTOR CONSTRUCTION
Viral vectors were again produced using the 1764 virus backbone, as described in 
section 3.4, and cassettes inserted into the UL43 gene.
The thirteen LATP2 deletion plasmids were linearised with Xmn1 and co-transfected 
with 1764/Ul43/CMV/GFP viral DNA (Figure 4-7). Recombinant vectors containing the 
cassettes were identified by loss of GFP and gain of lacZ marker genes and plaque 
purified. Insertion of the cassettes was confirmed by Southern blot analysis (see 
Figure 4-8a-b).
1764/ 
UL43/ 
CM V/ 
GFP
ICP34.5
dfc
Rl
Ul43
Flanking
Reaions
Ul43
Flanking
Regions
VP16
ICP34.5
Ul 43  gene
Ul43
Flanking
Reoions
Ul43
Flanking
Regions
a
Viral
DNA
Plasmid
DNA
Figure 4-7 Homologous recombination to produce recombinant HSV vectors
Plasmid DNA was co-transfected with 1764/UL43/CMV/GFP viral DNA into 
BHK cells. During lytic replication, homologous recombination occurs between 
the Ul43 flanking regions present in both plasmid and viral DNA.
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4577bp
N q{1 Not1
or
4460bp
Not1
I -  -  -_ 1 LAP1 L ALATP2 . J
U l 4 3
Probe
M + 1 2 3 4 5 6 7
4460-
4577bp
Figure 4-8a Southern blot analysis of viral recombinants -  series 2 viruses
Viral DNA was digested with Not 1 and probed for the lacZ gene. The two A/oM 
sites in UL43 are of similar distance either side of the inserted cassettes such 
that either orientation of cassette in the virus gives an almost equal size band. 
M = 1Kb+ Marker. + = Positive plasmid control, 1 = 1764/UL43/1a, 2 = 
1764/UL43/2a, 3 = 1764/UL43/3a, 4 = 1764/UL43/4a, 5 = 1764/UL43/5a, 6 = 
1764/UL43/3b, 7 = 1764/UL43/5b.
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1764
4577bp
Nq»  Not1 or4460bp Not1
- T .......... 1 LAP1 ! ALATP2 _ J z n
Ul 43
Trob^™
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ifionhp ^
Figure 4-8b Southern blot analysis of viral recombinants -  series 3 viruses
Viral DNA was digested with A/of1 and probed for the lacZ gene. The two A/of1 
sites in UL43 are of similar distance either side of the inserted cassettes such 
that either orientation of cassette in the virus gives an almost equal size band. 
M = 1Kb+ Marker, + = Positive plasmid control, 1 = 1764/UL43/1c, 2 = 
1764/Ul43/2c, 3 = 1764/UL43/3c, 4 = 1764/UL43/5c, 5 = 1764/UL43/3d, 6 = 
1764/UL43/5d.
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4.5 IN VITRO TESTING OF RECOMBINANT VECTORS
4.5.1 Viral Plaque Characteristics
On examination of the viral plaques of both series 2 and series 3 LATP2 deletion 
viruses on BHK cells, it was observed that when stained with X-Gal, the lacZ 
expression was stronger than that seen from the viruses in chapter 3. See figure 4-9a 
& b for example plaques.
It was supposed in the previous chapter, that the weak lacZ expression seen in vitro in 
the viruses containing the MMLV LTR and GFP was due to a repression of LAP1 by 
ICP4. However, as the weak expression is not seen in the viral plaques of the viruses 
here, without the MMLV LTR and GFP, it might have been a result of repression on 
the MMLV enhancer activity by a viral protein, in vitro.
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1764/U L43/1a
1764/U L43/2a
1764/U L43/3a 1764/U L43/3b
1764/U L43/4a
1764/U L43/5a 1764/U L43/5b
Figure 4-9a Example plaques expressing lacZ- series 2 viruses
BHK cells were infected with virus and plaques allowed to develop before 
staining with X-Gal to visualise lacZ expression.
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1764/UL43/1C
1764/UL43/2C
1764/UL43/3C
1764/UL43/3d
1764AJL43/5C 1764/UL43/5d
Figure 4-9b Example plaques expressing lacZ- series 3 viruses
BHK cells were infected with virus and plaques allowed to develop before 
staining with X-Gal to visualise lacZ expression.
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4.5.2 Growth curves
It would be expected that the growth characteristics of the two series of LATP2 
deletion viruses would be the same as that of the parental 1764 virus, as those in the 
previous chapter were. Just to confirm this, growth curves were carried out in BHK 
cells, at an MOI of 0.1. Figure 4-10a & b shows the growth curves of both series of 
viruses and as expected they have similar growth kinetics to the parental virus 1764.
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Figure 4-1 Oa Growth curves of series 2 viruses
BHKs were infected at an MOI of 0.1 and harvested at 4, 7.5, 22, 31 and 51 
hours and titred in a standard viral plaque assay.
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Figure 4-1 Ob Growth curves of series 3 viruses
BHKs were infected at an MOI of 0.1 and harvested at 4, 7.5, 22, 31 and 52 
hours and titred in a standard viral plaque assay.
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4.5.3 Infection of Cell Lines
Reporter gene expression from the LATP2 deletion viruses during acute infection in 
vitro was determined in BHK and ND7 cells. From the results obtained from the same 
experiments with the viruses in chapter 3, BHKs were infected at an MOI of 0.1 and 
ND7s were infected at MOIs of 1 and 5.
Four infections were carried out at the MOIs specified above for each virus. For 3 sets 
of the infections, the cells were harvested after 48 hours and the average level of lacZ 
expression per well determined using the high-sensitivity p-Galactosidase assay kit 
(Stratagene). The level of expression for each virus was expressed as a percentage of 
the total activity of 1764/UL43/5a for series 2 viruses or 1764/UL43/5c for series 3 
viruses. As the two virus series were infected at the same time, the data for 
1764/UL43/4a (No LATP2) and 1764/UL43/20.9 (control) is the same for each series. 
The results are shown in figure 4-11a-c.
The fourth set of infections was stained with X-Gal after 48 hours, to visualise lacZ 
expression. Examples of lacZ expression in the infected cells are shown in figure 4- 
12a-f.
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Figure 4-11 In vitro P-Galactosidase assays.
BHKs (a) and ND7s (b, c) were infected with virus at different MOIs and left for 
48 hours before assay. The positive control is the 1764/UL43/20.9 virus. The 
negative control is a 1764 virus expressing GFP in the UL43 locus.
(* - p<0.05, **-p<0.01)
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Figure 4-12a Examples of infected BHK cells -  series 2 viruses
BHK cells were infected at an MOI of 0.1 and stained for lacZ 48 hrs p.i.
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Figure 4-12b Examples of infected BHK cells -  series 3 viruses
BHK cells were infected at an MOI of 0.1 and stained for lacZ 48 hrs p.i.
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Negative
-
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1764/UL43/3b
1764/UL43/2a
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1764/UL43/4a
1764/UL43/5a
Figure 4-12c Examples of infected ND7cells (MOI = 1) -  series 2 viruses
ND7 cells were infected at an MOI of 1 and stained for lacZ 48 hrs p.i.
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Figure 4-12d Examples of infected ND7cells (MOI = 1) -  series 3 viruses
ND7 cells were infected at an MOI of 1 and stained for lacZ 48 hrs p.i.
173
Chapter 4 LATP2 deletion vectors (ii)
i * t> * 
■> ■
" ' *: •%% •*. *- ** * .j»
■' „ .
•> * 4 : v
, * r
*  * -* • IT
>■» ^  . ----- 7-----
*  -
-V . f
- ' J * ,
.A •’
v •* ft
. %-V <> •. ‘ -V <
Negative
1764/UL43/1a
1764/UL43/3b
1764/UL43/2a
1764/UL43/5b
1764/UL43/3a
1764/UL43/20.9
i , IK «'
m
. V . i&  £•*>-•
* •  *
1764/UL43/4a
1764/UL43/5a
Figure 4-12e Examples of infected ND7cells (MOI = 5) -  series 2 viruses
ND7 cells were infected at an MOI of 5 and stained for lacZ 48 hrs p.i.
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Figure 4-12f Examples of infected ND7cells (MOI = 5) -  series 3 viruses
ND7 cells were infected at an MOI of 5 and stained for lacZ 48 hrs p.i.
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4.5.4 The effect of LATP2 deletions on lacZ expression within 
the series of viruses
4.5.4.1 Series 2 viruses -  LATP2 in the opposite orientation to LAP1
The series 2 viruses only produced enough lacZ to be detectable by the lacZ assay 
when infected in BHK cells. The ND7 infections, although showing some lacZ 
expression in the photographs in figure 4-12c-f, did not produce enough lacZ from 
most viruses to be detectable in the lacZ assay.
The results from figure 4-11 in BHK cells show that when LATP2 is in the opposite 
orientation to LAP1 the 3’ half or mid section of LATP2 are sufficient to enhance 
activity from LAP1 at the same level as the full LATP2 (p<0.05). LacZ expression from 
viruses with the 5’ half of LATP2 is no greater than that from just LAP1. Removing the 
ICP4 responsive region from either the 5’ half or full LATP2 has no effect on lacZ 
expression from these viruses. The control virus, containing the MMLV LTR again 
gives greater lacZ expression than that without this promoter/enhancer (p<0.01).
4.5.4.2 Series 3 viruses -  LATP2 in the same orientation as LAP1
The series 3 viruses in vitro produced slightly more lacZ on the whole than the series 2 
viruses. The BHK infections produced enough lacZ to be detected, but only a few 
viruses gave enough lacZ in the ND7 infections to be detectable in the lacZ assay.
The results in figure 4-11 show that when LATP2 is in the same orientation as LAP1 
the 3’ and 5’ halves of LATP2 are both able to enhance lacZ expression to a level 
seen by that from the full LATP2 in BHK cells (all p<0.05 compared to LAP1 only) and 
to a higher level than that from the full LATP2 in ND7 cells at an MOI of 1. At the 
higher MOI of 5 in ND7 cells, the lacZ expression level from these two viruses 
increased further with respect to the full LATP2. The mid section of LATP2 is not able 
to enhance lacZ expression in vitro above the level of LAP1 alone when in the same
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orientation as LAP1. Again removing the ICP4 responsive region from either the 5’ half 
or full LATP2 has no effect on lacZ expression from these viruses.
4.5.5 The effect of orientation of LATP2 deletions on LacZ 
expression
The 5’ half of LATP2 allows the same or higher level of transgene expression as the 
full LATP2 only when in the same orientation as LAP1. The 3’ half allows the same 
level of expression when in either orientation in BHK cells, but can only enhance when 
in the same orientation as LAP1 in ND7 cells. The mid section of LATP2 can only 
enhance lacZ expression from LAP1 when in the opposite orientation to LAP1 in BHK 
cells, but not at all in ND7s. This could suggest an unusual uni-directional enhancer 
activity located in this section. Elements located in LATP2 that are deleted from the 
1764/UL43/2c virus (mid section of LATP2) i.e. in either end of the region appear to be 
required for activity when LATP2 is in the same orientation as LAP1.
A similar study carried out whilst this work was in progress (Berthomme et at. 2001) on 
viruses with similar deletions to those described here gave a different result in vitro. All 
of the deletion fragments were in the same orientation as LAP1, so most comparable 
with the series 3 viruses described here. Neither the 3’ half or the 5’ half of the region 
were capable of enhancing as high an expression level of iacZ as the full region in 
either BHK or ND7 cells so they predicted that elements throughout the region are 
required for full enhancer activity. The difference in the viruses used in that study and 
here is in the position of LATP2 with relation to LAP1. Berthomme et al. used deletions 
of the LATP2 region in its native locus, such that LATP2 was downstream of LAP1, 
whereas here, LATP2 is upstream of LAP1. This presumably accounts for the differing 
expression profiles of the viruses in vitro. This group also carried out their infections of 
ND7 cells at an MOI of 10, which in hindsight perhaps would have been wise here as 
the level of IacZ expression was mostly too low in ND7 cells at an MOI of 5 to obtain 
any useful data.
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4.6 IN VIVO TESTING OF RECOMBINANT VECTORS
To investigate the activity of LATP2 in the viruses described further, in vivo 
experiments were carried out.
4.6.1 Testing in the PNS
3-week-old Balb/C or Balb/C SCID mice were injected into the left footpad with 20pL of 
each virus at a titre of 1 x 108 pfu/mL (Total virus injected = 5 x 106 pfu). The dorsal 
root ganglia from the lumbar region ipselateral to the injection site were removed after 
3 days (Balb/C) and 1 month (Balb/C SCID). DRG were post-fixed and stained with X- 
Gal. /.acZ-positive neurons from DRG at positions L3-L6 were then counted and 
scored depending on the intensity of blue stain due to the two populations of stained 
neurons as explained in section 3.6.1.
4.6.1.1 LATP2 activity 3 days post-injection
Results for IacZ expression at 3 days post-injection (p.i.) are presented in figure 4-13 
and table 4-2. Selected ganglia from each virus series are shown in figure 4-14a & b.
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VIRUS I PALE 
NEURONS
DARK
NEURONS
WEIGHTED 
TOTAL SCORE
S.E.M.
1764/UL43/1a
(3’ Half LATP2)
18.6 2.5 23.6 2.67
1764/UL43/2a 
(Mid LATP2)
39.9 7.6 55.1 5.83
1764/UL43/3a
(5’ Half LATP2) 20 1
3 26.1 3.06
1764/UL43/4a1 
(No LATP2)
18.2 2.1 22.4 3.06
1764/UL43/5a 
(Full LATP2)
27.8 3.5 34.8 5.43
1764/UL43/3b
(5s LATP2AICP4) 8
1 10 1.93
1764/UL43/5b 
(Full LATP2AICP4)
24.3 3.2 30.7 5.94
1764/UL43/20.91
I (Control) 41 .9
52.1 146 17.4
I VIRUS | PALE
NEURONS
DARK
NEURONS
WEIGHTED 
TOTAL SCORE
S.E.M.
1764/UL43/1C 28.4 
(3’ Half LATP2)
7.1 42.6 5.14
1764/UL43/2C 1.3 
(Mid LATP2) |
0.1 1.5 0.6
1764/UL43/3C 
(5’ Half LATP2)
20 2.7 25.4 2.52
1764/UL43/431
(No LATP2)
18.2 2.1 22.4 3.06
1764/UL43/5C 
(Full LATP2)
32.6 7.3 47.2 7.6
1764/UL43/3d 
(5’ LATP2AICP4)
35.2 5.9 47 3.69
1764/UL43/5d 
(Full LATP2AICP4)
40.1 7.6 55.3 5.6
1764/UL43/20.9'
I (Control)
4 „ 52.1 146.1 17.43
Table 4-2 Averaged counts of /acZ-positive neurons 3 days p.i.
LacZ positive neurons from ganglia L3 -  L6 were recorded per animal, and 
scored according to whether staining for IacZ was pale or dark (n=10). 
Weighted total score = (# pale neurons + 2 times # of dark neurons)
 ^ Data for 1764/UL43/4a and 1764/UL43/20.9 is the same for both series of viruses
179
Chapter 4_____________________________________________ LATP2 deletion vectors (ii)
<5 180
|  160
Z  140 0}
Q. 120Q)
s 100
* *
LATP2 Orientation
■  Opposite to LAP1 (series 2)
■  Same as LAP1 (series 3)
3' LATP2
(1764/43/1 a,c) (1764/43/2a,c) (1764/43/3a,c) (1764/43/4a) (1764/43/5a,c) CP4 region) CP4 region) (1764/43/20.9)
(1764/43/3b,d) (1764/43/5b,d)
Md LATP2 5' LATP2 N0LATR2 Full LATR2 5' LATP2 (- Full LATP2 (- Control
LATP2 region in virus
Figure 4-13 LacZ expression from LATP2-deletion viruses 3 days post-injection in 
Balb/C mice
Weighted /acZ-positive neuron scores give a semi-quantitative measure of IacZ 
expression from the LATP2 deletion viruses.
(**-p<0.001 *-p<0.01)
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v ?KlV
1764/UL43/1a
1764/UL43/2a
1764/UL43/3a
1764/UL43/4a
1764/UL43/5a
1764/UL43/3b
1764/UL43/5b
1764/UL43/20.9
Figure 4-14a Representative ganglia 3 days post-injection showing IacZ
expression -  series 2 viruses.
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1764/UL43/1C
1764/UL43/2C
1764/UL43/3C
1764/UL43/4a
1764/UL43/5C
1764/UL43/3d
1764/UL43/5d
1764/UL43/20.9
Figure 4-14b Representative ganglia 3 days post-injection showing IacZ
expression -  series 3 viruses.
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4.6.1.1.1 Series 2 viruses -  LATP2 in the opposite orientation to LAP1
Figure 4-13 illustrates the effect of deletions of the LATP2 region on IacZ expression in 
vivo at 3 days p.i. The first striking result is the higher level of IacZ expression given 
from the 1764/UL43/20.9 virus, containing the MMLV LTR compared to the viruses 
without this promoter/enhancer. This shows that the MMLV LTR linked to LATP2 and 
LAP1 provides 4 times the expression level of that from just LAP1 and LATP2.
The virus containing the mid section of LATP2 (1764/UL43/2a) appears to give a 
slightly higher expression level than the rest of the series, but this is only significantly 
more than 1764/UL43/4a, the virus with no LATP2 (p<0.05) and 1764/UL43/3b, the 
virus with the 5’ LATP2AICP4 fragment (p<0.001). Only the mid LATP2 segment and 
the full LATP2 (with and without the ICP4 region) appear to be enhancing expression 
from LAP1 at all at this time-point. Removing the ICP4 region from the 5’ LATP2 and 
the full LATP2 does not increase expression in these viruses. If anything, in 
1764/UL43/3b, expression is reduced compared to that seen from the virus without this 
deletion in LATP2. If ICP4 were repressing at this site then at 3 days post-injection 
when immediate early proteins are present, deleting the region would be expected to 
result in an increase in expression, but the proposed reprieve from repression is not 
observed.
4.6.1.1.2 Series 3 viruses -  LATP2 in the same orientation as LAP1
Figure 4-13, demonstrates the effect of the LATP2 deletions in the series 3 viruses. 
The virus with the mid LATP2 region (1764/UL43/2c) is the only virus with a real 
difference in expression level of IacZ compared to the others. It gives barely any IacZ 
expression in vivo at 3 days post-injection. The IacZ expression is significantly lower 
than that from the 3’ half of LATP2, full LATP2 and 5’ half of LATP2AICP4-containing 
viruses (p<0.01). Comparing these results to the similar work of Berthomme et al. 
(Berthomme et al. 2001), there are some discrepancies. They found that a virus
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containing either the whole LATP2 region or the 5’ half gave much greater expression 
of IacZ than a virus either without LATP2, or with the 3’ half. Again this is probably 
explained by the positioning of LATP2 with respect to I.AP1 in the two different 
studies; in the viruses tested here LATP2 is upstream of LAP1, whereas the other 
group used it downstream of LAP1 in its natural position.
As with the series 2 viruses, removing the ICP4 region does not appear to have a 
great impact on the expression levels from the virus containing full LATP2. There is a 
very small increase in expression from the virus containing the 5’ half LATP2 when the 
ICP4 region is removed but the fact that this is not also seen in the full LATP2 
suggests that it is not due to alleviation of repression by ICP4.
4.6.1.1.3 The effect of orientation of LATP2 deletions on IacZ expression 
during lytic infection
Viruses containing the 3’ half LATP2, the 5’ half LATP2AICP4 and the full 
LATP2AICP4 show higher IacZ expression levels when in the same orientation as 
LAP1 than when in the opposite. They also are the only viruses to give higher levels of 
IacZ expression when in the same orientation as LAP1 than the virus lacking LATP2 
(i.e. they show enhancer activity). The mid section of LATP2 only shows enhancer 
activity when in the reverse orientation to LAP1. This mid section of I.ATP2 is the only 
fragment that gives better enhancer activity than the whole LATP2, suggesting that 
one or more repressive elements have been deleted, probably from both ends of 
LATP2. This relief from repression is only seen when LATP2 is in the reverse 
orientation to LAP1, which is not usual for a classic enhancer, which by definition is bi­
directional.
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4.6.1.2 LATP2 activity 1 month post-injection
Results for IacZ expression at 1-month p.i. are shown in table 4-3 and figure 4-15. 
Selected representative ganglia are shown in figure 4-16a & b.
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I VIRUS | PALE 
I NEURONS
DARK
NEURONS
WEIGHTED 
TOTAL SCORE
S.E.M.
1764/UL43/1a 19.1 
(3’ Half LATP2)
0.44 20 3.05
I 1764/UL43/2a 
(Mid LATP2)
14.4 0.44 13.8 2.22
1764/UL43/3a 
(5’ Half LATP2)
6.8 0.4 7.6 1.78
1764/UL43/4a1 I 8.3 
(No LATP2) |
0.4 9.1 1.38
I 1764/UL43/5a 
(Full LATP2)
11.1 0.3 11.7 1.66
1764/UL43/3b 
(5’ LATP2AICP4)
2.9 0 2.9 0.81
1764/UL43/5b 
I (Full LATP2AICP4)
8.2 0.1 8.4 1.15
I 1764/UL43/20.91 I 26.6 
1 (Control) |
1.3 29.2 17.4
I VIRUS I PALE
NEURONS
DARK
NEURONS
WEIGHTED 
TOTAL SCORE
S.E.M.
1764/UL43/1C 15 
(3’ Half LATP2)
0.3 15.6 2.73
1764/UL43/2C 
(Mid LATP2)
0.7 0 0.7 0.5
1764/UL43/3C
(5* Half LATP2)
7.78 0.11 8 0.88
1764/UL43/4ai 
(No LATP2)
8.3 0.4 9.1 1.38
1764/UL43/5C
I (Full LATP2)
23 0.6 24.2 3.44
I 1764/UL43/3d I 16.7 
(51 LATP2AICP4)
0.1 16.9 1.34
1764/UL43/5d 20.7 
(Full LATP2AICP4)
0.22 21.1 2.44
1764/UL43/20.91 26.6 
I (Control) I
1.3 29.2 17.4
Table 4-3 Averaged counts of /acZ-positive neurons 1 month p.i.
LacZ positive neurons in ganglia L3 -  L6 were recorded per animal, and 
scored according to whether staining for IacZ was pale or dark (n=10). 
Weighted total score = (# pale neurons + 2 times # of dark neurons)
1 Data for 1764/UL43/4a and 1764/UL43/20.9 is the same for both series of viruses
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3 LATP2 Md LATP2 5'IATP2 No LATP2 FUILATP2 5LATP2(- Ful LATP2(- Control 
(1764/43/1a,cl 17&4/43/2a,cf1764/43/3a,c) (1764/43/4a) (1764/43/5a,c) ICR region) CR region) (1764/43/20.9)
(1764/43/3b,d}1764/43/5b,d)
LATP2 Orientation
■ Opposite to LAP1 (series 2) 
□ Same as LAP1 (series 3)
LATP2 region in virus
Figure 4-15 LacZ expression from LATP2-deletion viruses 1 month post-injection in 
Balb/C SCID mice.
Weighted /acZ-positive neuron scores give a semi-quantitative measure of IacZ 
expression from the LATP2 deletion viruses. (* - p<0.05)
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These results show that the level of expression of IacZ at 1 month is lower (just over 2 
times) than at 3 days for the series 2 and 3 viruses. This is not as large a drop as 
observed from the viruses in chapter 3, suggesting that it was the reduction in activity 
of the MMLV LTR between lytic and latent time-points that was responsible in that 
case.
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1764/UL43/1a
1764/UL43/2a
1764/UL43/3a
1764/UL43/4a
1764/UL43/5a
1764/UL43/3b
1764/UL43/5b
1764/UL43/20.9
Figure 4-16a Example ganglia 1 month post-injection showing IacZ expression
-  series 2 viruses.
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: : V V . - r ;
1764/UL43/1C
1764/UL43/2C
1764/UL43/3c
1764/UL43/4a
1764/UL43/5C
1764/UL43/3d
1764/UL43/5d
1764/UL43/20.9
Figure 4-16b Example ganglia 1 month post-injection showing IacZ expression
-  series 3 viruses.
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4.6.1.2.1 Series 2 viruses -  LATP2 in the opposite orientation to LAP1
At 1 month p.i., when latency has been established, the viruses containing LATP2 
fragments in the opposite orientation to LAP1 all give significantly less IacZ expression 
(p<0.05) than 1764/UL43/20.9, with the MMLV LTR present, except 1764/UL43/1a, 
containing the 3’ half of LATP2. The virus without any part of LATP2 still gives some 
IacZ expression at 1 month from LAP1, which conflicts with the report of a similar virus 
in the literature (Berthomme et al. 2001), although others have found that there is low- 
level IacZ expression from LAP1 at latent times (Coffin et al. 1996b; Margolis et al. 
1993). In fact there is very little difference in IacZ expression between the virus with no 
LATP2 and a full LATP2 region. The viruses with either the 3’ half or the mid LATP2 
allow slightly higher IacZ expression than the full LATP2. This points to an element 
that represses enhancer activity having been deleted in these two viruses, possibly in 
the 5’ end not present in the mid LATP2 region.
4.6.1.2.2 Series 3 viruses -  LATP2 in the same orientation as LAP1
Looking at the results in figure 4-15, the virus with the whole LATP2 region allows 
greater IacZ expression than any others (with or without the ICP4 region). The 5’ half 
of LATP2 does not enhance expression from LAP1 alone and the mid-section of 
LATP2 causes reduced expression from the LAP1 promoter. This would suggest that 
an element required for long-term expression has been deleted from the mid section of 
LATP2, potentially in the region of DNA present only in the mid section but not the 5’ 
half. These results conflict with those from Berthomme et al. (Berthomme et al. 2001) 
where they found latent transgene expression in vivo from viruses with either the full 
LATP2 or the 5’ LATP2, but none from the 3’ half of LATP2. These discrepancies once 
again can only be explained by the differences in arrangement of the LAT 
promoter/enhancer regions in the two studies.
Removing the ICP4 region from the full LATP2 has no effect on expression but 
removing it from the 5’ half of LATP2 does increase expression slightly but not
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significantly. As ICP4 does not play a significant role during latency, this increase must 
be due to some other effect of deleting this part. This was seen at 3 days as well in 
these viruses.
4.6.1.2.3 The effect of orientation of LATP2 deletions on long-term IacZ 
expression
Figure 4-15 demonstrates the effect of orientation of the LATP2 fragments in these 
viruses. The 3’ LATP2 fragment and 5’ LATP2 fragment allow a similar expression 
level of IacZ in either orientation, whereas the other fragments all differed in their 
ability to enhance IacZ expression, depending on which orientation they were in with 
respect to LAP1. Full LATP2 and the two ICP4 region deletion fragments drove more 
IacZ expression when in the same orientation as LAP1, whereas the mid-LATP2 
fragment was only capable of driving IacZ expression when in the reverse orientation, 
which similarly to 3 days p.i. could be a result of an unusual enhancer activity.
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4.7 DISCUSSION
This chapter aimed to characterise the enhancer and long-term expression functions 
of LATP2 in viruses containing deletion fragments of LATP2 in either orientation with 
respect to LAP1 driving IacZ. The deletion of the MMLV LTR and GFP from the viruses 
used in chapter 3 was carried out in the hope of clarifying the effect of LATP2 on 
LAP1.
Two sets of viruses were created with LATP2 in either orientation with respect to LAP1 
driving IacZ in the UL43 locus within the 1764 viral backbone.
The different conditions under which the plasmids and viruses were tested gave 
differing results from the same fragments of LATP2. This is likely to be due to the 
variation in transcription and other factors depending on the cellular or viral 
environment as commented on previously. Also, different elements of the region are 
likely to be active at different times in the viral lifecycle. Therefore, general patterns of 
expression given by the different LATP2 fragments must be considered.
It has been shown previously that LATP2 has promoter, enhancer and long-term 
expression functions (Berthomme et al. 2000) and as such, assignment of elements 
within LATP2 to one function or another becomes complicated. Pure promoter activity 
from the LATP2 region should be studied without the presence of LAP1. The 
positioning of LATP2 with respect to LAP1 in the viruses tested in this chapter mean 
that promoter activity from LAP2 was not examined here.
Enhancer functions are complicated, with different mechanisms of action existing for 
different enhancers as discussed in section 1.2.2. By creating deletion mutants, 
positioning of various elements in relation to the promoter that they are acting on 
changes. This fact should be taken into account as well as the absence of DNA 
sequences.
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Enhancers often work by the synergy of a number of different activators and 
repressors, many of which may localise to a relatively small area of DNA. Due to this, 
making large deletions as those in the above experiments may remove multiple 
elements of the enhancer and therefore perhaps give limited information about the 
make-up of the enhancer region.
Enhancers can also function in a structural manner such that they bind DNA-structure- 
altering proteins such as the HMG-I(Y) proteins that are known to bind to the LAP2 in 
this region (French et al. 1996). It has been shown that single point mutations that 
move or remove the binding site for these, for example in the mammalian interferon 
beta enhancer, disable the enhancer suggesting that an overall protein/DNA 
superstructure is critical (Thanos and Maniatis 1995). Therefore it is possible that the 
deletions of the LATP2 region made, alter the DNA structure of the region to a greater 
or lesser extent by removing sites for transcriptional modifiers that exert their action in 
this manner. This mechanism of action however results in bi-directional enhancer 
activity, which has not been universally seen in the experiments described above.
In the experiments described, LATP2 allowed greater expression of IacZ from LAP1 
when in the same orientation than when in the opposite. No enhancer activity was 
seen from the 5’ half of LATP2 in either orientation with respect to LAP1 in vivo or 
when in the opposite orientation in vitro. The mid section was able to direct as much 
enhancer activity as the whole LATP2 during lytic and latent infection when in the 
opposite direction to LAP1 but not in the same direction, which is unusual. The 3’ half 
of LATP2 contains enhancer activity in vitro and in vivo during lytic infection when in 
the same orientation as LAP1 only and in both orientations at latent times. Therefore, it 
would seem that only the first 240bp of LATP2 does not contain any enhancer activity 
at all. This is in contrast to the similar work published concurrently (Berthomme et al. 
2001) in which they found that enhancer activity was contained within the 5’ half of the 
region only. This is probably explained by the differing arrangements of LAP1 and
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LATP2 in the two studies, although enhancer activity ought to be the same irrespective 
of positioning or orientation with relation to a promoter. However, the enhancer 
contained within this region may not be conventional in terms of directionality as 
discussed below.
An insulator site could possibly explain the unidirectional enhancer activity exhibited by 
the mid-section of LATP2. As discussed in chapter 1 (section 1.2.3.5), insulators are 
found at boundaries of transcriptionally active/inactive regions of DNA and serve to 
protect neighbouring genes from unwanted transcription or repression. They often 
work by binding the CCCTC binding factor (CTCF) protein (Bell et al. 1999). If an 
insulator site has been created in virus 1764/UL43/2c (mid LATP2 in the same 
direction as LAP1) at the junction between LAP1 and mid LATP2, then this could 
explain the unusual activity seen. Analysis by BLAST search of the sequence for the 
CTCF binding sequence CCCTC at this junction did not show any matches, however it 
is possible that a previously unidentified, different type of insulator site has been 
created. Alternatively, a repressive element may exist in the mid section of LATP2 that 
only functions in one direction.
The finding that when the 5’ half of LATP2 is removed from the plasmids or viruses 
studied here, an increase in expression from that given by the full LATP2 region is 
observed in neuronal cells in vitro or in vivo could suggest the presence of a neuronal 
repressive element in the 5’ half of LATP2.
It is possible therefore that repressive elements are located in the region of LATP2 
common to both the 5’ half and mid section. This is a 400bp stretch of DNA containing 
several putative transcriptional regulatory elements as discovered in chapter 3 using 
the TFSEARCH program (Heinemeyer et al. 1998) including binding sites for the 
potentially repressive factors MZF1 and ZID.
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Removing the ICP4 responsive region from the 5’ half or full LATP2 had little effect on 
expression levels; the only time any effect was seen was in the transient transfection 
of the plasmids where expression was increased when full or 5’ LATP2AICP4 
(depending on cell type) was in the same orientation as LAP1. However, ICP4 is not 
present in the transient expression experiments and the increase in expression 
observed there is probably due to removal of a transcriptionally repressive element 
found at the same position. The original reporting of repression within this region by 
ICP4 was on promoter activity of LAP2 (Goins et al. 1994), which is quite distinct from 
the enhancer activity seen in these studies, therefore it appears that ICP4 does not 
affect the enhancer activity within this region.
For long-term transgene expression, the 3’ half of LATP2, or part thereof seems to be 
required in either orientation. In the experiments described above, removing the 3’ half 
of LATP2 resulted in the same level of IacZ expression as that from LAP1 alone at a 
latent time in vivo, i.e. the 5’ half of LATP2 is not sufficient for increased long-term 
expression from LAP1. This is in contrast to the work published during these 
experiments (Berthomme et al. 2001) where they found that the 5’ half of the region 
was sufficient for long-term expression and that the 3’ half alone was not. As stated 
previously these differences are probably due to the slightly different arrangement of 
promoters in the two studies.
A summary diagram of the l_ATP2 region showing the location of potential enhancer 
and long-term expression elements as well as repressive elements as suggested by 
the experimental data is shown below (figure 4-17).
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5' half LATP2 3’ half LATP2
--------------- 1 I----------------------1
LATP2
Long-term
expression
activity
Enhancer
activity
Repressive
element?
Figure 4-17 Schematic illustration of the proposed location of enhancer and long­
term expression functions within LATP2
The hatched region shows enhancer or long-term activity that derives from the 
section when in one orientation only. The un-hatched areas show bi-directional 
activity.
This is no doubt an over-simplified model of LATP2 function, with possibly numerous 
activators and repressors of transcription working at different times in the viral lifecycle 
to modulate lytic infection and latency. The suggestion of these many active and 
repressive elements throughout LATP2 perhaps shows that the contribution of the 
region to LAT production in wild-type virus is tightly regulated in both lytic and latent 
infection.
The fact that the experiments described here show that maximum transgene 
expression in these vectors is provided when the full LATP2 region is in its natural 
orientation with respect to LAP1 during latency, suggests that elements located 
throughout the region are likely to be required for optimal long-term expression.
Mid LATP2
Uni-Directionality
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However, the results illustrated by the schematic of the elements found within the 
LATP2 region (figure 4-17) suggests that it would be interesting to create further 
deletion viruses, removing firstly the 400bp section of LATP2 common to the 5’ half 
and mid-section that potentially contains a repressive element and secondly, removing 
the first 242bp that does not seem to have any positive effect on LATP2 activity. These 
further deletions of LATP2 could potentially increase transgene expression levels 
further and lead to improved vectors for gene therapy.
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CHAPTER 5:
OPTIMISATION AND APPLICATION OF THE 
CHROMATIN IMMUNOPRECIPITATION 
ASSAY FOR STUDYING THE ACETYLATION 
OF THE GENOME OF HSV1
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5.1 INTRODUCTION
As discussed in section 1.2.3.2, a common method of transcriptional control is via 
histone modification; either by phosphorylation, methylation, acetylation, or 
occasionally ubiquitination. Acetylated histones are a marker of transcriptionally 
permissive euchromatin, whilst methylated and phosphorylated histones are 
associated with a more tightly packed, transcriptionally silent heterochromatin 
(Bradbury et al. 1973; Hebbes et at. 1988; Kleinschmidt and Martinson 1981; 
Marushige 1976; Rea et al. 2000). It is often the promoter and/or enhancer region of a 
gene that becomes associated with acetylated histones when it is active or about to be 
active (Kuo etal. 1998).
Evidence that modification of histones is involved in the control of transcription of 
herpes viruses has slowly appeared over time. It is known that the HSV-1 genome is 
associated with nucleosomes during latency in a chromatin-like structure (Deshmane 
and Fraser 1989). The LAP2 promoter contained within LATP2, can directly bind a 
protein similar to the group of small chromosomal chromatin-associated proteins HMG 
l(Y) (high motility group) (French et al. 1996). HMG proteins regulate transcription as 
part of an enhanceosome by binding to the DNA and altering the DNA configuration 
(Falvo et al. 1995; Grosschedl etal. 1994). Specifically, in I.AP2, HMG l(Y) appears to 
facilitate the binding of transcription factor Sp1. The same HMG 1 was also found to 
act as a co-activator of ICP4 expression (Carrozza and DeLuca 1998).
Perhaps the most convincing report of the involvement of histone modification in 
modulation of herpesvirus gene expression is that the genome of Epstein-Barr virus is 
arranged on nucleosomes (Dyson and Farrell 1985) and the promoter of the viral 
immediate-early gene BZLF1 is associated with acetylated histone H4 on induction of 
reactivation from latency in vitro (Jenkins et al. 2000).
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At the start of this project, the only evidence for histone modification as a 
transcriptional control mechanism for HSV1 was that described above and some 
emerging work that ICPO (both that of HSV1 and Bovine herpesvirus-1) had been 
found to interact with histone de-acetylases (HDACs) which was predicted to perhaps 
be a control mechanism used in the regulation of latency and reactivation (Hobbs and 
DeLuca 1999; Lomonte et al. 2001; Tsavachidou et al. 2001; Zhang and Jones 2001). 
Furthermore it was found that the inhibitor of HDACs, TSA, caused reactivation of 
HSV1 from neuronal cultures (Arthur et al. 2001).
The search performed to identify potential TF binding sites in LATP2 described in 
chapter 3 (section 3.2) identified a site for p300 within the 3’ half of I.ATP2. p300 
possesses histone acetyl transferase (HAT) activity (Ogryzko et al. 1996) and as such 
can help alter the DNA conformation to be more transcriptionally permissive. p300 
interestingly acetylates HMG l(Y) in vitro but this has a negative effect caused by 
disruption of the enhanceosome of which HMG l(Y) is a component (Munshi et al. 
1998).
This all led to the idea that studying the acetylation status of histones at HSV1 l_AT 
and non-LAT promoters at different times in the viral life-cycle may elucidate a 
mechanism by which the latency promoters stay active, the hypothesis being that the 
LAT region chromatin is differently acetylated as compared to the rest of the genome 
during latency and thus allow a more open chromatin configuration which allows 
continued transcription. It is thought that enhancers may regulate transcription through 
the acetylation of histones (Agalioti et al. 2000), (see section 1.2.3.2), so whether 
particular elements of the LATP2 region are responsible for this phenomenon, if 
observed, would be explored, as would whether they correspond with the 
active/repressive regions identified in the previous chapters.
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As discussed previously, it has been shown that l_ATP2 is capable of maintaining 
expression from exogenous promoters during latency when placed next to the region 
in a LAT or non-LAT locus (Lilley et al. 2001; Palmer et al. 2000). To investigate 
whether acetylation of associated histones is a mechanism by which this is achieved, it 
was decided that as well as looking at the acetylation status of promoters in the HSV1 
genome, the acetylation status of an exogenous promoter would be studied when 
linked to LATP2 and when separate from LATP2.
5.1.1 In vitro models of HSV1 latency.
An in vitro system was chosen to be set up in order to study the acetylation of these 
viral genomes both during the lytic cycle and during latency, as it was considered 
advantageous to be able to work with a higher quantity of virus than would be 
available from in vivo models. The use of in vitro models to study latency of HSV has 
been somewhat controversial over the years, with their relevance to the in vivo 
situation being debated. Three different types of in vitro model have been described, 
with differing attributes:
Primary cultures of neurons have been favoured as representing most closely the in 
vivo situation and used by a number of groups to establish an NGF-dependent 
infection (Kennedy etal. 1983; Wilcox and Johnson, Jr. 1987; Wilcox and Johnson, Jr. 
1988). They have been shown to allow reactivation on withdrawal of NGF and express 
LATs (Doerig et al. 1991; Smith et al. 1994) but not lytic cycle genes during latency. 
They do typically require viral replication to be limited either by antivirals or replication- 
defective mutants in order to allow a latent state. However, in the absence of ICP0, 
establishment of latency is greatly reduced, which is not seen in vivo (Wilcox and 
Johnson, Jr. 1987). These are troublesome to prepare and still a large amount of 
tissue is required to obtain reasonable numbers of neurons for study.
202
Chapter 5 ChIP assay of HSV1
Infected fibroblasts present perhaps a more contentious model of latency. They were 
first used by Wigdahl et al (Wigdahl et al. 1981; Wigdahl et al. 1982) in the form of 
human embryo lung cells. It was shown that only limited gene expression from HSV1 
is required to establish latency in fibroblasts and that ICPO is not necessary. However, 
ICPO is required and sufficient for reactivation (Russell et al. 1987). The HSV genome 
takes on a non-linear form as during in vivo latency (Harris and Preston 1991) but the 
fibroblasts do not allow the production of LATs, which is perhaps the biggest problem 
with this model, meaning that HSV is in a ‘quiescent’ state rather than a latent one, 
with the whole of the genome shut down.
The final in vitro model that has been used is that of infected neuronally derived cells. 
PC12s are from a rat adrenal pheochromocytoma and differentiate into cells 
resembling sympathetic neurons after treatment with NGF (Greene and Tischler 
1976). They were first used for infection with HSV1 by Rubenstein and Price 
(Rubenstein and Price 1983) and have been shown to support high-levels of LAT 
production during lytic and latent infection (Bratanich and Jones 1992; Danaher et al. 
1999; Leib et al. 1991). However it is the 2kB LAT rather than the 1.5kB species found 
in vivo that is produced and furthermore, this LAT production requires viral replication 
to have occurred -  ICPO mutants were found not to produce LATs (Rodahl and Haarr 
1997). HSV-infected PC12 cells cannot be reactivated by HSV1 super-infection as is 
possible in fibroblasts (Su et al. 2000).
ND7s are potentially the most useful cell line to create a similar latent model to that in 
vivo. They are a fusion of immortalized primary DRGs and a neuroblastoma cell line 
and have the properties of nociceptive sensory neurons (Wheatley et al. 1990; Wood 
et al. 1990). Both 1.5Kb and 2Kb LATs are transcribed in infected cells whilst the IE 
genes are not (Mador et al. 1995). A neuronal specific inhibitory factor binds to the 
TAATGARAT motif in the viral IE promoters and prevents transactivation (Wheatley et 
al. 1991).
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5.1.2 Choice of viruses for analyses
The backbone of the viruses was chosen as one that is disabled and replication 
incompetent. It has been shown that HSV1 viruses that do not express any IE genes 
are pushed towards the latent pathway and enter the quiescent state in vitro (Harris 
and Preston 1991; Preston and Nicholl 1997). Therefore the backbone of the viruses 
used have the 2 essential genes for ICP4 and ICP27 deleted and prevent 
transactivation of the remaining IE genes by including a disabling mutation in the gene 
for the virion protein VP16 (Lilley et al. 2001). The same viruses can be used to study 
acetylation at lytic timepoints by infecting a complementing cell line with the virus, in 
this case the cell line 27/12/M:4 which expresses ICP4 and ICP27 (Thomas et al. 
1999b). The VP16 mutation can be complemented by the addition of HMBA to the 
growth media (McFarlane etal. 1992).
Although it would have been consistent to study the pR20.9 cassette as used in 
chapter 3, with the MMLV LTR as the exogenous promoter linked to LATP2; as 
previously discussed, MMLV has been shown to have its own long-term expression 
capabilities and if these function in a similar way to those of LATP2, this could confuse 
the issue of whether any acetylation seen associated with MMLV was due to its 
positioning adjacent to LATP2 or due to its own characteristics. Therefore the 
cassettes chosen to be studied were one in which the non-HSV1 IE 
promoter/enhancer CMV, driving GFP was placed next to LATP2 in the LAT region 
(pR19GFP) and the second where the same CMV promoter driving GFP was 
positioned in a non-LAT locus, not linked to LATP2 (CMVGFP/US5). GFP expression 
from this virus does not occur during latency (unpublished observations), as CMV 
does not have long-term expression capabilities. Furthermore, a virus in which the 
CMV promoter was placed next to the LATP2 region has previously been shown to 
allow transgene expression during latency, whereas when the promoter was placed 
next to LAP1 only short-term expression was given (Palmer et al. 2000).
204
Chapter 5 ChIP assay of HSV1
These two viruses also allow the simultaneous study of the acetylation profile of LAT 
and non-LAT promoters. Figure 5-1 shows the structure of these viruses.
ICP34.5 ICP4 1CP4ICP34.5 VP16 ICP27 HSV1 Strain 
1764 4 -2 7 -
■pR19GFP’
LAP1 LATP2 CMV GFP
a. 1764 27- 4- 
PR19GFP
ICP34.5 VP16 ICP27
-x
ICP34.5 ICP4 ICP4
HSV1 Strain 
1764 4-27-
GFP
‘CMV/GFP-5’
b. 1764 27- 4- 
CMVGFP/5
Figure 5-1 Schematic diagram showing the structures of the two viruses used in the 
acetylation study.
a. The CMV promoter is placed next to the LATP2 promoter in the LAT region. 
This therefore is present in two copies per virus.
b. The CMV promoter is inserted into the US5 region and is therefore present in 
only one copy per virus.
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5.1.3 The chromatin immunoprecipitation (ChIP) assay
The chromatin immunoprecipitation (ChIP) assay is the most precise method currently 
available to identify specific proteins associated with a region of DNA. It has been 
refined since the first use in the 1980s (Gilmour and Lis 1985). The basis of the assay 
is that associated proteins are cross-linked to the DNA with formaldehyde; the 
chromatin is sheared or digested into smaller fragments and then the protein of 
interest immunoprecipitated using an antibody. This also brings down the DNA to 
which the protein is linked. The cross-links are then reversed, the protein digested and 
washed away, the DNA purified and the sample analysed for the presence of specific 
sequences. Figure 5-2 shows a summary of the assay.
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Crosslink the chromatin and shear
® CD® it $  p
MM M
Immunoprecipitate with antibody 
to protein of interest
I Reverse crosslinks and purify DNA
Analyse DNA for sequence of interest
Figure 5-2 Basic illustration of the ChIP assay
207
Chapter 5 ChIP assay o fH S V I
At the start of this study, there was no literature on the use of the ChIP assay with 
HSV1 infected cells or tissue. Therefore, the method had to be optimised in 
conjunction with the in vitro systems to be used.
5.2 MATERIALS AND METHODS 
5.2.1 TUJ1 Staining
1 x 3.5cm2 well of primary DRG neurons (see section 2.3.3) was fixed for 15 mins with 
4% (w/v) PFA (in water) at room temperature (RT). The well was then washed 3 times 
with 1x PBS. 0.1% (v/v) Triton X-100 in 1x PBS was added for 5 mins and then 
washed with 1x PBS. 20% goat serum (Invitrogen, Paisley, UK) in 1x PBS was added 
to block for 30 mins at RT. TUJ1 antibody was added at a final dilution of 1:5000 in 
10% goat serum in 1x PBS and left for 1 hour at RT. The well was then washed 3 
times with 1x PBS and the secondary antibody added of anti-mouse lgG2A -  
rhodamine conjugated (Chemicon, UK) at 1:100. This was then incubated for 2 hours 
at RT in the dark and then washed with 1x PBS.
5.2.2 ChIP Assay
The chromatin IP Kit from Upstate Biotechnology (Virginia, USA) was used throughout 
this study, following the protocol provided but with a few alterations. Optimisation of 
different parts of the assay was carried out as described later, but the final assay 
protocol used is described here.
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5.2.2.1 Crosslinking and sonication
Histones were cross-linked to DNA by adding 37% Formaldehyde (Sigma) to the 
culture medium to a final concentration of 1% and incubated at 37°C for 10 mins.
The media was removed and the cells washed twice in ice cold 1x PBS containing a 
cocktail of protease inhibitors (Roche, E. Sussex, UK). Cells were scraped into a 
1.5mL tube and pelleted at 4000rpm for 4 mins at 4°C in a 5417R microfuge 
(Eppendorf, Germany). The cell pellet was resuspended in 200|J_ of warmed SDS 
lysis buffer containing protease inhibitors and incubated on ice for 10 mins. 400pL of 
ChIP dilution buffer was added, containing protease inhibitors and the sample was 
sonicated in a cold room (4°C) for 4 bursts of 40 seconds, with 1 min rest on ice in 
between using a GE50 ultra sonic processor (Jencons, Beds., UK) set to 30% power. 
5pL of each sample was removed in order to check for the size of sonicated 
fragments. These were run on a 1.2% agarose gel and visualised under UV light. If the 
majority of the smear was <600bp then sonication was deemed to be efficient. The 
sonicated sample was centrifuged for 10 mins at 4°C at 13000rpm and the 
supernatant (s/n) transferred to a new tube. The s/n was then diluted with ChIP dilution 
buffer containing protease inhibitors so that the final volume of each sample was 2mL. 
50|iL of each sample was then removed and stored at -20°C until ready to reverse the 
crosslinks. This is the input sample.
5.2.2.2 Immunoprecipitation
The samples were then pre-cleared with 80pL of salmon sperm DNA/Protein A 
agarose-50% slurry for 30 mins at 4°C on a rotating wheel. The agarose was then 
pelleted by pulse spinning the sample and carefully removing the supernatant to a new 
tube. The immunoprecipitating antibody to acetylated histone H3 (K9,14) (Upstate, 
Virginia, USA) was then added at 5^L/mL to the sample and left overnight at 4°C on a
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rotating wheel. A control sample was always included in which an anti-IgG antibody 
(Sigma) was added at a concentration of 1 ^ iL/mL.
5.2.2.3 Washing and reversal of cross-links
60pL of salmon sperm DNA/protein A agarose slurry was added to each sample and 
left for 1 hour at 4°C on a rotating wheel to collect the antibody/histone complex.
The agarose was pelleted by pulse-spinning the samples for 7 seconds and the s/n 
that contained the unbound fraction was discarded. The pellet containing the 
agarose/antibody/histone was carefully washed for 4 mins each on a rotating platform 
with 1mL of each of the buffers in order: 1) Low salt immune complex wash buffer; 2) 
High salt immune complex wash buffer; 3) LiCI immune complex wash buffer; 4) 1x TE 
-  two washes. The histone complex was then eluted from the antibody by adding 
275pL fresh elution buffer (1% SDS, 0.1M NaHC03) (Sigma)) and incubating at RT for 
15 mins with rotation. The agarose was pulse-spun and 200pL of s/n carefully 
transferred to a new tube. The elution was repeated with 250pL elution buffer and after 
incubation 300pL removed to combine with the other aliquot of eluent. Reversal of 
cross-links was carried out by adding 5M NaCI (VWR) to each sample, including the 
input sample removed previously and incubating for 4 hours at 65°C.
5.2.2.4 Clean-up and purification
RNase A (sigma) was added to the samples at a final concentration of 40pg/mL, 
vortexed and then incubated for 30 mins at 37°C. Protein was degraded by adding 
EDTA to a final concentration of 0.01 M, Tris pH 6.5 to a final concentration of 0.02M 
and proteinase K (Roche, E. Sussex, UK) to a final concentration of 40|ag/mL. The 
samples were vortexed and incubated for 45°C for 1 hour.
Purification of the DNA was carried out using a QIAquick PCR purification kit (Qiagen, 
W. Sussex, UK), according to the manufacturer’s instructions and adding 3M sodium
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acetate (sigma), pH 6.5 to ensure that the pH of each sample was pH 7 or less before 
applying to the columns.
5.2.3 PCR
Where standard PCR was used, the GC rich kit (Roche, E. Sussex, UK) was used as 
described in section 2.2.4.2 due to the GC rich nature of HSV1 DNA.
5.2.4 Quantitative PCR
Quantitative PCR was carried out using SYBR Green from the QuantiTect SYBR 
Green PCR Kit (Qiagen, W. Sussex, UK) as per the manufacturers instructions. 
Primers for DNA regions of interest were used at 0.3|nM final concentration each. An 
ABI 7000 Sequence Detection System (Applied Biosystems, California, USA) was 
used to run the PCR with the following program:
50°C 2 mins x1 cycle
95°C 10 mins x1 cycle
95°C 15 secs l ,, >x40 cycles60°C 1 min J 3
Melting curves were examined for each set of primers used to ensure that the products 
were specific.
5.2.5 Nuclei Isolation
Nuclei isolation was carried out with the Nuclei EZ Prep Nuclei Isolation Kit (Sigma, 
Dorset, UK). Briefly, cells were grown on 90mm plates and infected as required. Cells 
were washed with 10mL of ice cold PBS, then harvested and lysed by adding 4mL of
211
Chapter 5___________________________________________________ChIP assay of HSV1
Nuclei EZ lysis buffer, centrifuging at 500g for 5 mins, 4°C and removing the s/n. The 
nuclei pellet was washed with 4mL of lysis buffer, centrifuged as before and the pellet 
placed on ice. The nuclei were resuspended in 200pL of ice-cold Nuclei EZ storage 
buffer and used immediately.
5.3 OPTIMISATION OF THE IN V MODELS
5.3.1 Lytic model
The lytic model chosen was the use of 27/12/M:4 cells as described above they 
complement for the proteins ICP4 and ICP27. HMBA was always included in the 
growth medium to counteract the mutation in VP16. As there was no alternative to this 
cell line then this set-up did not need much optimisation as it was well established in 
the laboratory. An infection at an MOI of 1 had been shown previously to be efficient at 
delivering virus to all cells. Figure 5-3 shows the infections at 1 and 2 days post­
infection with the virus 1764 4- 27- pR19GFP. It was initially chosen to look at 
acetylation of the virus in these cells after 1 day, representing a lytic infection.
27/12/M :4
Day 1 Day 2
Figure 5-3 1764 4- 27-pR19GFP virus in the complementing cell line 27/12/M:4
Cells were infected an MOI of 1 in serum free media. After 1-hour full growth 
media was added containing HMBA.
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5.3.2 Latent model
To establish which cell line would be most appropriate for the latent model a number of 
different non-complementing cell lines available in the lab were infected and left for up 
to 6 days -  a period of time far in excess of that required for a replication incompetent 
virus to become quiescent to ensure their suitability for the assay. The infections were 
assessed for infectability and stability throughout the experiment. The cell lines used 
were BHKs, Veros, HT1080s and ND7s. They were all infected an MOI of 5 with the 
virus 1764 4- 27- pR19GFP. This virus had been filtered to ensure that no viral 
proteins were carried over from the 27/12/M:4 complementing cells that they were 
grown on. Figure 5-4 shows the infected cell lines at different times post-infection.
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Day 1 Day 2 Day 3 Day 6
Vero
BHK
HT1080
ND7
Figure 5-4 1764 4- 27-pR19GFP virus in a panel of non-complementing cell lines.
Cells were infected an MOI of 5 in serum-free-media. After 1-hour full growth 
media was added. The media was changed every two days during the period 
of infection.
From figure 5-4 it can be seen that BHK cells were the most efficiently infected with 
the replication incompetent virus, followed by the Vero cells and then the ND7 cells. 
However, the BHK cells were looking very unhealthy by 2 days post-infection. The 
ND7 cells looked the healthiest at the end of the experiment and also appeared to 
show an increase in GFP expression from the virus between 1 and 2 days post­
infection, suggesting that latency may be being established. Therefore these cells 
were deemed to be the most suitable for the in vitro assay. These are also the most 
appropriate as ND7 cells have been shown to allow the production of LATs from
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viruses that infect them (Wheatley et al. 1990), (unlike all fibroblast cell lines studied) 
thus most closely mimicking the latent state in vivo.
Whether the use of primary dorsal root ganglia cultures for the latent model may be 
advantageous was investigated. As described above, this model is probably even 
closer to the situation in vivo. Therefore, a culture was set-up, infected with a 
replication incompetent virus at a MOI of 5 and maintained for 10 days to assess the 
infectability and stability. Figure 5-5 shows the infected cultures.
DRG
Culture
Day 2 Day 7 Day 10
Figure 5-5 1764 4- 27-pR19GFP virus in a 1° DRG Culture
Cells were infected an MOI of 5 in serum-free-media. After 1-hour full growth 
media was added. The media was changed every two days during the period 
of infection.
The infected DRG cultures looked healthy up to at least 10 days.
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To show that the cells being infected were in fact neurons and not supporting cells, a 
new infection was set up and after 2 days they were processed for 
immunofluorescence with the anti-neuronal specific p-tubulin antibody TUJ1 as in 
section 5.2.1. Figure 5-6 shows that when the staining is compared to the GFP 
infection at 2 days it can be seen that indeed the same neurons as stain positive for 
TUJ1 are infected.
Phase Contrast Fluorescence TUJ Stain
Figure 5-6 1764 4- 27-pR19GFP virally infected and TUJ1-stained primary DRG
culture.
Adult mouse primary DRG cultures were infected with 1764 4- 27- pR19GFP 
and 2 days p.i. photographed for GFP expression before processing for 
immunofluorescence and photographing the same frame.
5.3.3 Production of LATs in vitro
As stated above, infected ND7 cells allow production of LATs. To check that the 
replication-incompetent virus 1764 4- 27- still produced LATs in vitro, the RNA at 
different times post-infection was examined. ND7s were infected at an MOI of 5 with 
1764 4- 27- CMV/GFP/5, the RNA extracted at 16, 24, 48 and 72 hours post-infection
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and cDNA made (see section 2.2.5). To compare the production of LATs in primary 
DRG cultures, RNA was also extracted from a similarly infected culture at 4, 7 and 10 
days post-infection. PCR was carried out using the primers below for the cellular gene 
cyclophilin A, the HSV1 LAT region and the IE gene for ICP22. Figure5 -^ shows the 
results of the PCRs. (Only ICP22 and LAT primers were used for the 1° DRG culture).
GENE FORWARD PRIMER REVERSE PRIMER I
CYCLOPHILIN CGAGCT GTTT GCAGACAAAG TT CTT GCT GGT CTT GCCATT
ICP22 GCTT CCTT GTTT GGAG ACC A GT CCAGT CAAACT CCCCAAA
LAT GACAGCAAAAATCCCCTGAG ACGAGGGAAAACAATAAGGG
Table 5-1 Primers used in RT PCR reactions
217
Chapter 5 ChIP assay of HSV1
No RT
RT
3. cyclophilin
95°C - 3 mins x1 cycle 
95°C -1 min
55°C -1 min 
72°C - 1 min -
x30 cycles 
72°C - 10 mins x1 cycle
-410bp
N U 16 24 48 72
N U 16 24 48 72
b . ICP22
95°C - 3 mins x1 cycle
95°C - 1 min ~|
56°C - 1 min x30 cycles 
72°C - 1 min J
72°C - 10 mins x1 cycle
255bp
M -
M -
N U 16 24 48 72
N U 16 24 48 72
C. LAT
95°C - 3 mins x1 cycle
95°C - 1 min “|
52°C - 1 min x30 cycles 
72°C - 1 min J
72°C - 10 mins x1 cycle
-210bp
Figure 5-7 PCR on cDNA made from RNA of ND7 cells infected with 1764 4- 27- 
CMVGFP/5
a. With primers for the cellular gene cyclophilin A
b. With primers for the IE gene ICP22
c. With primers for the LAT gene
M= 1Kb+ DNA Marker, - and + are PCR controls, N = No sample RT, U =
uninfected cells, 16, 24, 48 & 72 denote hours post-infection.
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No
RT
RT
I M - + N U 4 7 10 a. ICP22 -  30 cycles
No
RT
RT
M - + N U 4 7 10
b. LAT -  30 cycles
<------- 210bp
I M - + N~U 4 7 10 C. LAT & ICP22 -  25 cycles
LAT
ICP22
Figure 5-8 PCR on cDNA made from RNA of a primary DRG culture infected with 
1764 4- 27- CMVGFP/5
a. With primers for the IE gene ICP22 -  30 cycles of PCR
b. With primers for the LAT gene -  30 cycles of PCR
c. With primers for both LAT & ICP22 -  25 cycles of PCR
M= 1Kb+ DNA Marker, - and + are PCR controls, N = No sample RT, U = 
uninfected cells, 4, 7 & 10 are days post-infection.
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As can be seen in figure 5-8, in ND7 cells, the ICP22 level decreases after 24 hours 
whereas the LAT level appears to increase up to 72 hours at which point the virus 
should be latent. This confirms that this in vitro model is reasonable to study the latent 
characteristics of this disabled virus. In figure 5-8a, the RNA level of ICP22 seems to 
be a lot higher for longer in the DRG culture than in ND7 cells. However, when a PCR 
of only 25 cycles was used, the decrease in ICP22 RNA level over time can be seen 
compared to that of the LATs, which remain constant. As the ND7 model seems to 
reach a latent state more quickly than the primary DRG model and is easier to prepare 
and maintain it was decided to pursue only the ND7 model of latency.
The difference in GFP expression at 3 days in ND7 cells between the two viruses to be 
tested was confirmed as shown in fig. 5-9. (I.e. in 1764 4- 27-pR19GFP the GFP 
expression is kept on whereas in 1764 4- 27-CMVGFP it is turned off).
1764 4 -27- 1764 4 -27-
CMVGFP/5 pR19GFP
Figure 5-9 ND7 cells infected with 1764 4- 27-pR19GFP and 1764 4- 27- CMVGFP/5 
after 3 days.
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5.3.4 Nucleosomal structure of the virus in vitro
Several groups have previously tested the structure of HSV1 DNA by micrococcal 
nuclease digestion. It was first carried out on cells infected with wild-type HSV1; one 
group observed no nucleosomal units on digestion (Mouttet et al. 1979), whilst another 
observed only a small fraction (Leinbach and Summers 1980). It was subsequently 
carried out on cell preparations from lytically infected brainstems of mice upon which a 
nucleosome-like fraction was detected (Muggeridge and Fraser 1986). When latently 
infected brainstems of mice were analysed it was found that an even larger fraction of 
the HSV1 DNA was in a nucleosomal form (Deshmane and Fraser 1989). The 
nucleosomal structure of a ‘quiescent’ infection in fibroblasts was studied by MNase 
digestion and analysis of the TK gene (Jamieson et al. 1995). No nucleosomal 
structure was found at this locus.
As this digestion has never been carried out on latently infected cells producing LATs 
and the nucleosomal structure of the LAT region looked at, it was thought interesting 
to do so, as well as to further check that the ChIP assay would be relevant to this in 
vitro latent model.
ND7s were infected or mock infected at an MOI of 5 with 1764 4- 27- CMVGFP/5 
virus. 27/12/M:4 cells were infected at an MOI = 1. After 3 days for the ND7s and 1 
day for the 27/12/M:4 cells, nuclei were isolated using the Nuclei EZ Prep Nuclei 
Isolation kit (Sigma, Dorset, UK) according to the manufacturer’s instructions and 
digested with 225U micrococcal nuclease (Roche, E. Sussex, UK) for 5, 10 or 15 mins 
at 37°C. Samples were then treated with proteinase K (10ug/mL) at 37°C for 30 mins 
and purified by phenol extraction. Samples were then run on a 1.5% agarose gel with 
equivalent digestions viral DNA and visualised by UV. The gels were then used in 
Southern blots and probed with a Not3.5 fragment of the LAT region (nt 118439 - 
122025). Figure 5-10 shows the digested samples prior to blotting and the resulting 
probed blots.
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Figure 5-10 Micrococcal nuclease digestion of HSV1 lytic and latent viral chromatin.
ND7 and 27/12/M:4 cells were infected with 1764 4- 27- CMVGFP/5 at an MOI 
of 5 and 1 respectively and the nuclei harvested at 3 and 1 days post-infection 
respectively. Nuclei were digested with micrococcal nuclease for the times 
indicated, along with uninfected cells and viral DNA. The gels were then used 
for Southern blots, probed with a 3.5kb section of the LAT region. The blot for 
27/12/M:4 infected cells was exposed for 1 hour and the blot for ND7 cells 
exposed for 3 days. The extra section of ND7 blot shown is the first 4 lanes 
exposed for 1 hour.
The digestion of nuclei with micrococcal nuclease shows the classic nucleosomal 
ladder pattern in the agarose gels. Digestion for 5, 10 or 15 minutes did not give a 
great difference in pattern, although overall smaller units of nucleosomes can start to
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be seen in the 15 minute digest of the ND7 cells. There are more viral genomes in the 
lytically infected cells than the latently infected as illustrated by the fact that although 
the agarose gels for both infections show equivalently bright bands, the Southern blot 
for the latent infection required a far longer time of exposure in order to visualise the 
positive samples.
Both Southern blots show that the viral genome at the LAT region is at least partially in 
a nucleosomal form during both lytic and latent infection. The smears point to some of 
the viral genome not being nucleosomal, but there are also bands present 
corresponding to a mononucleosomal and dinucleosomal form for both infections. This 
has been shown before for lytic infection in vitro (Leinbach and Summers 1980), 
although not by all groups that have tried this (Mouttet et al. 1979) but not for in vitro 
latent infection of HSV1.
This result shows that a ChIP assay for acetylated histones associated with HSV1 is 
relevant for both a lytic and latent in vitro infection.
5.4 OPTIMISATION OF THE SONICATION PROCEDURE
5.4.1 Volume of buffer for sonication
The first part of the ChIP protocol that needed optimising was the sonication 
procedure. The volume in which to sonicate the crosslinked samples needed to be 
looked at. The protocol stated that 200pL of lysis buffer should be used, but using this 
volume resulted in frothing of the sample, even after turning the power of the sonicator 
down, and further sonication was not possible. To increase the volume of sample, 
instead of adding more lysis buffer, which would have altered the final SDS 
concentration, ChIP dilution buffer was used. As the subsequent step to sonication
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was dilution of the sample with this buffer anyway, it seemed reasonable to add this 
prior to sonication and adjust the volume of the buffer added afterwards. In order to 
keep the volume to a minimum, a range of volumes from 300 - 1000jiL, in 100pL 
increments was tested. This was carried out on samples of non-infected 27/12/M:4 
cells that had been cross-linked as per the first part of the protocol.
Volumes below 600pL had a tendency to froth, whereas those above did not and 
sonication was possible. Therefore, 400nL of dilution buffer was chosen as the volume 
of ChIP dilution buffer to add to the sample prior to sonication, and then afterwards, 
the remainder of the 1800pL total volume of buffer (i.e. 1400pL) would be added.
5.4.2 Time of sonication
The aim of the sonication step is to disrupt the chromatin into smaller fragments that 
may be immunoprecipitated. There seems to be varying opinion on the desired size of 
chromatin post-sonication, ranging from <1.5kb to 300bp. Supposedly the smaller they 
are, the better the resolution of the assay. Using a probe sonicator on 30% power for 
40-second bursts; sonication of infected cells was attempted. Wells of 1 x 106 
27/12/M:4 cells were infected at an MOI of 1 with 1764 4- 27- pR19GFP virus and ND7 
cells were infected at an MOI of 5 with 1764 4- 27- CMVGFP/5 virus and a range of 
the number of sonication bursts was carried out, resting the samples on ice between 
each one to keep the samples cool. The sonication procedure was also carried in a 
cold room to minimise heating of the samples.
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3 4 5
M N S N S N S
a. 27/12/M:4 cells infected with 1764 4- 27- pR19GFP
M 3 4 5 M
b. ND7 cells infected with 1764 4- 27- CMVGFP/5
Figure 5-11 Sonication of infected samples
Samples were sonicated for bursts of 40 seconds, the number above indicating 
for how many. M = 1 kb+ DNA marker. Panel a. N = non-sonicated, S = 
sonicated.
Figure 5-10 shows that it did not appear to make a great difference if 3, 4 or 5 bursts of 
40 seconds were applied to the samples. The difference in average size of chromatin 
pre-and post-sonication can be seen in fig 5-11a, although it was expected that the 
pre-sonication band would be larger than it was. As all sonicated fragments were
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reduced to <600bp, it was decided that 4 x 40 second bursts was a reasonable 
sonication method for both cell types and viruses.
5.5 CHOICE OF ANTIBODY
Transcriptionally permissive chromatin is associated with histone H4 acetylated on 
lysines 8 and 16 and histone H3 acetylated on lysines 9 and 14 (Kuo et al. 1996). 
Therefore an antibody to the modified histone (anti-Ac-H3, K9&14, Upstate Biotech, 
Virginia USA) was used in these experiments. A negative control antibody was also 
used in the optimised assays- chicken anti-IgG (Sigma).
5.6 OPTIMISATION OF PCR
The protocol used suggested PCR as a method of analysing the immunoprecipitated 
DNA. Therefore PCR conditions were optimised using primers for the promoters of 
interest. These were chosen as LAP1, LATP2-5’, LATP2-mid, LATP2-3’, the promoters 
for the IE protein ICPO, the early gene for TK and CMV. US5, where the CMVGFP 
cassette is inserted is an early gene and it may be expected that any promoter 
inserted would take on the expression timings of an early gene. TK is also an early 
gene and therefore the promoter should be transcriptionally active at a similar time to 
the US5 gene. Thus acetylation of the CMV promoter in the 1764 4- 27- CMVGFP 
virus can be compared to that of the TK promoter. Viral DNA 1764 4- 27- pR19GFP 
was used in the optimisation. Conditions for the cellular gene promoters Adenine 
phosphoribosyl transferase (APRT) and cyclophilin were also optimised using genomic 
DNA from ND7 cells.
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The target sequences had to be relatively small, as the sonicated fragments were 
~600bp in general. Where possible primers were designed to amplify a sequence of no 
more than 200bp.
Table 5-2 shows the primers whilst figure 5-12 shows the resulting PCR bands and 
conditions used.
PROMOTER
REGION
FORWARD PRIMER REVERSE PRIMER
LAP1 T GCCCGCG AGAT AT C AAT CACGT GGGT AGGT GAT GT AA
LATP2-5' T CGGCG AC AT CCT CCCCCTAA GAAACATT CCGGCGACGGAA
LATP2-MID T GAG AT GAACACT CGGGGTTAC T GGT GT GCT GT AACACG AG
LATP2-3’ CCCT AAAGTT GTT CCT AAAGC AGGGGAT GGGCGT GTT GGTT A
ICPO ATT GGGGGAAT CGT CACT G AGGT GCAAAT GCGACCAGA
TK CT AT GAT GACACAAACCCCG CC AC ACGCGT C ACCTT AAT A
CMV AT CAT AT GCCAAGTACGCCC GTGCCAAAACAAACTCCCAT
APRT GGCAAGCGT AC AAAAT GC AA T GAGGTGGT GGAGT GT GT GA
CYCLOPHILIN CG AGCT GTTT GCAGAC AAAG TT CTTGCT GGT CTT GCCATT
Table 5-2 PCR primers used for detection in the ChIP assay
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LATP2-5’ LATP2-mid
LATP2-3’
Gradient PCR program used for all 
primers
95°C -  3 min 
95°C -30sec  ~
X°C -  30 sec X 30 cycles 
72°C -  45 sec 
72°C -  7 min
Figure 5-12 Optimisation of PCR conditions for primers used in ChIP assays
1764 4- 27- pR19GFP viral DNA was used as the template for all of the 
reactions. Amplified DNA size is indicated for each set of primers.
All primer sets worked at most annealing temperatures tested. Temperatures used 
subsequently were picked from the middle of the tested range, except where stronger 
bands were seen for one temperature of the range as for the LAP1 primers.
228
Chapter 5 ChIP assay o fH S V I
5.7 VALIDATION OF THE ASSAY
To validate the assay uninfected cells were used in a full ChIP assay with primers for 
cellular constitutively active genes. 3 x 3.5cm2 wells of ND7 cells were used in the 
assay -  crosslinked, sonicated, immunoprecipitated, cross-links reversed and cleaned. 
Then PCR was carried out on the samples using the conditions determined above for 
the genes APRT and cyclophilin. Figure 5-13 shows the result of the assay.
M - 1 2  3 4
Cyclophilin
1 = anti-IgG Input
2 = anti-IgG IP
3 = anti-ac-H3 Input
4 = anti-ac-H3 IPM 1 2  3 4
APRT
Figure 5-13 PCR for ChIP assay validation
PCR was carried out using the program described in fig. 5-12 above for 30 
cycles with primers under optimised conditions. 10pL of each sample was run 
on a 1.5% agarose gel. M = 1kb+ DNA Marker, - = PCR negative control.
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The results show that the assay has worked. The input samples contain the genes and 
whilst the APRT gene has not been precipitated, the gene for cyclophilin has (top, lane 
4), showing that it is associated with acetylated histone H3 and therefore 
transcriptionally active in these cells. It is unexpected that APRT does not appear to be 
positive for acetylation of this histone, but as the reason for this is not relevant in this 
study it was pursued no further.
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5.8 INITIAL CHIP ASSAYS
5.8.1 Analysis of samples by PCR
Firstly the detection of the viral chromatin in the input samples (i.e. after sonication, 
before precipitation) was obviously required if it was to be detected downstream in the 
assay after precipitation. To check this 3 x 3.5cm2 wells per sample of 27/12/M:4 and 
ND7 cells were infected with 1764 4- 27- CMVGFP-5 virus at an MOI of 1 and 5 
respectively. The first steps of the ChIP assay were carried out up to the point of 
sonication. The samples then had the cross-links reversed and were cleaned up. They 
were then used in a PCR reaction with the CMV primers, as optimised above, at 54°C 
annealing temperature. Figure 5-14 shows the results.
Uninfected Infected
M - + 0.5 1 0.5 1
27/12/M :4 mm mm
Figure 5-14 Agarose gel from PCR with CMV primers of input samples from 
uninfected and infected cell lines.
0.5 and 1 pL of each sample was used per PCR reaction as indicated. 10pL of 
each PCR reaction run on 1.5% agarose gel. M = 1kb+ DNA ladder, - and + = 
negative and positive viral DNA PCR controls (1764 and 1764/C M V/G FP  
respectively).
231
Chapter 5 ChIP assay of HSV1
The PCR of the input samples show that the lytic virus sample is picked up by PCR 
but the latent virus is not. It was apparent that either a higher MOI of virus would need 
to be used for latent infection, or a more sensitive detection method used. As using 
more virus was not desirable due to the large amounts required for the assays and 
also the health of the cells being infected, it was decided that a more sensitive 
detection method would be attempted.
It was decided to see if any of the lytic virus when precipitated would be detectable by 
PCR, so the same infections were carried out on both 27/12/M:4 and ND7 cells as 
before. This time the full ChIP assay was carried out and the samples cleaned up. 
Higher volumes of input sample were used in the PCRs than before -  1 and 5pL as 
opposed to 0.5 and 1pL in the hope of detecting the latent samples. The precipitated 
samples were also used at 1, 5 and 10pL in the PCRs to increase chances of 
observing positive samples. Primers for the CMV promoter were again used with a Tm 
of 54°C using the program shown in figure 5-12 Figure 5-15 shows the results of the 
PCR.
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Infected
Uninfected ND7 Infected ND7 Uninfected-------------------------27/12/M:4 27/12/M:4
M - + i1 i5 1 5 10 i1 i5 1 5 10 i1 i5 M M - + 1 5 10 i1 i5 1 5 10
ig g m r
Figure 5-15 PCR with CMV primers from ChIP assay of 1764 4- 27- CMVGFP-5 virus in 
lytic and latent infections.
10fj.L of each PCR was run on a 1.5% agarose gel. i1 and i5 = 1 and 5 of 
input sample used in the PCR respectively. 1, 5 and 10 are the volumes of IP 
samples used in the PCR. -  and + are viral DNA PCR controls.
As shown in figure 5-15 the immunoprecipitated (IP) samples are positive for the CMV 
promoter in 27/12/M:4 cells, suggesting that it is acetylated during the lytic infection. 
Again the input samples for the latent infection did not show up by PCR. Although the 
result for the lytic infection was encouraging there was no point in analysing the 
samples further until the problem of detection in the latent samples had been resolved.
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5.8.2 Analysis of samples by PCR and Southern blot
To improve detection of the latent samples in ND7 cells without having to use more 
virus per infection, it was decided to try PCR followed by a Southern blot of the PCR 
gel. It was suggested that this should pick up DNA present on the gel that could not be 
visualised.
3 x 3.5cm2 wells of ND7 cells were infected at an MOI of 5 with 1764 4- 27- pR19GFP 
virus and left for 3 days. 2 days post-infection, one set of infections had sodium 
butyrate added to the media at a final concentration of 3mM. Sodium butyrate causes 
hyperacetylation of histones (Riggs et al. 1977) by inhibition of histone de-acetylases 
(HDACs) (Boffa et al. 1978; Candido et al. 1978; Sealy and Chalkley 1978). The ChIP 
assay was then carried out as described and the samples cleaned up and used in a 
PCR firstly for the CMV promoter and also for the TK promoter using the program 
shown in figure 5-12. As previously, no positive bands were seen for any of the input 
or IP samples (see figure 5-16). The gels were then used for a Southern blot (see 
section 2.2.8) each with a probe for the relevant promoter. Probes were made from the 
PCR product with the relevant primers using 1764 4- 27- pR19GFP viral DNA as a 
template and labelled as in 2.2.3.8.2. The gels and blots are shown in figure 5-16.
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Agarose Gel Southern Blot
M - + 1 2 3 4 5 - + 1 2 3 4 5
IPs *
Inputs •  m m m
a. TK
M - + 1 2 3 4 5
IPs
- + 1 2 3 4 5
t
Inputs
• ----------
b. C M V
Figure 5-16 ChIP assay on 1764 4- 27- pR19GFP in ND7 cells 3 days p.i.
Agarose gels for PCR and corresponding Southern blots for the same samples 
for a. TK and b. CMV. 10jiL of each PCR reaction was run on a 1.5% agarose 
gel and then used in a Southern blot with an appropriate probe for each 
promoter of interest.
1 = ND7 cells only (no antibody), 2 = ND7 cells + anti-acH3, 3 = Infected cells 
(no antibody), 4 = Infected cells + anti-acH3, 5 = infected cells + sodium 
butyrate + anti-acH3.
(NB The bands in the gel in panel b. are non-specific and do not come up on 
the southern blot.)
Using the PCR gel for a Southern blot does therefore appear to give a more sensitive 
method of detection. The bands on the blots are positive and yet cannot be seen in the 
PCR gel. However, there is a problem in that because it is so sensitive there is some
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contamination or background in the IP samples. Lanes 1, 2 and 3 on the blots should 
not be positive, as they are in both cases. This makes it impossible to draw any 
conclusions from these results, as well as the fact that the levels of inputs and IP 
samples are not comparable between the two gels.
This method of using PCR followed by Southern blot was used again in a ChIP assay, 
to see if the contamination was a one-off problem. This time, both ND7 and 27/12/M:4 
cells were infected with 1764 4- 27- pR19GFP at an MOI of 5 and 1 respectively and 
left for 3 day and 1 day respectively. Again, 3 x 3.5cm2 wells were used per sample 
and to one of the samples for each cell type 3mM sodium butyrate was added 24 
hours prior to the assay to induce hyper-acetylation of histones. A negative sample 
was also included in which infected cells were precipitated with an anti-chicken IgG. 
Cleaned samples were used in a PCR reaction with primers for TK as above. Figure 5- 
17 shows the gel and Southern blot from this experiment.
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Latent
ND7
Infections
Lytic
27/12/M:4
Infections
Figure 5-17 ChIP assay on 1764 4- 27- pR19GFP on ND7 and 27/12/M:4 cells.
Agarose gel for PCR and corresponding Southern blot. 10^L of each PCR 
reaction was run on a 1.5% agarose gel and then used in a Southern blot with 
an appropriate probe for the TK promoter.
1 = Cells only (no antibody), 2 = Cells + anti-acH3, 3 = Infected cells (no 
antibody), 4 = Infected cells + anti-acH3, 5 = infected cells + anti-IgG, 6 = 
infected cells + sodium butyrate + anti-acH3.
Figure 5-17 shows that the lytically infected samples do not require the Southern blot 
to detect the IPs as the results can be seen from the agarose gel alone. This also 
highlights the contamination or background problem with the Southern blots, as when 
the corresponding blot is looked at there are bands in the ‘negative’ samples. Again 
this is seen in the latently infected ND7 samples and although the contaminating 
bands are probably just background, it is not ideal as it makes it difficult to judge a 
positive result.
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The other two drawbacks of this method of analysis are that firstly there is no way of 
quantitatively comparing results between different promoters and different infections. 
Secondly, the acetylation is probably not just ‘on’ or ‘off such that there will be differing 
levels in different situations on different promoters, which again cannot be accurately 
assessed by Southern blot.
5.8.3 Analysis of Samples by Quantitative PCR
As a possible solution to the problems described above in detection of precipitated 
DNA, the use of quantitative or real-time PCR was investigated. This allows accurate 
quantification of DNA by measuring the amplified PCR product during the linear phase. 
By running the samples with multiple primer sets simultaneously should also allow a 
direct comparison of the acetylation profile of different promoters in the same sample.
5.8.3.1 Primer Validation
As the primers used above to optimise the standard PCR had different melting 
temperatures (section 5.6) and the quantitative PCR (qPCR) cycle normally runs at 
60°C annealing temperature, firstly all of the viral primers were used in a PCR reaction 
on 1764 4- 27- CMVGFP/5 viral DNA to ensure that they could still be used. The 
program shown in figure 5-12 was used as before. Figure 5-18 shows the PCR 
products on a gel.
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1 -LAP1
2 -  LATP2-5’
3 -  LATP2-mid
4 -  LATP2-3’
5 -CMV
6-TK
7-ICPO
Figure 5-18 PCR of 1764 4- 27- CMVGFP/5 viral DNA using all primers at 60°C 
annealing temperature.
10pL of each sample was run on a 1.5% agarose gel.
Figure 5-18 shows that all the primers should be able to be used at 60°C. Any 
variations in PCR efficiency between primer sets will not matter in the qPCR as the 
difference between input samples and IP samples will be measured for each primer 
set used.
The same viral DNA and primers were then used in a qPCR reaction on an ABI7000 
real-time PCR machine as described in section 5.2.3. The same 1764 4- 27- 
CMVGFP/5 viral DNA was used for the standard curves with serial dilutions from 1 -  1 
x 10'5 pL. Figure 5-18 shows the standard curves generated by plotting the log volume 
of viral DNA against the Threshold Cycle (CT).
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Figure 5-19 Standard curves generated by qPCR
qPCR was carried out on viral DNA with primers for the different promoters of 
interest simultaneously. The linear equation given by each primer set and the 
R2 value is shown on each chart.
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Figure 5-19 shows that the primer sets appeared to be working in the qPCR, some 
better than others, i.e. those with lower CT values are more efficient. The LAT 
promoter regions in particular appear to be reaching the limit of detection at the lower 
volumes as seen by the flattening out of the slope. As the assay is relative this should 
not be a problem. For each assay done, the standard curve for each primer set has to 
be checked to ensure that the IP values fall within the linear range to be valid and also 
to obtain the linear equation with which to calculate the IP values (see below).
5.8.3.2 Detection of acetylated latent virus
To see whether the qPCR would be a successful method for detection of the 
acetylated latent HSV1 chromatin, a full ChIP assay was carried out on ND7 cells 
infected with 1764 4- 27- CMVGFP/5 for 3 days. As it was not known where the IP 
values would fall in the linear range (if at all), the standard curve was created by using 
1764 4- 27- CMVGFP/5 viral DNA and making serial dilutions of 0.05, 0.1, 0.2, 0.5, 1 
and 2 pL as a starting point (based on the standard curves obtained above for each 
primer set). 1pL of each input and IP sample was amplified simultaneously in the 
qPCR with each set of primers as described above. The standard curves are shown in 
figure 5-20 and the calculated values for the input and IP samples shown in figure 5-21 
and table 5-3.
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Figure 5-20 Standard curves for ChIP assay on ND7 cells infected with 1764 4- 27- 
CMVGFP/5 3 days p.i.
NB: The highest viral DNA concentration sample for the CMV primer set was 
lost, therefore the graph only has 5 points as opposed to 6.
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■  Cells only
■  Virus (+ IgG)
■ Virus + anti-acH3
LAP1 LATP2-5' LATP2 LATP2-31 CMV TK ICPO 
MID
Promoter
\  /
Figure 5-21 IP values obtained for each promoter tested in 1764 4- 27- CMVGFP/5
Promoter Input Infected (a- 
acH3) IP 
Value
Adjusted
IP/Input
Value
LAP1 0.438 0.250 0.529
LATP2-5’ 0.381 0.156 0.409
LATP2 MID 0.968 0.521 0.538
LATP2-3’ 0.796 0.355 0.355
CMV 0.742 0.045 0.024
TK 0.698 0.165 0.236
ICPO 0.843 0.088 0.104
Table 5-3 IP values from qPCR for ND7 cells infected with 1764 4- 27- CMVGFP/5 3 
days p.i.
IP values are calculated using the formula y= mx + c with the values for the 
standard curve for each set of primers used shown on the charts in figure 5-20. 
The adjusted values account for any background given by the samples 
precipitated with the control a-IgG antibody falling within the linear range (only 
LAP1 and CMV in this case)
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Figure 5-22 Relative acetylation of histone H3 at promoters in 1764 4- 27- CMVGFP/5
3 days p.i. in ND7 cells compared to at the TK promoter.
The relative acetylation is calculated by dividing the IP value for any given 
promoter by that of the TK promoter.
The standard curve for each primer set in fig 5-20 gives a linear equation that is used 
to calculate the IP values of the samples from their CT values. As x is the log volume of 
the viral DNA standard and y is the CT, the IP value can be calculated as:
Log IP = ( C t - c )  
m
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The value is relative to the volume of viral DNA used for the standard curve, but as the 
same viral DNA was used for all of the primer sets, they can be compared to each 
other. The input value is the amount of the promoter in the sample prior to 
immunoprecipitation and the IP value is the amount of promoter associated with 
acetylated histone H3 in the sample after immunoprecipitation, thus the ratio IP/input 
gives the amount of acetylated promoter relative to how much was present in the 
sample to start with. As the conditions for each assay may vary, comparisons cannot 
be made between IP values in different assays. However, if the IP/input values of each 
promoter are displayed relative to one other each time as in figure 5-19 then these 
values can be compared assay to assay and thus should show the relative differences 
in acetylation of H3 at promoters between viruses under different infection conditions.
Figures 5-20 to 5-22 show that the assay has worked nicely for latently infected ND7 
cells. The samples precipitated with anti-acH3 (K9, 14) have given IP values within the 
linear range of the standard curves and the negative control samples are out of range 
and low. This was exciting as at the time it was the first evidence that HSV1 chromatin 
can be acetylated and that there are potential differences between lytic and latent 
regions.
5.8.3.3 Detection of acetylated lytic virus
As the detection was successful for the latent virus a ChIP assay was also carried out 
on lytically infected cells to check that qPCR can be used to detect acetylated 
promoters. It was likely that they would be as there is generally more viral chromatin 
present in the lytic samples than the latent as seen in section 5.3.4.
The standard curve was created by using 1764 4- 27- pR19GFP viral DNA and making 
serial dilutions to 10‘1 to IO 'V l as it was known that the viral DNA was more 
concentrated than the viral DNA used in the latent assay standard curve (from 
visualisation on an agarose gel). 1pL of each input and IP sample was amplified
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simultaneously in the qPCR with each set of primers as described above. The 
standard curves are shown in figure 5-23 and the calculated values for the input and 
IP samples shown in figure 5-24 and table 5-4.
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Figure 5-23 Standard curves for ChIP assay on 27/12/M:4 cells infected with 1764 4- 
27- pR19GFP 1 day p.i.
The standard curves for the LAT promoter regions only have 4 points as 
opposed to the other standard curves. This is because for all four primer sets, 
the lowest dilution of viral DNA had a CT value equal or below the negative 
control CT and was therefore excluded from the graph.
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Figure 5-24 IP values obtained for each promoter tested in 1764 4- 27- pR19GFP
Promoter Input Infected (a- 
acH3) IP 
Value
Adjusted
IP/Input
Value
LAP1 0.00175 8.92E-05 0.05092
LATP2-5’ 0.00229 8.96E-05 0.03916
LATP2 MID 0.00266 0.00021 0.07806
LATP2-3’ 0.00299 0.00016 0.05337
CMV 0.00188 5.97E-05 0.03184
TK 0.00095 2.11E-05 0.02232
ICP0 0.01527 0.00106 0.06947
Table 5-4 IP values from qPCR of 27/12/M:4 cells infected with 1764 4- 27- pR19GFP 
1 day p.i.
IP values are calculated using the formula y= mx + c with the values for the 
standard curve for each set of primers used shown on the charts in figure 5-20. 
The adjusted values account for any background given by the samples 
precipitated with the control a-IgG antibody failing within the linear range (none 
in this case).
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Figure 5-25 Relative acetylation of histone H3 at promoters in 1764 4- 27- pR19GFP 1 
day p.i. in 27/12/M:4 cells compared to at the TK promoter.
The relative acetylation is calculated by dividing the IP value for any given 
promoter by that of the TK promoter.
The figures above show that the assay is also usable for the lytic virus infection. From 
the IP/input ratios values given in tables 5-3 and 5-4 for the two assays, there appears 
to be a smaller proportion of the total promoter acetylated in the lytic infection than the 
latent for all promoters studied.
These were only preliminary experiments and were done in singular and therefore are 
not suitable for drawing conclusions, however there are possible differences in 
acetylation between the LAT and non-LAT promoters during latent infection, which 
prompted further investigation.
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5.9 USE OF THE OPTIMISED CHIP ASSAY TO ANALYSE THE 
ACETYLATION OF TWO HSV1 VECTORS GENOMES
Following optimisation of the assay for a lytic and latent infection in vitro, a set of 
experiments was set up to test the acetylation status of histone H3 at different 
promoters within two different viruses during lytic and latent infections.
The two viruses to be analysed were described in section 5.1: 1764 4- 27- pR19GFP 
in which the CMV promoter drives GFP under the influence of the LAT region and 
1764 4- 27- CMVGFP/5 where CMV drives GFP without influence from the LAT 
region.
To study acetylation during acute infection, an earlier time of 3 hours was examined 
rather than 1 day, after work was published in which the promoters for ICPO, TK and 
VP16 were shown to all be associated with acetylated histone H3 at 3 hours p.i. but 
that by 6 hours p.i. only the ICPO promoter was still acetylated in an in vitro lytic model 
(Kent et al. 2004). The same report showed by micrococcal nuclease digestion that by 
3 hours p.i. in vitro, viral DNA is assembled in a chromatin-like structure.
To study acetylation of the viral genomes during latent infection, infected cells were 
processed after 3 days as before.
The assays were carried out as described above, in both 27/12/M:4 cells and ND7 
cells for each virus. The immunoprecipitated samples and inputs from each assay 
were then used in qPCR reactions with the primers for promoters as described in 
section 5.6.
Each assay was carried out in triplicate and for each repeat the samples were used in 
a qPCR 3 separate times.
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This generated 9 sets of ChIP data for each virus in both lytic and latent infections. 
The averaged relative acetylation values from the three qPCR runs for both lytic and 
latent assays are displayed in figure 5-26 for 1764 4- 27- CMVGFP/5 and in figure 5- 
27 for 1764 4- 27- pR19GFP.
Ideally, a positive control of infected cells treated with TSA or sodium butyrate would 
have been included in these assays, however, due to the limitations of size of the 96- 
well plate used for the qPCR, this was not possible.
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Figure 5-26 Acetylation values of promoters within 1764 4- 27- CMVGFP/5 during 
acute and latent infection
For each assay, 3 PCR runs were carried out and the means are displayed for 
each assay. Error bars represent the S.E.M.
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Figure 5-27 Acetylation values of promoters within 1764 4- 27- pR19GFP during acute 
and latent infection.
For each assay, 3 PCR runs were carried out and the means are displayed for 
each assay. Error bars represent the S.E.M.
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The three assays for each situation of viral infection have a fair amount of variation 
between them. This is the reason that the total average (of 9 PCR runs) results for 
each assay are not initially displayed. Despite this it can be seen from figures 5-26 and 
5-27 that the LAT region appears to contain more acetylated histone H3 in general 
than the TK and ICPO promoters, particularly at latent times. For a full analysis the 
results were plotted on two graphs, one for lytic infection with the two different viruses 
and one for latent infection. For these graphs, the 9 IP values generated for each 
infection situation were averaged. These are presented in figure 5-28.
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Figure 5-28 Comparison of acetylation of histone H3 at promoters in two different 
viral vectors
a. Lytic infection data
b. Latent infection data
Each data series represents the average of 3 assays per condition, with 3 
qPCR runs each (i.e. n=9). Values are represented as relative to the IP/Input 
value for the TK promoter. (* - p<0.05)
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Figure 5-28 shows the differences in acetylation of histone H3 at HSV1 LAT and non- 
LAT promoters and the CMV promoter in both lytic and latent infections.
5.9.1 Acetylation of the LAT regulatory region
The first observation from the graphs is that during lytic infection the average 
acetylation values (given by IP/Input and relative to the IP/Input for the TK promoter) of 
all of the LAT region analysed are generally much closer to that of the TK promoter 
than in the latent infection -  a maximum of 3.8 times more acetylated during lytic 
infection compared to 40.9 in latent infection (note the difference in scale between 
figure 5-28 a & b). This is perhaps unsurprising as acetylation is a marker for 
transcriptional permissiveness of DNA and during a lytic infection more of the HSV1 
genome is transcriptionally dynamic than during the latent cycle when the LAT 
promoters are active whereas the rest of the genome is quiescent. The ICPO promoter 
has less acetylated H3 in latent infection in both viruses, again which may be expected 
for a promoter that is ‘off.
Statistical analyses of the individual ChlPs for each infection type (figure 5-26 and 5- 
27) and for the averaged data (figure 5-28) reveal that there is no significant difference 
in the associated acetylation of histone H3 at the different parts of the LAT promoters 
-  either LAP1 or any of the LATP2 region except for during lytic infection with 1764 4- 
27- CMVGFP/5 where the 5’ half of LATP2 has a significantly (p<0.05) higher 
acetylation ratio than any of the other promoter regions studied. However this is not 
seen in lytic infection with the 1764 4- 27-pR19GFP virus and they would perhaps be 
expected to have a similar acetylation profile in this region. Nevertheless, the 
positioning of the two cassettes could have an effect.
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Comparing the two viruses in figure 5-28 shows that the LAT promoters studied in the 
1764 4- 27- pR19GFP virus generally appear to be associated with more acetylated 
histone H3 than the TK promoter, in both lytic and latent situations, than in the 1764 4- 
27- CMVGFP/5 virus. The fact that the 5’ half of LATP2 in the 1764 4- 27- CMVGFP/5 
does not fit this pattern perhaps means that this is an anomalous result. This suggests 
that in inserting the cassette containing CMV and GFP into the LAT region, the virus 
has been altered such that the region is more transcriptionally permissive. This is true 
for the ICPO promoter only in a lytic infection, which is interesting as at that time the 
promoter is active, whereas during a latent infection it is inactive. This suggests that 
ICPO is somehow ‘protected’ from the transcriptionally permissive neighbouring LAT 
region during latency, perhaps by an insulator element (see section 1.2.3.5). This data 
might suggest that this insulator is not present during lytic infection, allowing the ICPO 
region to be influenced by changes in the local genome such as appears to have 
occurred in the 1764 4- 27- pR19GFP virus.
5.9.2 Acetylation of the exogenous CMV promoter
In order to assess whether the acetylation status of H3 at the CMV promoter is altered 
by placing it within the LAT region, compared to placing it outside of the LAT region, 
the difference in acetylation between it and the LAT region must be looked at in both 
cases. If the IP/Input values for the viral promoters are compared to that of the CMV 
promoter rather than the TK promoter this is easier to see (figure 5-29):
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Figure 5-29 Mean acetylation values (IP/Input) relative to CMV acetylation values in 
two different viral vectors
Each data series represents the average of 3 assays per condition, with 3 
qPCR runs each (i.e. n=9). IP/input values are represented as relative to the 
CMV promoter IP/input values. (* - p<0.05).
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The relative acetylation values of the LAT region compared to the CMV promoter are 
generally higher for the 1764 4- 27- CMVGFP/5 virus than for the 1764 4- 27- 
pR19GFP virus, where CMV is linked to the LAT region. This suggests placing the 
CMV promoter in the LAT region alters its acetylation profile. This would result in the 
promoter being transcriptionally permissive during latency and could account for its 
activity during this time.
5.10 DISCUSSION
This chapter described the optimisation and application of the ChIP assay for study of 
the acetylation of the HSV1 genome.
At the time the work was started, there was no literature on the use of the ChIP assay 
with HSV1 and in fact little literature on histone modifications associated with the virus.
An in vitro system for latency was set-up after testing a number of cell lines for 
infectivity and stability. The chosen model was validated, by showing that disabled 
HSV1 does take on at least a partially nucleosomal structure during latent infection of 
ND7 cells and that LATs are produced during this time.
The ChIP assay was optimised for all procedures involved and was validated by the 
use of PCR primers for the cellular gene cyclophilin. The use of standard PCR turned 
out to be limiting in detecting the acetylation of histone H3 associated with promoters 
in the latent infection due to the smaller amount of virus present. Therefore the use of 
quantitative PCR was looked at and proved to be a successful way of analysing the 
acetylated nucleosomes, of both latent and lytic in vitro infections.
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The optimised ChIP assay was then used to analyse the acetylation profiles of two 
different viruses -  1764 4- 27-CMVGFP and 1764 4- 27-pR19GFP in which the CMV 
promoter was either in a cassette distinct from or linked to LATP2 respectively. The 
acetylation of histone H3 at the LAT regulatory region was also examined by using 
primers to the LAP1 promoter and to the different sections of the LATP2 region as 
studied in chapters 3 and 4. Acetylation at the ICPO promoter was also looked at as it 
is both an IE gene and in close proximity to the LAT region. Acetylation at the TK 
promoter was studied, as it is an early gene promoter located away from the LAT 
region in the HSV1 genome.
The acetylation profiles of the two viruses were examined during acute infection and 
during latent infection. The LAT region promoters studied were enriched in acetylated 
histone H3 compared with the non-LAT promoters, particularly during latency. The rest 
of the genome is transcriptionally silent during this time and therefore this data shows 
that acetylation of histone H3 occurs where the viral genome is transcriptionally active. 
There were no consistent differences seen between the acetylation at the LAP1 
promoter and at the sections of LATP2. This shows that this entire region is 
transcriptionally permissive during both lytic and latent infection. Acetylation is not a 
measure of promoter/enhancer activity, but rather the potential for activity, thus the two 
cannot be reconciled.
During the course of these experiments, a number of publications appeared in which 
acetylation of the HSV1 genome was examined in a similar manner. Kubat et al. 
showed that latent HSV1 DNA from mice DRG was associated with acetylated histone 
H3 at the LAP1 promoter whereas the HSV1 DNA polymerase, ICP4 and UL54 genes 
were not enriched in this acetylated histone (Kubat et al. 2004b). This concurs with the 
work described above in so much as the LAP1 promoter is enriched in acetylated 
histone H3 during latency compared to non-LAT regions. This paper also points out 
the fact, as mentioned above, that small changes in the fold enrichment of acetyl
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histone H3 can result in huge changes in transcriptional activity of a promoter, as 
exemplified by a study in which quantification of hormone-induced hyperacetylation of 
H3 on transcription from the steroidogenic acute regulatory protein promoter was 
carried out (Christenson et al. 2001). This showed that a 5-fold increase in acetylation 
resulted in a 45-fold increase in mRNA accumulation and a 6-fold increase in 
acetylation resulted in a 125-fold increase in mRNA accumulation. This again would 
perhaps explain why differences in promoter/enhancer activity from the LATP2 region 
were seen in chapters 3 and 4, but no big differences in acetylation between the 
different parts are seen from the ChIP assays carried out above.
A second publication by Kubat et al. went on to study histone H3 acetylation at the 
LAT 5’exon by ChIP assay (Kubat et al. 2004a). This corresponds to part of the LATP2 
region studied above, specifically, primers used for qPCR were localised to the section 
of LATP2 present in both the 5’ half and mid-section. They showed that the 5’ exon is 
at least as acetylated, if not more so, than the LAP1 promoter during latency, again by 
carrying out ChIP assays on HSV1 DNA from infected mice DRGs. They also showed 
that ICPO is not as enriched in acetylated histone H3 as the LAT region at this time. 
The data also showed a similar amount of variation as in the experiments described in 
this chapter. These results again concur with the results from the In vitro latent 
infection above. This supports that the latent infection obtained in ND7 cells is a good 
model of a latent infection in vivo in terms of transcriptional activity and genome 
structure.
The work in this chapter also suggested that when the CMV promoter is placed 
adjacent to the LATP2 region, it becomes enriched in acetylated histone H3 compared 
to when it is placed in a non-LAT locus, during lytic and latent infection. A similar virus 
in which CMV was in the same position next to LATP2 but drove lacZ expression 
rather than GFP, allowed transgene expression during latency (Palmer et al. 2000). 
The CMV promoter does not allow this when placed elsewhere in the HSV1 genome.
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This would suggest then that CMV becomes associated with modified histones in a 
similar manner to the LAT region and is allowed to remain active. The positioning of 
CMV next to LATP2 appears to allow this to occur. It was previously postulated that 
the altered dinucleotide content of the LAT region could reflect an altered DNA 
structure and that this could keep the chromatin in an ‘open’ transcriptionally 
permissive state (Coffin et al. 1995). Specifically, LATP2 could cause this alteration in 
structure and confer this onto neighbouring promoters. It now seems possible that this 
altered structure is to do with histone tail modifications in the region, specifically 
acetylation allowing the region to remain in an open, transcriptionally permissive state 
that is conferred onto exogenous promoters when placed next to LATP2.
Two other papers were published during the course of this work describing acetylation 
of H3 associated with HSV1. These looked at lytic infections, in vitro. The first group 
(Herrera and Triezenberg 2004) studied acetylation at 2 hours p.i. and found that the 
IE early promoters for ICPO, ICP4 and ICP27 were hypoacetylated on histone H3 at 
this time, but that promoters for delayed-early or late genes were hyperacetylated. 
When they repeated the study with a virus lacking the VP16 activation domain, they 
found that none of the viral promoters were acetylated at this time, suggesting that 
VP16 plays an important role in the epi-genetic modification of the genome during lytic 
infection.
The second study published at the same time (Kent et al. 2004), studied acetylated 
histone H3 at 1, 2 and 3 and 6 hours p.i. associated with IE, E, and L gene promoters 
and showed a correlation between timing of RNA appearance for the genes and 
acetylation of the promoters. This provides further evidence for the role of histone 
modification in the regulation of HSV1 transcriptional patterns.
The results presented in this chapter shows that LAP1 is apparently as enriched in 
acetylated histone H3 as LATP2 during latency, yet does not confer latent expression
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onto exogenous promoters as LATP2 does. It would be interesting to see whether 
LAP1 would be as enriched in acetylated histone H3 if it were placed at a different 
locus in the genome than next to LATP2, i.e. whether or not LATP2 is responsible for 
this acetylation status. The fact that LAP1 is turned off during latency when LATP2 is 
not adjacent suggests that it would not. LATP2 contains enhancer activity, and this 
may well be due to or causing more acetylation of H3 in the associated nucleosome(s) 
at this locus. The finding in chapter 3 that there is a binding site for the TF p300 that 
contains HAT activity within the 3’ half of I.ATP2, gives weight to this hypothesis.
The fact that the CMV promoter appears to become enriched in acetylated histone H3 
when placed next to LATP2 does suggest that this histone modification is involved in 
conferring latent activity. It seems that the MMLV LTR plays a similar role to LATP2 in 
maintaining long-term activity from the I.AP1 promoter and so it would be interesting to 
see whether the MMLV LTR also has/causes an increase in the acetylation of 
associated histones.
The fact that LATP2 can confer activity onto neighbouring promoters leads to the point 
that although the ICPO promoter is proximal to the LAT region, it is not enriched in 
histone H3 during latency and thus LATP2 is not conferring latent expression onto this 
neighbouring promoter. It is an attractive hypothesis therefore, that there is a factor 
present such as an insulator element between LATP2 and ICPO, which would prevent 
this open chromatin structure from being spread to the ICPO gene, or more importantly 
the closed heterochromatin structure of the rest of the genome spreading to the LAT 
region. Insulator elements are also commonly found in the proximity of enhancers for 
the purpose of preventing enhancer activity on promoters where it is not wanted. If 
there is such an insulator element present, the CMV promoter in the 1764 4-27- 
pR19GFP virus must have been placed upstream of it, in order to allow activity during 
latency.
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In conclusion, the LAT regulatory region including LATP2 does appear to be enriched 
in acetylated histone H3 as compared to the non-LAT promoters studied, particularly 
during latency and furthermore this enrichment appears to be conferred onto the CMV 
promoter when placed next to the LATP2 promoter/enhancer.
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HSV-1 is a good candidate for a gene therapy vector, particularly for delivering genes 
to the nervous system. The beneficial characteristics making it an appealing vector to 
develop include the ability to have large gene sequences inserted, to naturally infect 
neurons and to sustain a latent infection for the lifetime of the host.
The harnessing of the virus’ ability to maintain transcriptional activity from a small 
genetic region asymptomatically is a key aim in the development of vectors with the 
ability for continued transgene expression. Various groups have achieved this with 
greater or lesser success, by utilising the LAT regulatory region or parts thereof to 
drive continued gene expression.
The LATP2 region has previously been shown to be responsible at least partly for 
maintaining long-term expression of inserted transgenes and has been used in our 
laboratory to achieve continued expression in the nervous system from two different 
promoters placed in a bicistronic arrangement to this region.
The work presented in this thesis attempted to characterise the LATP2 region in order 
to understand better its mechanism of action such that future vectors may be designed 
with optimised long-term expression capabilities.
The first two results chapters (chapters 3 and 4) presented here investigated which 
regions of LATP2 are responsible for its enhancer and long-term expression 
characteristics. The third results chapter (chapter 5) examined whether the virus uses 
epigenetic mechanisms to maintain transcriptional activity of the LAT region during 
latency.
In chapter 3, vectors were created that contained LATP2 deletion mutants in a central 
position within a cassette, flanked by the LAP1 promoter and the MMLV LTR promoter 
on either side driving lacZ and GFP respectively. Through in vitro and in vivo testing, 
repressive elements were suggested in the 5’ half and 3’ half of LATP2 not
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encompassing the mid fragment i.e. the extreme ends. This appeared to be 
functioning during lytic and latent infection. However, the fact that expression from 
both promoters was at its highest without LATP2 at all suggested that the MMLV 
enhancer activity was conferring long-term expression onto LAP1 (a feature of the 
MMLV LTR that had previously been reported) and being repressed by the presence 
of LATP2. Thus the enhancer activity of LATP2 was not conclusive, as it was 
potentially being obscured by the presence of the MMLV LTR.
Therefore, in chapter 4, the MMLV LTR and GFP were removed from the LATP2 
deletion viruses used in chapter 3, giving a set of viruses with the LATP2 deletions in 
the opposite orientation to LAP1, driving lacZ expression. A further series of LATP2 
deletion viruses were also created with the same deletions, but orientated in the same 
direction as LAP1, to allow study of the directionality of the region. When these vectors 
were tested in vitro and in vivo, the data again suggested a repressive element, 
although this time in the mid section of LATP2, which only caused repression when in 
the same orientation as LAP1. It is not clear exactly where this was located as neither 
the 3’ half or the 5’ half alone seemed to exhibit this repression. It is possible that in 
whichever half it is, it contains active elements that balance the effects out. However, 
removing the 5’ half of LATP2 seemed to cause an increase in enhancer activity, 
therefore the repressive region is perhaps more likely to be located in the region of 
LATP2 common to the 5’ half and mid-section.
As mentioned, the mid section of LATP2 tested repressed LAP1 activity when in the 
same orientation as LAP1. However, it actually enhanced the activity when placed in 
the opposite orientation. This seems unusual, but it appears that a sequence has been 
deleted from LATP2 that would allow the region to function in both directions. This 
appears to have created a unidirectional enhancer, which although unusual, has been 
reported in the literature before (Carlberg et al. 1988; Gerasimova et al. 1995; Hen et 
al. 1983). It is also possible that the joining of this deletion fragment to the adjacent
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DNA, in the same orientation as LAP1 has allowed a site for an insulator element or 
for a repressor to bind, thus preventing the enhancement of I.AP1 activity in one 
orientation only. Some directionality is also seen from the full LATP2 region and the 
5’LATP2AICP4 fragment, suggesting that maybe the region does not possess equally 
bi-directional activity and that deletion of certain parts emphasises this.
As stated above, the 5’ half of l_ATP2 generally exhibited no enhancer activity, whilst 
the 3’ half was required for enhancer activity in most situations tested and long-term 
expression. The mid section was able to enhance LAP1 activity when in the opposite 
orientation to LAP1 in vivo, therefore it seems that only the first 242bp of LATP2 
exhibits no enhancer activity. This is in contrast to similar work carried out by 
Berthomme et al who showed that the 5’ half of this region was sufficient for full 
enhancer activity of the region whilst the 3’ half exhibited none (Berthomme et al. 
2001). This could be explained by the different arrangement of the LAT promoter and 
enhancer elements in the two studies. It is possible that introducing deletions either 
destroys or creates binding sites for repressive or active elements, as does joining 
different sections of DNA, which could have occurred in either or both sets of 
experiments resulting in different enhancer profiles. Further to this it was reported that 
an enhancer element could be shared between LAP1 and LAP2 (Soares et al. 1996), 
which if this were so could explain why enhancer activity was not seen from the 5’ half 
of LATP2 in the work in this thesis as the arrangement of I.AP1 and I.AP2 here would 
have disrupted this element.
A question posed by Berthomme et al was whether the enhancer and long-term 
expression functions are the same or distinct. Enhancers often function by creating an 
open conformation of the local chromatin structure. If this is so in LATP2 then it seems 
difficult to imagine that the long-term expression function is different from the enhancer 
function, i.e. the long-term expression that it allows is probably due to continued 
opening of the region as directed by the enhancer. The work presented here suggests
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that they are the same. The fragments that enhance activity from LAP1 at lytic 
timepoints also tend to allow enhanced long-term expression. The other group 
investigating this region arrived at the same conclusion from their experiments, even 
though the different arrangement pointed to different active or repressive regions 
(Berthomme et al. 2001).
The full LATP2 region gives the best long-term expression of a transgene from LAP1 
when in the same orientation as LAP1. Taken together with the results from the 
deletion fragments, this suggests that the LATP2 region is made up of a complex 
linear array of c/s-acting elements, more than one of which is required for optimal 
transgene expression during latency.
Having said this, future work should include creation of further LATP2 deletion mutants 
with both the section unique to the 5’ half deleted (i.e. the first 242bp) and separately, 
the section common to the 5’ and mid-section (~400bp) deleted and introduced into 
similar vectors to examine whether the repressive region can be further localised and 
deleted to produce optimal long-term expression vectors for delivery to the PNS.
In chapter 5, the hypothesis that the LAT regulatory elements, specifically LATP2, 
maintain the local region in a transcriptionally active state by means of histone 
modifications was tested. It is known that HSV1 is associated with histones during 
latency (Deshmane and Fraser 1989) and acetylated histones are a marker of 
transcriptional activity; therefore acetylation of the LAT promoter and enhancer were 
compared to that of non-LAT promoters. The acetylation status of a non-HSV promoter 
that has previously been shown to remain active when placed next to LATP2 was 
examined, to also see whether this is achieved by the acetylation of associated 
histones.
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In vitro models of lytic and latent infection were set-up and it was shown that HSV1 is 
at least partially associated with nucleosomes during both of these infections. The 
ChIP assay on HSV-1 infected cells was optimised and then used to examine the 
acetylation of histone H3 associated with two different viruses, containing a CMV 
promoter either within the LAT region or placed elsewhere in the genome.
The assays showed that the LAT promoter and enhancer regions are more associated 
with acetylated histone H3 than non-LAT promoters during latency. The different parts 
of LATP2 do not appear to have differently acetylated histones to each other, but this 
is maybe not surprising when a number of factors are considered. As mentioned 
previously, changes in promoter/enhancer activity do not necessarily have a linear 
relationship with changes in the acetylation of associated histones. Therefore, small 
changes in the activity of different sections of LATP2 will probably not be detectable in 
the acetylation of the associated histones. As well as this, the fact that acetylation of 
histones is a marker of the transcriptional ability of the associated DNA rather than the 
actual transcriptional activity shows that the region as a whole is active. Furthermore, 
as the data from chapter 4 suggests, it appears that elements throughout LATP2 
function to keep the region active. Activating or repressing element motifs usually 
consist of a maximum of about 15-20 bp whereas each nucleosome has 146bp of 
DNA wound round it, therefore each two H3 histones contained in a nucleosome could 
have many differently acting elements associated with them.
In chapter 3, a putative binding site for the TF p300 was identified in the DNA unique 
to the 3’ half of LATP2. p300 has HAT activity and could therefore be involved in the 
acetylation of this region. This is backed up by the fact that in chapter 4, the 3’ half of 
the region was required for long-term activity and was able to allow continued 
expression without the 5’ half of LATP2. This would correspond to the presence or 
absence of this p300 binding site which could allow p300 to confer acetylation onto the 
associated histones and lead to continued activity.
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The CMV promoter showed a selective association with hyperacetylated histone H3 
during latency when linked to the LATP2 promoter, as compared to when it was placed 
in the Us5 gene. Therefore, it appears that LATP2 may confer long-term expression 
onto the CMV promoter by allowing it to stay in a transcriptionally active open 
conformation, via acetylation of associated histone H3 at a time when it would 
otherwise be shut off.
This continued acetylation might be achieved by inhibition of HDACs during latency. 
How the virus might bring this about remains to be discovered. Presumably some 
mechanism perhaps modulated by the LATs, which are the only viral product at this 
time, functions to prevent this deacetylation and switching off of the region.
It seems quite likely that the distance that continued activity can be conferred onto 
proximal promoters by LATP2 is limited by a barrier element. The fact that the ICPO 
promoter is shut off during latency and is hypoacetylated at histone H3 suggests that a 
barrier may exist somewhere between LATP2 and ICPO to prevent this action of 
LATP2 on the IE gene promoter. In fact, very recent evidence has shown that this is 
likely, as a CTCF insulator protein motif cluster has been identified exactly in this 
location; between LATP2 and ICPO (Amelio and Bloom 2005). It would be interesting 
to delete these motifs and see the effect on activity of ICPO during latency and indeed 
on the establishment of latency.
Similarly, in the region upstream of LAP1, there must be another barrier to prevent 
chromatin condensation from the rest of the genome spreading to the LAT region from 
this direction, as barriers exist in pairs to create distinct domains of hetero- or eu- 
chromatin.
An interesting experiment to conduct would be to insert an artificial barrier between 
LATP2 and LAP1 or CMV and examine the effect on transgene expression driven by
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these promoters during latency. This would allow confirmation that it is LATP2 that the 
acetylated, transcriptionally permissible chromatin originates from.
As seen in chapter 3 and in previous reports, the MMLV LTR also has the ability to 
confer activity onto LAP1, as does LATP2, making it an attractive hypothesis that it 
functions in a similar manner to LATP2. It would be interesting to examine the 
acetylation status of histones associated with MMLV LTR when linked to LAP1 in a 
non-LAT locus (an arrangement that allows long-term expression) to discover whether 
this is so.
As LATP2 can be placed outside of the LAT region and confer long-term expression 
onto related promoters it would also be interesting to examine the acetylation of 
histones in surrounding regions (e.g. in UL43 as in the chapter 3 and 4 viruses) to see 
how far this extends from LATP2, as barriers presumably exist in the proximity of the 
inserted regions to prevent shut-off of promoters within the cassettes during latency. 
Either the cassettes have benefited from fortuitous placement, or LATP2 somehow 
prevents shut-off by another means. It is unlikely that this is due to fortuitous 
placement, as the latent transgene expression can be conferred by LAT elements 
whether in the UL43 locus (Palmer et al. 2000), the Us5 locus, or gC (Berthomme et al. 
2001) in a similar manner.
However this compartmentalisation is achieved, placement of transgene expression 
cassettes within HSV1 vectors would potentially benefit from the introduction of barrier 
protein binding elements at each end to ensure that inappropriate genes are not kept 
on during latency. This should perhaps be considered in future HSV1 vector design.
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